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A  General Introduction 
 
1 Structure and Function of Estrogen Receptors (ERs) α and β 
 
Estrogens are involved in a number of biological functions in many target organs such 
as mammary gland, uterus, bone, cardiovascular system and brain. Estrogen actions 
are predominantly mediated through two nuclear estrogen receptor (ER) subtypes 
namely α and β. The ER belongs to the superfamily of nuclear steroid hormone 
receptors that are ligand-activated transcription factors initiating gene transcription by 
interaction with specific hormone response elements of the DNA (Tsai and O'Malley, 
1994). 
An estrogen receptor protein was identified and isolated from the rat uterus in the 1960s 
(Toft and Gorski, 1966; Toft et al., 1967) and finally cloned from human tissue in the mid 
1980s (Walter et al., 1985; Green et al., 1986; Greene et al., 1986). From the first 
discovery to the mid 1990s research was focused only on one ER protein. In 1996 a 
second ER protein was identified and cloned initially from rat (Kuiper et al., 1996), and 
shortly later also from man (Mosselman et al., 1996; Enmark et al., 1997) and mouse 
(Tremblay et al., 1997). Henceforward the originally known subtype was termed ERα 
and the 30 years later discovered isoform became known as ERβ. Several splice 
variants of the human ERβ subtype, designated ERβ long (Ogawa et al., 1998a), ERβ 
short (Mosselman et al., 1996) and ERβ cx (Ogawa et al., 1998b) have been identified.  
Like other members of the superfamily of nuclear receptors, ERα and ERβ are made up 
of several distinct functional domains (Kumar and Thompson, 1999) (cf. Figure A1). The 
N-terminal A/B region is the one with the lowest sequence homology between ERα and 
ERβ. This domain harbors the transcriptional activation function AF-1 that was believed 
to be constitutively active and ligand independent (Kumar et al., 1987; Metzger et al., 
1995). Ligand independent ER activation was shown to be induced by receptor 
phosphorylation via different cytoplasmic signaling pathways (cf. Paragraph 3.2). 
The DNA binding domain (region C) is the most conserved region and shows 
approximately 95% sequence homology between ERα and ERβ. Eight highly conserved 
cysteine residues of this domain coordinate two zinc (II) cations to form two zinc finger 
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motifs that are involved in dimerization and DNA binding. The so-called P-box is a 
sequence of six amino acids located within the N-terminal zinc finger being responsible 
for the recognition of the ERE on the DNA. The second zinc finger harbors the so called 
D-box as a dimerization interface (Pettersson and Gustafsson, 2001). D-box mediated 
protein-protein interactions and P-box mediated DNA-protein binding are cooperative 
and stabilize the ER-DNA-complex in concert (Freedman, 1992).  
The DNA binding domain is linked to the large ligand binding domain (LBD, region E) by 
a poorly characterized hinge region (D-domain). The LBD is a highly conserved region 
that mediates ligand induced transcriptional activation through the second ligand 
dependent activation function AF-2. The LBD is the key domain for the development of 
new ligands and therefore, a number of crystal structures of ERα and ERβ LBD in 
complex with various ligands have been reported (Brzozowski et al., 1997; Shiau et al., 
1998; Pike et al., 1999; Pike et al., 2001; Shiau et al., 2002). The molecular mechanism 
of signal transduction after ligand binding will be explained in paragraph 3.1. 
 
 
 
Figure A1:  Schematic structure and signal transduction of human estrogen receptors α and β 
(from (Jordan, 2003a)) 
 CoA: Coactivator, CoR: Corepressor, E2: 17β-estradiol  
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The ERα and ERβ proteins differ from each other in size and show a relatively low 
sequence homology of 47%. ERα is a 66 kD protein comprising 595 amino acids, 
whereas ERβ consists of 530 amino acids with a molecular weight of 59 kD. The ligand 
binding domain of ERα and ERβ show only 55% sequence homology, but the binding 
pockets of the two subtypes differ only in two amino acids: Leu 384 and Met 421 in ERα 
correspond to Met 336 and Ile 373 in ERβ (Pike et al., 1999). This similarity of the 
binding site explains the very similar affinity of the endogenous ligand 17β-estradiol to 
both estrogen receptors α and β (Kuiper et al., 1997).  
The two estrogen receptor isoforms have different tissue distribution in the human body. 
ERα regulates the development and maintenance of both male and female reproductive 
organs and is the predominant subtype expressed in breast carcinoma. ERβ was 
reported to be the main isoform in normal breast tissue and was also found in a number 
of other tisssues such as the cardiovascular system, reproductive organs, brain and 
bone (Enmark and Gustafsson, 1998) 
 
 
2 Ligands of the Estrogen Receptor 
 
The increasing knowledge about the physiological functions of estrogens during the 20th 
century brought along the development of a large number of compounds active as 
agonists as well as partial- or full antagonists on ER. The class of antiestrogens and 
selective estrogen receptor modulators (SERMs) that are important in breast cancer 
therapy and ER subtype selective ligands developed in recent years will be reviewed in 
the following paragraphs. 
 
2.1 Clinically Relevant ER Ligands: Antiestrogens and SERMs  
 
Breast cancer is one of the most common forms of cancer in women. Approximately two 
third of all mammary carcinomas express estrogen- and progesterone receptors, which 
are well established prediction factors for the likelihood of response to hormonal therapy 
(Hopp and Fuqua, 2003). Besides other approaches focused on the blockade of 
estrogen biosynthesis, the functional blockade of the ER by antagonists (antiestrogens) 
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has become a leading strategy for the treatment of hormone sensitive mammary 
carcinoma. Tamoxifen (cf. Figure A2) was the first - and for a long time - the only 
available antiestrogen for breast cancer therapy on the market. The antiestrogen 
provides effective palliation in patients with advanced disease and reduces the risk of 
recurrence when applied as adjuvant therapy (Osborne, 1998). Contrary to its 
antagonistic activity in the breast, tamoxifen was found to be an agonist in other tissues 
such as bone, blood and endometrium. In the case of bone and blood the estrogen-like 
side effect was a benefit, as estrogen is important for preservation of bone mineral 
density (Turken et al., 1989; Love et al., 1992) and reduces blood lipids such as 
cholesterol as cardiovascular risk factors (Love et al., 1994). On the other hand, the 
estrogenic action in the endometrium brings along an increased risk for the 
development of endometrium carcinoma during tamoxifen treatment (Fisher et al., 
1994). The tissue specific effects of tamoxifen were the basis for the development of 
selective estrogen receptor modulators (SERMs). Due to the estrogenic effect in bone 
SERMs were found to be a favorable form of treatment of osteoporosis, providing a 
lowered risk of breast cancer development as beneficial side effect. Osteoporosis is a 
common disease in aged women, which is caused by a reduced bone mineral density 
as a consequence of lowered estrogen production after menopause. The second 
generation SERM raloxifene (cf. Figure A2), was introduced for the treatment and 
prevention of osteoporosis and was also discussed as a preventive for breast cancer 
and coronary hart deseases (Jordan et al., 2001). A number of new SERMs based on 
the stilbene structure of tamoxifen, such as toremifene, droloxifene and idoxifen, or fixed 
ring analogues such as arzoxifene have been developed (Jordan, 2003b). Despite 
some improved pharmacokinetic and pharmacodynamic properties of most of the new 
compounds, clinical trials revealed no benefits of the new SERMs in terms of efficacy 
and tolerability in breast cancer therapy. Cross resistance to tamoxifen is another 
important problem on the search of usefull alternative SERMs (Jordan, 2003b). Up to 
date tamoxifen and raloxifene are the only SERMs available for the treatment of breast 
cancer and osteoporosis, respectively.  
As a second line therapy of hormone sensitive breast cancer the “pure ER antagonist” 
fulvestrant (ICI 182.780, FaslodexTM, cf. Figure A2) was introduced on the European 
market in 2004. Contrary to tamoxifen, the steroidal antiestrogen is completely devoid of 
any estrogenic activity and has been successfully applied in tamoxifen-resistant breast 
tumors in postmenopausal women (Robertson et al., 2001; Robertson et al., 2003). 
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Besides the effective blockade of the ER function, fulvestrant was shown to down-
regulate the ER and PR expression (Robertson, 2001). This phenomenon suggests a 
mode of action different from SERMs such as tamoxifen and lead to the designation 
“selective estrogen receptor down-regulator (SERD)”. 
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Figure A2:  Estrogen receptor ligands with clinical relevance: The SERMs tamoxifen and 
raloxifene and the full ER antagonist fulvestrant 
 
 
2.2 ER Subtype-Selective Ligands: Recent Advances 
 
Induced by the discovery of ERβ as the second ER protein about ten years ago, an 
intensive search for selective ligands of both receptor subtypes began. As ER subtype 
specific physiological functions are unknown to a large extent, the initial goal of 
developing selective ligands has been their application as pharmacolocical tools. 
 
In 2000 the synthesis and characterization of a library of pyrazole based compounds 
resulted in the 400-fold ERα selective highly potent agonist 1,3,5-tris(4-hydroxyphenyl)-
4-propyl-1H-pyrazole (“propylpyrazole triol”, PPT, cf. Figure A3) (Stauffer et al., 2000). A 
shortly later developed class of ERα selective agonists was based on a triphenylfuran-
scaffold (Mortensen et al., 2001). In vivo studies using PPT as a pharmacological tool 
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revealed that many classical estrogenic effects, such as uterotrophy, increase in bone 
mineral density and reduction of plasma cholesterol levels are mediated by ERα (Harris 
et al., 2002).  
Besides full agonists, a number of potent SERMs with selectivity for ERα such as 
triarylpyrazoles (Stauffer et al., 2001) or tetrahydroisoquinolines (Renaud et al., 2003) 
have been reported. In the field of nonsteroidal “pure ER antagonists” first advances 
towards ERα selectivity have been achieved with the recent development of 
diphenylfuran based compounds in our work group (cf. Figure A3) (Zimmermann et al., 
2005). 
 
NN
CH3
HO
HO OH
PPT O
CH3
NH3C
S
C5H11
HO OH  
 
Figure A3: The ERα selective agonist PPT and a 2,5-diphenylfuran-based moderately ERα 
selective “pure antagonist” 
 
Phytoestrogens were the first ER ligands to be characterized as moderately ERβ 
selective. The best known and most intensively studied isoflavone-type phytoestrogen 
genistein (cf. Figure A3) reveals an ERβ-selectivity of approximately 20-fold and was 
characterized as a full agonist via ERα but only a partial (50%) agonist via 
ERβ (Barkhem et al., 1998; Kuiper et al., 1998). 
A first synthetic breakthrough in the field of selective ERβ agonists was achieved with 
DPN (cf. Figure A3). The compound shows increased ERβ selectivity referred to binding 
(70-fold over ERα) and agonist activity (78-fold over ERα) compared to genistein and is 
a full agonist via ERβ (Meyers et al., 2001). More recent studies of the Wyeth Research 
Institute resulted in potent ERβ agonists with highest selectivities known up to date. The 
compounds are based on a benzofuran or benzoxazole scaffold bearing small 
hydrophobic groups in position C7 (cf. Figure A4). The ERβ selectivities reach up to 
100-fold in case of C7 substituted benzofurans and more than 200-fold in case of the 
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benzoxazole ERB-041, while their affinities for ERβ are comparable to 17β-estradiol. 
The C7-substituent was found to be an essential structural element to obtain the 
observed selectivities (Collini et al., 2004; Malamas et al., 2004). The molecular basis 
for this high selectivity affected by the small, relatively hydrophobic groups in position 
C7 was investigated in X-ray crystallography studies of benzofurans and benzoxazoles 
bound to the ERβ LBD. The 7-substituents extend into the relatively narrow groove 
formed by Ile 373, Ile367 and Phe 377. A substitution of the ERβ Ile 373 by a 
methionine mimicking ERα Met 421 is hypothesized to lead to a dropping binding 
affinity due to a combination of steric and electrostatic repulsion. The compounds 
named above were characterized as full agonists via ERβ in transcription assays using 
transfected cells overexpressing the recombinant ERβ. Furthermore the ERβ selective 
agonists were used as pharmacological tools for in vivo experiments to probe the 
physiological role of ERβ. For example, by using ERB-041 as ERβ selective agonist a 
role of ERβ in certain inflammatory diseases was demonstrated, while classical 
estrogenic effects were missing (Harris et al., 2003). This finding opened new field of 
potential clinical relevance of ERβ selective agonists 
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Figure A4:  Top: The partial ERβ agonist genistein and the full agonist DPN; bottom: Highly 
potent benzoxazole- (ERB-041) and benzofuran-based ERβ selective agonists. 
 
ERβ selective antagonists with selectivities comparable to agonists have not been 
described in literature. THC (cf. Figure A5) is a “pure antagonist” of ERβ that acts as an 
agonist via ERα. As a typical “antiestrogenic” side chain is lacking in the THC molecule, 
a “passive antagonism” has been proposed for its mode of action. In a high throughput 
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screening by the company Glaxo-Smith-Kline triazines were identified as SERMs with 
modest selectivity for ERβ. Structure optimization lead to a maximum selectivitiy of 26-
fold in the case of the compound depicted in Figure A5 (Henke et al., 2002). Structure 
and substitution pattern of the triazines are not conform to common nonsteroidal ER 
ligands such as stilbenes or corresponding ring closed analogues.  
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Figure A5:  The “passive” ERβ antagonist THC and a triazine based SERM with modest ERβ 
selectivity 
 
 
3 Molecular Mechanisms for Estrogen Action  
3.1 The Classical Pathway to Transcription Activation: Ligand Binding 
 
Estrogens exert their transcriptional activity by high affinity binding to a hydrophobic 
cleft localized in the LBD of ERα and ERβ. After binding of an estrogen, the ER 
dissociates from chaperone proteins, such as the heat-shock proteins Hsp90 and 
Hsp70, stabilizing the inactive receptor in a favorable conformation (Pratt and Toft, 
1997). The activated estrogen receptor dimerizes, interacts with the ERE in the 
promoter region of estrogen responsive genes and activates transcription through 
activation of AF-1 and AF-2. The ERE of ERα is a specific DNA region compromising 
two inverted palindromic half-sites separated by three non-defined nucleotides (5’-
AGGTCAnnnTGACCT-3’) (Schwabe et al., 1993). The two activation functions AF-1 
and AF-2 of ERα can mediate gene transcription independently, but in most cases they 
act synergistically in a cell-type and promoter context specific manner (Tzukerman et 
al., 1994). ERβ activates transcription similar to ERα and is capable of forming 
Molecular Mechanisms for Estrogen Action 9
functional heterodimers with the latter (Pace et al., 1997). Gene expression is not under 
direct control of the ERs. A number of coregulatory proteins (coactivators and 
corepressors) is involved as mediators in the transcription process that is not fully 
understood yet (Horwitz et al., 1996). Besides the classical ERE, several non-classical 
promoter sites, such as AP-1 have been identified. ERα stimulates gene expression 
through the AP-1 site indirectly by interacting with the DNA-bound transcription factors 
jun and fos. Contrary to ERα, the estradiol-ERβ complex was shown to inhibit 
transcription via the AP-1 promoter (Paech et al., 1997). 
Crystal structures of the ERα and ERβ LBDs bound to various ER ligands have been 
available since 1997. They enabled a detailed insight into the molecular basis for 
agonistic and antagonistic ER action. Location and affinity of ligands is determined by a 
combination of hydrophobic interactions and specific hydrogen bonds.  
The first crystal structure of ERα in complex with estradiol and raloxifene was published 
by Brzozowski and collegues (Brzozowski et al., 1997) (cf. Figure A6).  
 
 
BA 
 
Figure A6:  Arrangement  of estradiol (A) and raloxifen (B) in the binding pocket of ERα, 
adapted from (Brzozowski et al., 1997) 
 
The crystal structure of estradiol bound to the ERα LBD revealed two hydrogen bonds 
of the two hydroxy groups at both ends of the molecule. The phenolic hydroxy group 
localized at the A-ring of estradiol forms a multiple hydrogen bond to the carboxylate of 
Glu 353, the guanidinium group of Arg394 and an additional water molecule. Another 
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hydrogen bond is formed between the D-ring-hydroxy function and the His524 residue 
of the ERα binding pocket (cf. Figure A6 A).  
With its two phenolic hydroxy functions, the SERM raloxifen forms the same hydrogen 
bonds as estradiol, whereas the OH-group positioned at the heterocyclic phenol ring 
corresponds to the A-ring of estradiol. As a characteristic structural element of SERMs, 
the amine sidechain of raloxifen is additionally anchored to the receptor by a hydrogen 
bond between the carboxylate of Asp351 and the protonated piperidine nitrogen (cf. 
Figure A6 B). 
To be active as a full agonist of ERα, a ligand must be capable of being enveloped in 
the hydrophobic pocket that is closed by helix 12. The proper positioning of helix 12 
over the hydrophobic pocket is crucial for the recruitment of coactivators and 
subsequent initiation of RNA polymerase activity. By the bulky side chains of SERMs 
the repositioning of helix 12 is prevented, leading to a conformational arrest in the 
inactive state of the receptor. The crystal structure of raloxifene in the rERβ LBD 
suggests an analogous mechanism as demonstrated for ERα (Pike et al., 1999). The 
position of helix H12 was accepted as a general key mechanism for estrogenic and 
antiestrogenic activity. 
“Pure antagonists” generally have longer side chains than SERMs with additional 
functionalities at the outer extension. The crystal structure of ICI 164,384, bound to the 
ERβ LBD, suggests a “double blocking” effect of the extended side chain to the position 
of helix H12. The helix is prevented from sealing the ligand binding pocket and 
additionally from an alternative positioning along the coactivator binding site observed in 
the ER-SERM complex (Pike et al., 2001). Favored corepressor recruitment and 
neutralizing effects on AF-1 caused by the alternative H12 orientation were discussed 
as possible explanations for the full antagonism of fulvestrant and related compounds 
contrary to the partial antagonism of SERMs. 
The binding mode of the partial agonist genistein was analyzed in X-ray crystallographic 
studies in complex with ERβ. The crystal structure revealed hydrogen bonds between 
the 4’-hydroxy group of genistein and the Glu305-Arg346-water triad and between the 
phenolic hydroxy group in position C7 and His 457 respectively. In the ERβ-genistein 
complex, helix 12 was found to seal the binding pocket not totally in the manner as it is 
the case for full agonists (Pike et al., 1999). This different conformation of H12 was 
suggested as an explanation for the poor agonist activity of the phytoestrogen via ERβ. 
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A Similar conformation of H12 was also found for the “passive” ERβ antagonist THC 
bound to the ERβ LBD (Shiau et al., 2002).  
 
3.2 Cross-Talk Signaling Pathways: Estrogen Receptor Phosphorylation 
 
In several studies it has been shown that activation of the ER by estrogens is 
associated with increases in overall receptor phosphprylation. Five different 
phosphorylation sites have been mapped within the ERα protein, which are 
predominantly serine residues and in rare cases also tyrosine residues. A detailed 
review on phosphorylation sites and mechanisms is given by Lannigan (Lannigan, 
2003). 
ER activation was reported to be induced by several compounds that are not ligands of 
the ER, such as cyclic adenosine monophosphate (cAMP), dopamine, epidermal growth 
factor (EGF) and insuline like growth factor type 1 (IGF-I). As such agents are not able 
to stimulate the ER by the classical way of ligand binding, the denotations “non-
classical” or “ligand-independent” activation were formed. The growth factors and 
related compounds cross-talk with the ER in a complex system of cytoplasmic signaling 
pathways that involves cytoplasmic proteins or protein kinases leading to an ER 
phosphorylation (reviewed in (Driggers and Segars, 2002)). 
cAMP activated protein kinase A (PKA) has been shown to activate the ERα via 
phosphorylation in a ligand independent manner (Aronica and Katzenellenbogen, 1993). 
Furthermore, an increased cAMP level triggered by the G-protein activators IBMX and 
cholera toxin enhanced the 17β-estradiol induced transcriptional activity in ER positive 
MCF-7 breast cancer cells (Cho and Katzenellenbogen, 1993). In similar experiments, a 
cAMP induced cross-talk activation of ERβ has been shown in HeLa cells transfected 
with the ERβ gene, whereas a distinct mechanism in ERα and ERβ phosphorylation 
was demonstrated (Coleman et al., 2003). As PKA induced activation was reported to 
be involved in the development of tamoxifen resistance, it is of potential clinical 
relevance (Fujimoto and Katzenellenbogen, 1994; Michalides et al., 2004). Contrary to 
tamoxifen, the “pure ER antagonist” fulvestrant inhibits cAMP induced ER activation 
(Michalides et al., 2004). 
Another important cross talk activation of the ER is induced by growth factors such as 
EGF and IGF-1. EGF stimulates receptors of the EGFR family consisting of four distinct 
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members (EGFR/ErbB1/HER1, ErbB2/HER2/c-neu, ErbB3/HER3 and ErbB4/HER4) 
upon binding to the extracellular domain. The activated receptor undergoes 
dimerization, autophosphorylation at specific tyrosine residues and subsequently 
acquires the potential to activate a number of intracellular enzymatic activities. EGF can 
induce Erk1/2 / MAPK or phosphatidylinositol 3’-kinase (PI3K)/AKT pathways leading to 
ER phosphorylation and subsequent ligand independent activation (Smith, 1998). 
EGFRs - particularly HER2 - were found to be expressed in many tumors of the breast 
making them an important target for diagnosis and treatment of breast cancer. 
Furthermore the cross-talk between EGFRs and the ER was suggested as a possible 
molecular mechanism for the development of antiestrogen resistance (Osborne et al., 
2005). Similarly, IGF-I was shown to activate the ER mediated luciferase activity in 
MCF-7 breast cancer cells transfected with a luciferase reporter plasmid. The IGF-I 
induced cross-talk activation was blocked by the full ER antagonist fulvestrant, 
demonstrating the ER specificity (Hafner et al., 1996). 
The role of G-Protein coupled receptor (GPCR) mediated protein kinase C (PKC) 
signaling pathways in ER activation are less well understood than the PKA and growth 
factor pathways. GPCRs gained increasing interest in endocrine related cancer 
research in recent years. For example the neuropeptide Y (NPY) Y1 receptor, a 
peptidergic GPCR was found to be expressed in many human cancers. Cell type 
specific regulative effects of NPY on cancer cell proliferation have been reported 
(Körner and Reubi, 2007). NPY was recently shown to induce Erk1/2 phosphorylation in 
prostate cancer cells that was cell line specifically blocked by a PKC inhibitor (Ruscica 
et al., 2006). Cross-talk effects between the ER and the NPY Y1R in breast cancer cells 
remain to be investigated (cf. chapter D of this thesis). Furthermore, GPCRs can 
mediate the transactivation of growth factor receptors via tyrosin phosphorylation (Daub 
et al., 1997). Recently, it was shown that GPCR agonists such as thrombin or 
phospholipids can trigger an EGFR mediated signaling cascade in ER positive MCF-7- 
and ER negative MDA-MB-231 breast cancer cells (Hart et al., 2005). 
A simplified overview of important cross-talk activation pathways is given in Figure A7.  
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Figure A7:  Schematic overview of important cross-talk ER activation pathways; due to 
clearness, not all, but only some key signaling molecules and enzymes involved in 
cross talk-pathways are depicted. For abbreviations see glossary. 
 
 
4 Non Genomic Estrogen Action via Membrane Bound ER 
 
Some estrogen actions cannot be explained by the classical functions of nuclear ERα 
and ERβ as transcription factors. For example, estrogen was reported to rapidly rise 
cAMP levels by stimulation of the adenylyl cyclase (AC) (Aronica et al., 1994) and to 
trigger the mobilization of intracellular calcium (Morley et al., 1992) and 
inosityltriphosphate (IP3) (Le Mellay et al., 1997). As such effects are typical for 
membrane bound receptors, in particular GPCRs, a membrane ER (mER) was 
postulated in the 1990s. Evinger and Levin suggested a co-existent population of the 
nuclear ERα protein localized in the membrane (Evinger and Levin, 2005). Other 
studies demonstrated that estrogen induced Erk1/2 activation can occur independently 
of nuclear ERs as it also was observed in ER negative SKBR3 cells. The involvement of 
GPR30, so far known as an orphan GPCR, was suggested (Filardo et al., 2000). In the 
same study mechanistic investigations revealed an estrogen induced, GPR30 mediated 
transactivation of EGFR via activation of matrix metalloproteinase (MMP) and heparin 
bound (HB-) EGF release leading to Erk1/2 phosphorylation. GPR30 was originally 
cloned by Carmeci and coworkers within the scope of a differential screening study, 
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aiming on the identification of genes overexpressed in ER positive MCF-7 breast cancer 
cells but not in ER negative MDA-MB-231 cells (Carmeci et al., 1997). Besides in MCF-
7 and SKBR3 breast cancer cells, GPR30 was later reported to be expressed in 
estrogen responsive tissues such as breast, heart, brain and leucocytes (Filardo, 2002). 
Thomas and co-workers finally demonstrated that GPR30 bears a single high affinity 
binding site for 17β-estradiol in ER-/GPR30+ SKBR-3 breast cancer cells and ER- 
/GPR30- human embryonic kidney (HEK) cells transfected with a GPR30 construct. 
Besides 17β-estradiol, the classical antiestrogens tamoxifen and fulvestrant were 
reported to induce an increased cAMP level in cells overexpressing GPR30, suggesting 
an agonist function towards GPR30 (Thomas et al., 2005). Another group confirmed 
estrogen binding to GPR30 and demonstrated its functional coupling to calcium- and IP3 
pathways (Revankar et al., 2005). In this study GPR30 was found to be localized in the 
endoplasmatic reticulum of cells overexpressing the receptor by confocal microscopy 
using a fluorescent estradiol analogue. 
Recently, an agonist of GPR-30 named G-1 was identified by Bologna and co-workers. 
G-1 was reported to bind selectively to GPR30, but not to classical ERs and to trigger 
intracellular calcium mobilization selectively via GPR 30 (Bologa et al., 2006).  
Taken together, the existence of GPR30 as functional estrogen binding GPCR appears 
to be evident. However there are still some open questions concerning the location 
within the cell (membrane or endoplasmatic reticulum) as well as its actual function and 
physiolocical role. The large number of recent reports on GPR30 mediated cellular 
functions suggests a key role in non-genomic estrogen action, but other mechanisms 
involving the classical ERs or other receptors might also contribute to this complex 
signaling. Compounds that are exclusively active via GPCR30 or the classical ERs 
respectively might open new doors for the understanding of nongenomic estrogen 
functions. 
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 B  Scope and Objectives 
 
1 Scope and Objectives of the Thesis 
 
The discovery of an estrogen binding protein in the 1960s and the increasing knowledge 
about its key role in the growth and development of the majority of breast cancers 
opened the doors for antiestrogens in breast cancer therapy. For many years tamoxifen 
has been the drug of choice in adjuvant therapy and the treatment of advanced and 
metastasized estrogen receptor (ER) positive breast cancer. Ten years ago, the 
discovery of a second ER protein designated ERβ complicated endocrine research, 
because until then endocrinologists focused on the existence of only one receptor 
protein that was believed to mediate all estrogenic effects. The physiological roles of the 
two distinct ER subtypes, in particular in the tumorigenesis and the growth of breast 
cancer, are only understood to some extent.  
While highly selective agonists and moderately selective SERMs for both ER subtypes 
α and β are available, there is still a gap in the field of subtype selective “pure 
antagonists”. Compounds based on a diphenylfuran scaffold, that were recently 
developed in our group provide a first approach towards ERα selective “pure 
antagonists”, although the compounds with the highest selectivities are only weak 
antiestrogens (Zimmermann et al., 2005). Potent subtype selective ER antagonists are 
required as pharmacological tools to investigate, if cellular effects such as cross-talk 
signaling are subtype specific. Furthermore, ERα selective “pure antagonists” might be 
attractive candidates in the therapy of ER positive breast cancer, as ERα has been 
reported to be the main subtype involved in tumor growth. 
Therefore, one aim of this thesis was the development of new non-steroidal subtype 
selective pure antagonists of the estrogen receptor. 2-Phenylbenzofurans are known as 
ERβ selective agonists from literature and from our own studies performed during the 
past few years (Collini et al., 2004; Zimmermann, 2005). It was shown that the 
introduction of long functionalized side chains in position C3 of the benzofuran core 
leads to antagonists with high potency, but lack of subtype selectivity. Within the scope 
of this thesis side chains characteristic for pure ER antagonists have to be linked to 
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position C7 of the benzofuran molecule, as C7-substituents were recently shown to be 
crucial for ERβ selectivity of benzofurans and benzoxazoles. A straight forward 
Sonogashira coupling route should afford a 7-formyl-2(4-methoxypenyl) building block, 
which has to be linked to aliphatic Grignard-nucleophiles or Wittig-ylides via the 
benzaldehyde function.  
In the field of ERα selective ligands, tetrahydroisoquinolines (THIQs) were recently 
reported as ERα selective SERMs (Renaud et al., 2003; Renaud et al., 2005). In the 
present study, the replacement of the side chains in position C1 of the THIQ based 
SERMs by a long functionalized aliphatic side chain should give rise to full antagonists. 
The consequences of these structural modifications with respect to receptor binding and 
subtype selectivity had to be investigated. A published Bischler-Napiralski synthetic 
route, and an alternative route via a dihydroisoquinolone building block were evaluated 
regarding their applicability in an effective parallel synthesis in view of a library of THIQ 
based target compounds.  
Binding affinities and selectivities of all synthesized compounds were to be determined 
in a radiometric binding assay with recombinant ERα and ERβ proteins and compared 
to known reference compounds. For compounds revealing sufficiently high receptor 
binding, further in vitro characterization, namely regarding (ant)agonistic activity in a 
gene reporter transcription assay and antiproliferative activity in a cytotoxicity assay with 
human breast cancer cells, had to be carried out.  
The side chains of the devised THIQs are anchored via the chiral C1 atom to the THIQ 
core, yielding pairs of enantiomers, so that an appropriate method for enaniomeric 
separation had to be worked out. In order to identify eutomers and distomers, after 
successful resolution of the enantiomeric mixtures, the individual enantiomers had to be 
characterized with respect to ERα and ERβ binding . 
 
In recent years membrane bound receptors such as GPCRs and tyrosine kinases (e.g 
EGFRs) gained increasing interest in breast cancer research. Cytoplasmic signaling 
pathways mediated by membrane receptors were shown to activate the unoccupied 
nuclear ER via phosphorylation at specific serine residues. The NPY Y1 receptor (Y1R), 
a peptidergic GPCR was reported to be expressed in many human primary tumors with 
particularly high incidence (85%) and receptor densities in breast cancers (Körner and 
Reubi, 2007). In MCF-7 breast cancer cells the Y1R mRNA was recently shown to be 
up-regulated by estrogen (Amlal et al., 2006).  
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Within this project different breast cancer cell lines were selected to be analyzed with 
respect to Y1R expression on the protein level, using the recently developed Y1R 
selective radioligand [3H]-UR-MK114 (Keller et al., 2008). In different subclones of MCF-
7 breast cancer cells ER and Y1R expression had to be quantified using tritiated 17β-
estradiol or [3H]-UR-MK114, respectively. ERα and β subtype expression in the 
investigated MCF-7 sublines had to be analyzed by Western-Blots using specific 
antibodies on the protein level on one hand, and on the mRNA level by reverse 
transcription - polymerase chain reaction (RT-PCR) on the other hand. Furthermore, the 
effect of (anti)estrogens on Y1R protein expression in ER positive breast cancer cell 
lines had to be characterized. Available or newly synthesized (ant)agonists, selective for 
either ERα or ERβ, were considered to provide information on subtype specificity of 
estrogen induced Y1R expression. 
As reports on the function of Y1Rs in breast cancer cells are scarce and contradictory in 
part, NPY induced inhibition of adenyl cyclase activity and its effect on the mobilization 
of intracellular calcium were investigated. Moreover, efforts were made to explore, if 
ER-mediated transcriptional activity and cell proliferation depend on Y1R activation.  
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 C Synthesis and Biological Characterization of New 
Estrogen Receptor Ligands 
 
1 Pharmacological Test System 
1.1 Radiometric Binding Assay 
 
Radiometric binding assays are standard procedures in many academic and industrial 
research institutes. Target-specific binding is one of the most important criteria in the 
search for new drugs and pharmacological tools.  
In most cases, the concentration dependant displacement of a well characterized, target 
selective radioligand with high binding affinity by a tested compound is analyzed. The 
radioligand is applied at a constant concentration, while the concentrations of the test 
compounds vary within a certain range. In the case of the estrogen receptor, the tritiated 
endogenous ligand 17β-estradiol is commonly used as radioligand. In our group, a 
cytosol prepared from calf uteri was used for many years as estrogen receptor source. 
Since ERβ as the second ER subtype besides ERα was discovered about ten years 
ago and recombinant full length human ERα and ERβ proteins have become available, 
these proteins are used for the determination of receptor affinity by most researchers. A 
new binding assay using commercial human ERα and ERβ proteins was established in 
our group by Dr. Zimmermann (Zimmermann, 2005). Within the scope of this thesis, all 
compounds were characterized by their binding profiles using both recombinant ER 
subtypes. 
17β-Estradiol reveals similar affinities to both ER subtypes with KD values of 
approximately 0.35 for ERα and 0.2 for ERβ (given by Invitrogen / pan Vera as the 
manufacturer of the recombinant proteins). In all experiments [3H] estradiol was present 
at a concentration of 0.5 nM, guaranteeing the occupation of almost all binding sites. In 
each assay, the maximum number of occupied binding sites and the number of 
unspecific binding sites were determined by applying the radioligand alone and in 
presence of a 500-fold excess of unlabeled (“cold”) estradiol respectively. All new 
compounds and reference compounds including 17β-estradiol, 4-hydroxytamoxifen and 
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fulvestrant (ICI.182.780) were tested at six different concentrations each, covering a 
concentration range of two decades. According to this procedure, only the linear part of 
the displacement curve (20-80 % specific binding) was recorded. IC50 values 
(concentration of test-compound to inhibit specific radioligand binding by 50%) were 
determined after logit-log-transformation of the experimental data, where 
 
logit = log [displacement (%) / (total specific binding (100%) – displacement (%))] 
 
RBA (relative binding affinity) was calculated as the ratio of IC50 of estradiol and IC50 of 
test compound multiplied by 100. By definition the RBA value of the endogenous ligand 
17β-estradiol is 100.  
 
1.2 Luciferase assay 
1.2.1 Principles of the Gene Reporter Assay 
 
The luciferase assay is a very sensitive method for the determination of hormonal 
activity in vitro. In our research group, ER positive MCF-7 breast cancer cells were 
stably transfected with the plasmid ‘EREwtc luc’ harboring the ERE-controlled luciferase 
reporter gene (Meyer et al., 1994), isolated from the North American firefly Photinus 
pyralis (de Wet et al., 1987). The resulting subline has been termed MCF-7/2a and is 
routinely used in the screening of new compounds for estrogenic and antiestrogenic 
activity. Contrary to cell proliferation, gene expression is a very early event (proximal) in 
the estrogen signaling cascade and therefore exclusively mediated by the activation of 
the estrogen receptor. 
When the assay is run in the agonist mode, potential estrogens are incubated with the 
cells for 48-50 h, until the luciferase expression reaches its maximum level. The 
estrogenic effect is generally expressed as the percentage of the luminescence evoked 
by 17β-estradiol at a concentration of 1nM. In the antagonist mode, potential 
antiestrogens are incubated with the cells in the presence of 17β-estradiol as 
stimulating agent.  
The luciferase catalyses a reaction sequence known as firefly luminescence. The 
bioluminescence reaction requires the substrate D-luciferin and the cosubstrates ATP 
and Mg2+. During a two-step-reaction sequence, the substrate undergoes oxidative 
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decarboxylation, which results in the production of oxyluciferin and visible light (cf. 
Scheme C1). The mechanism of this enzymatic reaction has been reported elsewhere 
(White et al., 1969). 
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Scheme C1:  The luciferase catalyzed reaction 
 
 
1.2.2 Optimization of the Luciferase Assay 
 
In previous studies of our research group, the assay was performed using a 
commercially available luciferase assay kit (Promega). This procedure is rapid and 
convenient, but the screening of compound libraries is very expensive.  
To perform the assay, two buffers, the substrate D-luciferin and the co-substrates ATP 
and Mg2+, which are all included in the luciferase assay kit, are required. In initial 
experiments the feasibility of an economical method, using a self-made buffer system 
containig the substrate D-luciferin, purchased from a cheaper commercial source was 
explored, and the results were compared to those obtained with the luciferase assay kit. 
The buffers were based on tricine (N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine), 
adjusted to pH 7.8. Among several common buffers, tricine buffer was reported to least 
affect luciferase activity (Webster et al., 1980). Additives and concentrations were 
adopted from a published protocol (Brasier, 1990). The lysis buffer for the preparation of 
cell extracts was supplemented with the detergent TritonTM X-100, DTT and Mg2+. The 
second buffer, termed “luciferase assay buffer”, contained the co-substrates ATP and 
Mg2+. The selective calcium chelator EGTA (ethyleneglycoltetraacetic acid) was added 
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to both buffers. D-lucifrin was injected as a solution in luciferase assay buffer to the cell 
lysates. 
Luminescence is known to have a relatively short half-life in the range of seconds. 
Therefore, a possible enhancing or stabilizing effect of coenzyme A (CoA) on the 
luminescence signal was investigated in an exploratory experiment. Such effects of CoA 
to the luciferase signal have been described by several groups (Airth et al., 1958; Ford 
et al., 1995; Fraga et al., 2005). The concentration range for CoA was 50-100 µM 
according to a literature report (Fraga et al., 2005). It should be mentioned that the 
previously reported stabilizing effect of CoA on the luciferase signal was obtained with 
the purified enzyme, rather than in a cellular assays. 
Figure C2 shows the comparison of the signals measured with the new assay system in 
the presence and the absence of CoA with those obtained with the commercial 
luciferase assay kit. 
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Figure C1:  Comparison of luciferase signals in different assay systems 
Values represent means of triplicates ± SEM 
 
CoA had no significant effect to the luciferase signal up to a concentration of 100 µM. A 
possible explanation might be a stabilizing / enhancing effect of the detergent TritonTM 
X-100, a component of the lysis buffer on the luminescence signal, which cannot be 
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further enhanced by additives such as CoA. Effects of TritonTM X-100 on luciferase 
activity have been reported by Kricka and de Luca (Kricka and De Luca, 1982). 
When the assay was performed in the self-made tricine buffer system, the absolute 
signal was decreased by approximately a factor of 2 compared to the signal obtained 
with the luciferase assay kit. However, for the determination of (anti)estrogenic effects 
not the absolute signal, but the signal to noise ratio is decisive. Irrespective of the height 
of the signals, the basal luciferase activity was approximately 50% of the 17β-estradiol 
stimulated control in all assay systems tested. This basal luciferase expression is 
assumed to mainly result from hormones and growth factors present in FCS (fetal calf 
serum), a culture medium supplement, at low concentrations and from ligand 
independent ER activation. Attempts to lower basal estrogen activity by depriving FCS 
from small molecular components using the dextran-coated charcoal (DCC) method 
failed, as the proliferation of MCF-7/2a cells ceased, when FCS was replaced with 
charcoal treated fetal calf serum (ct-FCS). 
In a number of experiments the home-made tricine buffer system prooved to be 
appropriate for the reproducible determination of estrogenic and antiestrogenic activity. 
Thus, as alternative to the luciferase assay kit, an inexpensive and robust assay system 
was established for compound screening. 
 
1.3 Proliferation Assay Using Human Mammary Carcinoma Cell Lines 
 
Compounds revealing sufficient binding affinity and antiestrogenic potency in the 
luciferase assay were submitted to a microculture chemosensitivity assay described by 
Bernhardt et al. (Bernhardt et al., 1992). The assay relies on the quantification of cell 
mass by staining cells with crystal violet.  
Two different breast cancer cell lines were used for the characterization of the new 
compounds: MCF-7 cells are endowed with a relatively high estrogen receptor content, 
and their growth is estrogen dependent. This cell line was used to demonstrate an 
estrogen receptor mediated antiproliferative effect of new antiestrogens. As the level of 
estrogen receptor expression in MCF-7 cells is not stable during long culture periodes 
(Bernhardt et al., 1992; Leichtl, 1994), the sensitivity of the cells against aniestrogen 
treatment must be routinely monitored using potent reference antiestrogens such as 
fulvestrant (ICI 182.780) or 4-hydroxytamoxifen. Detailed information on ER expression 
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in different MCF-7 subclones is given in section D of this thesis. As the growth of MDA-
MB-231 cells is estrogen independent, these breast cancer cells are used to exclude 
unspecific toxic effects of (anti)estrogens.  
In each assay identically treated cells were fixed at different time points within a period 
of eight to ten days of incubation. Analyses of growth curves provide information on the 
type of drug action: In case of a cytotoxic effect cell proliferation is initially inhibited, but 
with progressing incubation, the cell density of the treated population approximates that 
of the corresponding vehicle control. In the case of a cytostatic effect, the optical density 
remains either on the level of the initial value or is slightly increased and stays at a 
certain plateau. Cytocidal effects are characterized by a decrease in cell density below 
the initial level, as the main part of the cell population dies. 
Corrected T/C (test/control) values (T/Ccorr.) are calculated as the ratio of the optical 
densities of treated to non treated cells. Each density is corrected by subtraction of the 
initial cell density T0. 
 
T/Ccorr. = (T-T0)/(C-T0) · 100% 
 
The corrected T/C values obtained after maximal incubation periods (end points) were 
plotted as a function of the concentration. From these graphs the IC50 values were 
determined as molar concentration, which is required to inhibit cell growth by 50 %. 
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2 2-Arylbenzo[b]furans  
 
Compounds based on the 2-(4-hydroxyphenyl)benzo[b]furan scaffold have been 
extensively investigated in our research group (Erber, 1989; Leichtl, 1994; 
Zimmermann, 2005). In these studies, the benzo[b]furan partial structure has been 
substituted with a hydroxy function in position C5 or C6 and a wide variety of different 
side chains in position C3 (cf. Figure C2). The side chains of the earlier studies reached 
from simple alkyl moieties to monofunctionalised long chains. Dr. Zimmermann 
synthesized a library of 6-hydroxy-2(4-hydroxyphenyl)benzofurans equipped with 
aforementioned substituents as well as a newly developed bifunctional side chain 
(Walter, 2002) in position C3 of the benzofuran. The design of the side chains will be 
explained in the next paragraph.  
The knowledge about the two subtypes of the ER, ERα and ERβ and a newly 
established binding assay using recombinant receptors enabled our group to screen the 
previously synthesized as well as the recent benzofuran libraries for subtype selectivity. 
In his studies, Dr. Zimmermann found, that C3-usubstituted 5- and 6-hydroxy 
benzofurans bind selectively to ERβ (~20 fold over ERα). Introduction of small 3-alkyl 
substituents lowered or abrogated the selectivitiy as in case of long thioether, sulfone, 
and bifunctional chains (Zimmermann, 2005). 
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Figure C2:  5-Hydroxy-2-(4-hydroxyphenyl)benzo[b]furans; B2 was synthesized by Dr. Leichtl 
(Leichtl, 1994) 
 
In recent studies the Wyeth Research Institute focused on the development of new ERβ 
selective agonists, also including 2-aryl-benzo[b]furans (Collini et al., 2004; Manas et 
al., 2004). A library of 2-arylbenzo[b]furans substituted with small relatively lipophilic 
groups in position C7 was synthesized and tested for ERα/ERβ binding selectivity. The 
majority of 7-substituted 2-(4-hydroxyphenyl)benzo[b]furans exhibited a higher 
selectivity for ERβ in comparison to the corresponding unsubstituted analogue B1. Co-
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crystallization experiments of the 7-substituted benzofurans in complex with ERβ show, 
that the C7 substituents extend into a narrow pocket formed by Ile 373, Ile367 and Phe 
377. ERβ Ile373 corresponds to ERα Met421, the residue of which is supposed to 
cause a higher steric repulsion with the benzofuran C7-substituent compared to the 
isoleucine residue, explaining the selectivity of the compounds in favor of ERβ.  
 
2.1 Design of Potential New ERβ-Selective 2-Arylbenzo[b]furan-based 
Antiestrogens  
 
As Dr. Zimmermann’s approach, developing new ERβ-selective antiestrogens by 
introducing “antiestrogenic” side chains into the benzofuran C3 position failed, a new 
strategy was followed. Inspired by the work of the Wyeth Research Institute, the 
approach for this study was the synthesis and biological evaluation of 2-(4-hydroxy)-
phenylbenzofurans with antiestrogenic side chains in position 7.  
Two types of side chains that should afford full antagonism were adopted from 
antiestrogens that have demonstrated high antiestrogenic potencies in previous studies 
of our research group (cf. Figure C3). The first type, the “monofunctional” side chains 
possess either a sulfanyl or a sulfonyl group in a distance of 9 or 10 carbon atoms from 
the benzofuran core. The “bifunctional” side chain has in addition to the sulfanyl group a 
basic methylamine function in place of the methylene group in position C7 of the side 
chain. This bifunctional chain with an additional terminal fluorination was first used by 
scientists in the research laboratories of Schering AG in Berlin to modify the structure of 
fulvestrant (ICI 182.780). The resulting steroidal antiestrogen was ZK191.703 (cf. Figure 
C3), which has shown a better oral bioavailability in comparison to fulvestrant 
(Hoffmann and Sommer, 2005). 
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Figure C3:  Potent steroidal and nonsteroidal antiestrogens 
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ERβ selective “pure antagonists” have not been described in literature. Such 
compounds would be useful tools for the investigation of ER subtype specific cellular 
functions, which is a topic in Chapter D of this thesis. 
 
2.2 Chemistry 
2.2.1 Synthesis of Side Chains 
 
The monofunctional side chains were synthesized from pentanethiolate, generated with 
sodium hydride, and added to a 4-fold excess of 1,10-dibromodecane (Biberger, 1996). 
The desired monosubstituted product and the bisubstituted byproduct were separated 
by column chromatography (cf. Scheme C2). 
 
CH3(CH2)4SH     +    Br(CH2)nBr Br(CH2)nSC5H11
NaH
1 n=8
2 n=9  
Scheme C2: Synthesis of thioether side chains 
 
The synthesis of the amine precursor of the bifunctional side chain is depicted in 
Scheme C3. The multi-step reaction started from ethyl-3-bromopropionate, which was 
converted by nucleophilic substitution with pentanethiolate to the corresponding sulfide 
3. Subsequent ester hydrolysis to 4, formation of the acid chloride 5 with oxalyl chloride 
and reaction with aqueous methylamine afforded the amide 6 that was reduced to the 
amine 7 by LiAlH4 (Walter, 2002). In further reactions, 7 was alkylated or acylated by 
residues attached to the pharmacophore. 
 
Br(CH2)2CO2C2H5 CH3(CH2)4S(CH2)2CO2C2H5
NaHCH3(CH2)4SH
3
KOH
CH3(CH2)4S(CH2)2CO2H
4
(COCl)2
CH3(CH2)4S(CH2)2COCl
5
H2NCH3
CH3(CH2)4S(CH2)2CONHCH3
6
LiAlH4
CH3(CH2)4S(CH2)3NHCH3
7
+
 
Scheme C3: Synthesis of the amine precursor for bifunctional side chains 
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Phosphorous ylid 9 was required as Wittig reagent to build up the bifunctional side chain 
in the benzofuran C7 position. The synthesis of 9 started from 5-bromovaleric acid, 
which was converted by SN reaction with triphenylphosphine to the triphenyl-
phosphonium bromide 8 (Bhalerao et al., 1970). Deprotonation to the corresponding 
phosphorous ylid 9 was achieved by LiN(SiMe3)2 (Horillo-Martinez et al., 2007) (cf. 
Scheme C4). 
 
Br(CH2)5COOH Ph3P(CH2)5COOH + BrPPh3
8
+ Ph3P OLi
O9
LiN(SiMe3)2
Scheme C4: Synthesis of phosphonium ylid 9 from 5-bromovaleric acid 
 
2.2.2 Synthesis of the 2-Aryl-7-formylbenzofuran Building Block 
 
The 2-aryl-7-formyl benzofuran building block can be synthesized in a one-pot 
Sonogashira coupling and cyclisation. The palladium(0) / copper(I) catalyzed reaction 
requires a halogenated aryl component that is coupled to an acetylene moiety. Due to 
their high reactivity, aryliodides as starting materials are the first choice in this type of 
reaction. Starting from 2-hydroxy-5-methoxybenzaldehyde iodination in position 3 was 
achieved by the iodination reagent tetraethylammonium diacetoxyiodate (Doleschall and 
Toth, 1980; Hart and Mannino, 1996) in 36% yield (cf. Scheme C5).  
 
H
O
OH
I
MeO
H
O
OH
MeO 10
Et4NI(OAc)2
H
O
OH
Br
MeO
11
36%
62%
-15 °C
Br2
HOAc / NaOAc
 
Scheme C5: Iodination and bromination of 2-hydroxy-5-methoxybenzaldehyd 
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Conventional iodination methods were also tested using the model compound methyl-5-
methoxy salicylate. The iodination of this educt by iodine and KOH has been described 
in a recent publication (Collini et al., 2004). As reported by other groups (Kometani et 
al., 1985; Hart and Mannino, 1996) the iodination by this method as well as by a mixture 
of chloramine T and sodium iodide lead almost exclusively to the formation of the biaryl 
product 12 (cf. Scheme C6). 
 
HO
OH H
MeO
MeO
O
OMe
O
12
I2, KOH
or: NaI, Chloramine-T
OMe
O
OH
MeO
 
 
Scheme C6: Formation of biaryl 12 by conventional iodination methods 
 
For the preparation of the aryl iodides the only successful synthetic route required 
strictly controlled conditions and a long reaction time, while the yield was very 
moderate. Alternatively, the corresponding bromo analogue 11 was synthesized in a 
fast and simple reaction with bromine in acetic acid/sodium acetate (Evano et al., 2004) 
(Scheme C5). Amounting to 62%, the yield in this bromination reaction was acceptable. 
The aryliodides and arylbromides were then coupled to 4-ethinylanisol in a Sonogashira 
coupling reaction (Arcadi et al., 1986). The furan ring was closed in situ via the free 
hydroxy group and the product 13 was formed in a single step (Scheme C7). Due to the 
relatively mild coupling conditions, the aldehyde function was retained.  
 
H
O
OH
X
MeO
10 X = I
11 X = Br
O
HO
MeO
OMe
H OMe
Pd(PPh3)2Cl2, 
NaI, CuI, HNEt2, DMF
13
X = I: 2h, 61%
X = Br: 14h, 46%  
 
Scheme C7:  Sonogashira coupling of iodo- and bromoaryl 10 and 11 with 4-ethinylanisol to 
the 2-aryl-7-formyl benzofuran building block 13 
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Starting from aryliodide 10, with 2 h and 61% the reaction time was shorter and the yield 
higher compared to 14 h and 46 % in case of arylbromide 11 as starting material. The 
overall yield of the two steps from 2-hydroxy-5-methoxybenzaldehyde to the building 
block 13 was 22 % via the iodide and 29 % via the bromide. Because of this slight 
difference in the overall yield and the fact, that the bromination was much faster and 
easier, the route via bromide 11 was preferred for up-scaling. 
 
2.2.3 Introduction of Aliphatic Side Chains 
 
The alkyl groups were linked to the aldehyde function in the benzofuran C7 position by 
Grignard reaction. The commercially available or synthesized alkylbromides were 
converted into Grignard reagents by reaction with elementary magnesium. The Grignard 
nucleophiles attacked the aldehyde 13 to give the secondary alcohols 14-17. 
Dehydratation under catalysis with p-toluenesulfonic acid led to the E-olefins 18-23. In 
the case of compounds 20 and 21, bearing thioether side chains, the sulfur was 
oxidized by meta-chloroperbenzoic acid to the corresponding sulfones 22 and 23. The 
methoxy protecting groups were cleaved throughout by BBr3 (Scheme C8). Mechanistic 
and experimental details to this ether cleavage will be given in the next paragraph.  
 
O
HO
MeO
OMe
13
O
MeO
OMe
14, 18, 24 R = CH3
15, 19, 25 R = CH2CH3
16, 20, 26 R = (CH2)7SC5H11  
17, 21, 27 R = (CH2)8SC5H11
R
MCPBA
O
MeO
OMe
R
HO
TosOH BBr3
24-29
RCH2MgBr
14-17
22 R = (CH2)7SO2C5H11
23 R = (CH2)8SO2C5H11
20, 21
O
HO
OH
R
18-23
28-29
BBr3
Scheme C8:  Synthetic route to 7-alkenyl benzofurans  
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Certain functional groups such as amines, amides, carboxylic acids and esters are not 
compatible with the Grignard reaction. Such groups are included in the bifunctional side 
chain itself or its synthetic precursors. Therefore the synthetic strategy, to attach a 
bifunctional side chain to the 7-aldehyde function of 13 was different from the one 
described for the other side chains. 
The key reaction was a Wittig olefination of the benzaldehyde derivative 13 with the 
phosphourous ylide 9, which was prepared as described in paragraph 2.2. Generally the 
E/Z stereoselectivity in the Wittig reaction is controlled by the properties of the 
phosphorous ylide. Compound 9 is a so-called labile ylide, as the electron donating alkyl 
chain effects a destabilization of the nucleophilic carbanion. Labile ylides commonly 
lead to Z selectivity. As an exception of this rule, the ω-carboxyl ylide 9 afforded the 
corresponding Wittig olefin 30 with a slight E-selectivity. Such directing effects of 
nucleophilic groups in appropriate distance to the ylide-phosphorous have been 
described in previous publications (Maryanoff et al., 1985; Ding et al., 1995). The 
stereoselectivity is of minor importance, as in the final deprotection step the the E-
olefine is formed almost quantitatively. 
 
O
HO
MeO
OMe
13
Ph3P OLi
O9
O
MeO
OMe
OH
O
30
O
MeO
OMe
SC
EDC, HOBt, DIPEA O
HO
OH
SC
BBr3
31, 32 SC = (CH2)3CON(CH3)(CH2)3-S-C5H11
33 SC = (CH2)4N(CH3)(CH2)3-S-C5H11
LiAlH4
31 32
-15 °C
C5H11
S
H
N
CH3
7
32
E : Z = 65 : 35
E : Z = 65 : 35 E : Z = 99 : 1
E : Z = 94 : 6  
Scheme C9:  Synthetic route to the 2-(4-hydroyxphenyl)benzofuran with a bifunctional sidechain 
in position C7  
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Amine 7 was attached to the carboxylic group of 30 by the coupling reagents EDC and 
HOBt to obtain amide 31. The reaction sequence ended with the cleavage of the 
methoxy groups and the final reduction of amide 32 to the amine 33 (cf. sheme C9).  
In all of the synthesized test compounds, the methyl ether cleavage with BBr3 required a 
careful control of the reaction progress. In previous works of our group a reaction time 
of 7 h for the deprotection of 3-substituted benzofurans (Zimmermann, 2005) was 
reported. In the case of the 7-(alk-1-enyl)benzofurans, after 7 hours the compounds 
decomposed. Acceptable yields were obtained after reaction times of 1.5-2 h. This 
difference might possibly be due to a tautomeric stabilization (cf. Scheme C10) of the 
R2O+-BBr2 intermediate at the ring oxygen by the C1-C2 doublebond in the sidechain. 
This effect possibly favors the opening of the heterocyclic benzofuran ring, which might 
be responsible for the observed decomposition of the compounds after long reaction 
periods. 
As detected by proton NMR spectroscopy, deprotection of the E/Z mixture 31 with BBr3 
afforded 32 as an almost pure E olefin. A proposed mechanism for the doublebond 
inversion is depicted in Scheme C10. 
 
O
MeO
OMe O
O
OBBr3
BBr2
BBr2
R
R
O
O
BBr2
BBr2
R
H2O
 B(OH)3 + HBr
O
HO
OH
R
2 MeBr
Br2B
Br
Br
O
BBr2
O H
H  
Scheme C10:  Proposed mechanism for the BBr3 induced doublebond inversion 
 
A second isomeric form of the intermediate is possible, when the BBr2+ is shifted from 
the benzofuran ring-oxygen to the side chain position 2, while 3-electron-pairs are 
delocalized. The second isomer bears a single bond between C1 and C2 of the side 
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chain, which is able to rotate. This proposed mechanism explains, why only the thermo-
dynamically favored E olefin was almost exclusively formed. 
An overview of all synthesized test compounds based on a benzofuran scaffold is given 
in table C1. 
 
Table C1: List of synthesized 2-phenylbenzofurans 
                                              
O
OH
HO
R  
 
Comp. 
 
R 
 
24 
 
-CH3 
25 -CH2-CH3 
26 -(CH2)7-S-C5H11 
27 -(CH2)8-S-C5H11 
28 -(CH2)7-SO2-C5H11 
29 -(CH2)8-SO2-C5H11 
32 -(CH2)3-CO-N(CH3)-(CH2)3-S-C5H11 
33 -(CH2)4-N(CH3)-(CH2)3-S-C5H11 
 
 
2.3 Biological Characterization of the 2-Phenylbenzofurans 
2.3.1 Binding Affinities to Human Estrogen Receptors (ERα and ERβ) 
 
Synthesized compounds and reference compounds were submitted to the competitive 
[3H]-17β-estradiol binding assay. The relative binding affinities for both receptor 
subtypes are depicted in table C2. 
IC50 values were determined by liner regression of the logits as a function of the 
logarithmic concentrations, comprising at least 4 data points. Generally the slopes of the 
linear regression functions were comparable to the slope of the logit-log-plot of 17β-
estradiol, indicating a competitive binding mechanism. 
Synthesis and Biological Characterization of New ER Ligands 40 
The RBA values of all synthesized benzofurans and reference compounds are listed in 
table C2. 
 
Table C2: Binding affinities of 2-phenylbenzofurans 
 
                                       
O
OH
HO
R  
 
Comp. 
 
 
R 
 
RBAa 
ERα 
RBAa 
ERβ 
 
24 
 
Me 1.0 ± 0.4 34 ± 7 
25 Et 0.57 ± 0.14 11 ± 2 
26 (CH2)7SC5H11 <0.01 n.d. 
27 (CH2)8SC5H11 <0.01 n.d. 
28 (CH2)7SO2C5H11 0.080 ± 0.021 0.65 ± 0.43 
29 (CH2)8SO2C5H11 0.066 ± 0.013 0.47 ± 0.29 
32 (CH2)3CON(CH3)(CH2)3SC5H11 < 0.02 < 0.02 
33 (CH2)4N(CH3)(CH2)3SC5H11 2.7 ± 0.5 0.77 ± 0.01 
 
B1b 
 
 5.2 109 
B2b  4.3 8.8 
 
E2 100 100 
Hexestrol 
 
14 ± 5 10 ± 3 
 
aRBA = IC50(E2) / IC50(test-compound) · 100; Values represent means of at least two indepen-
dent determinations ± SEM; bdetermined by Dr. Zimmermann (Zimmermann, 2005) 
 
Among the synthesized compounds, the 2-phenylbenzofurans with small alkenyl 
substituents in 7-position showed the highest affinities. Compound 24, with a 7-propenyl 
moiety, revealed an RBA value for ERβ of 34 and a selectivity of >30 fold over ERα. For 
25 the affinities for both subtypes decreased and the selectivity was about 20-fold. 
Compared to the unsubstituted benzofuran B1 the total binding affinity of 24 was 
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reduced, but the selectivity was significantly increased. This result confirms a recent 
publication on 7-substiuated highly ERβ selective benzofurans (Collini et al., 2004).  
The long thioether side chains in compounds 26 and 27 abolished binding affinity up to 
micromolar concentrations. Compounds 28 and 29 are moderate binders at ERβ with 
RBA values in the range of 0.5 with around 10 fold selectivities over ERα. Compared to 
compound B2 with a sulfone side chain in position 3 the affinity is strongly decreased, 
when the side chain is moved to position 7. On the other hand the ERβ selectivity of 28 
and 29 is higher, as it is only two fold for B2. 
The binding profile of 33 with a bifunctional side chain is totally different from the other 
synthesized compounds. Surprisingly the compound binds preferably to ERα with a 
relatively high RBA of 2.7. From many examples the basic amine group in the side 
chain is known to form an essential hydrogen bond to the carboxylate of Asp351 in the 
ER binding pocket. This additional binding might effect, that the binding mode of 
compound 33 is different from the other benzofurans without an amine group in the side 
chain. Compound 32 bearing an amide side chain does not bind to any ER subtype up 
to micromolar concentrations. This underlines the theory of an additional binding effect 
of the basic amine group in the side chain of 33.  
 
2.3.2 Determination of Estrogenic and Antiestrogenic Activity in the Luciferase 
Assay 
 
The synthesized compounds were tested for estrogenic and antiestrogenic effects in the 
luciferase assay (cf. Figure C3 and C4). 24 and 25 were weak agonists in the 
micromolar range. At a concentration of 3 µM, both compounds induced a normalized 
lucifease activity of 80 % compared to 1nM 17β-estradiol.  
 
In the antagonist mode, compounds 28 and 29 with sulfone side chains showed no 
inhibition of the 1 nM 17β-estradiol induced luciferase activity. Compound 33 with a 
bifunctional side chain proofed to be a poor antiestrogen. At a concentration of 3 µM the 
relative luciferase activity was still 40% of the 17β-estradiol control. For comparison, the 
“pure antagonist” fulvestrant reduced the E2 induced bioluminescence to 20% of the 
control (cf. Figure C4).  
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Figure C3:  Estrogenic effects of benzofurans 24 and 25 in stably transfected MCF-7/2a cells 
 The luciferase activity induced by 1nM 17β-estradiol was set to 100% 
 
Summarizing all the results from the luciferase assay, none of the compounds revealed 
a remarkable estrogenic or antiestrogenic effect. The strongest antiestrogenic effect 
was achieved by compound 33, while binding experiments revealed a slight preference 
for ERα. All of the other benzofurans investigated in the luciferase assay showed some 
selectivity for ERβ, but with moderate binding affinities. This suggests ERα as the 
subtype which is mainly responsible for estrogenic activity in MCF-7/2a cells. Co-
transfection assays with recombinant ERα or ERβ and an estrogen responsive gene 
reporter in an appropriate cell line might reveal subtype specific actions of synthesized 
compounds. Such assays have not been available for this study.  
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Figure C4:  Effect of 2-phenylbenzofurans 28 and 29 with sulfone side chains (top) and 
compound 33 bearing a bifunctional side chain (bottom) on the 17β-estradiol-
induced luciferase expression. 
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3 Estrogen Receptor Ligands Based on a Tetrahydroisoquinoline 
Scaffold 
 
In terms of biological activity, 1,2,3,4-tetrahydroisoquinolines (THIQs) were first 
described in 1985 (Nagarajan et al., 1985). In this publication, the inhibitory activity on 
the attachment of the blastocyst to the epithelial lining of the uterus (“antiimplantation”) 
by a library of 1,2-diaryl-THIQs was demonstrated. Almost 20 years later, this class of 
compounds was re-discovered by scientists at Novartis in a high throughput screening, 
aiming at the discovery of new SERMs (Renaud et al., 2003). To optimize this “hit”, a 
series of new 1,2-diaryl-THIQs bearing side chains characteristic of SERMs at position 
1 of the THIQ moiety was synthesized by varying of the substituents at the nitrogen. 
Most of the compounds exhibited high binding affinities and marked selectivities for 
ERα (Renaud et al., 2003; Renaud et al., 2005). A hydroxy group at the meta position of 
the aniline partial structure was shown to be favorable for preferential binding to ERα. A 
research group at Pfizer published other subtype-selective THIQs with various N-
substituents such as benzyl, sulfonyl or trifluoroacetyl (Chesworth et al., 2004). 
 
 
3.1 Design of Potential ERα Selective “Pure Antagonists”  
 
The strategy of combining partial structures of known ERα-selective ligands with typical 
“antiestrogenic” side chains was partly successful in a recent study of our reaearch 
group (Zimmermann et al., 2005). Here the diphenylfuran core was adopted from ERα 
selective triphenylfurans published by others (Mortensen et al., 2001). A similar strategy 
was applied in this study, aiming at the synthesis of new ERα selective antagonists with 
a THIQ scaffold. Therefore the 1-aminoethoxyphenyl-group of the described THIQ-
based SERMs was replaced by established “antiestrogenic” side chains (cf. paragraph 
2.1).  
New potent ERα-selective full antagonists are useful as pharmacological tools to study 
subtype specific cellular effects. Additionally, such agents might be beneficial for breast 
cancer therapy, as ERα is claimed to be the main subtype involved in the proliferation of 
hormone sensitive breast cancer cells.  
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3.2 Chemistry 
 
The tetrahydroisoquinolines were prepared via a previously published route involving a 
Bischler Napiralski cyclization (Nagarajan et al., 1985). The corresponding amide 
precursors were prepared by coupling of an appropriate phenylethylamine derivative to 
the aliphatic side chain activated as carboxylic acid chloride.  
 
3.2.1 Synthesis of Side Chains 
 
The thioether side chains were prepared from ω-bromo-carboxylic acid ethylesters 34 
and 35 and pentanethiolate to obtain the thioethers 36 and 37. Successive ester 
hydrolysis by KOH and chlorination with oxalyl chloride afforded the carboxylic acid 
chlorides 40 and 41 (cf. Scheme C11), which were ready to use for coupling to the 
phenyletylamine precursors  
 
Br(CH2)nCOOEt
34, 35
HSC5H11
H11C5S(CH2)nCOOEt
KOH
H11C5S(CH2)nCOOH
36, 37 38, 39
H11C5S(CH2)nCOCl
(COCl)2
40, 41
34, 36, 38, 40 n = 9
35, 37, 39, 41 n = 10
 
Scheme C11:  Preparation of thioether side chains. 
 
For the synthesis of the sulfone side chain, thioether 37 was oxidized by MCPBA. The 
following steps were the same as described for the thioether side chains to obtain the 
carboxylic acid chloride 44 (cf. Scheme C12). 
 
H11C5S(CH2)10COOEt H11C5SO2(CH2)10COOEt
37 42
KOH
 43
MCPBA
(COCl)2
 44
H11C5SO2(CH2)10COOH
H11C5SO2(CH2)10COCl
 
Scheme C12:  Preparation of the sulfone side chain. 
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As precursor for the amine side chains 7-bromoheptanoic acid chloride was prepared 
from ethyl-7-bromoheptanoate by ester hydrolysis with LiOH and chlorination with oxalyl 
chloride (cf. Scheme C13) 
 
Br(CH2)6COOHBr(CH2)6COOEt Br(CH2)6COCl
LiOH (COCl)2
45 46  
Scheme C13:  Preparation of 7-bromoheptanoic acid chloride 
 
 
3.2.2 Synthesis of N-Aryltetrahydroisoquinolines 
 
As depicted in Scheme C14, the synthesis of N-aryltetrahydroisoquinolines started from 
2-phenyl-acetic acid derivatives 47 and 48, which were chlorinated by oxalyl chloride to 
the corresponding acid chloride that was coupled to aniline or 3-methoxyaniline to yield 
the amides 49 and 50.  
 
O
R1 COOH
47 R1 = Bn
48 R1 = Me
1. (COCl)2
2. NH2
R2
O
R1
N
H
R2
49 R1 = Bn, R2 = H
50 R1 = Me, R2 = OMe
N
H
O
R2O
R1
LiAlH4
51 R1 = Bn, R2 = H
52 R1 = Me, R2 = OMe
N R2O
R1
R3O
R3 COCl
1. POCl3
2. NaBH4 O
R1
N R2
R3
53, 61 R1 = Bn; R2 = H; R3 = CH2CH3
54, 62 R1 = Bn; R2 = H; R3 = (CH2)2CH3
55, 63 R1 = Bn; R2 = H; R3 = (CH2)9SC5H11
56, 64 R1 = Bn; R2 = H; R3 = (CH2)10SC5H11
57, 65 R1 = Bn; R2 = H; R3 = (CH2)10SO2C5H11
58, 66 R1 = CH3; R2 = OCH3; R3 = CH2CH3
59, 67 R1 = CH3; R2 = OCH3; R3 = (CH2)10SC5H11
60, 68 R1 = CH3; R2 = OCH3; R3 = (CH2)10SO2C5H11
53-60
61-68
 
 
Scheme C14:  Synthetic route to a library of THIQs.  
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After reduction with LiAlH4 the phenylethylamine building blocks 51 and 52 were 
obtained. 51 and 52 were then linked to propionyl and buturyl chloride as well as the 
long-chaine carboxylic acid chlorides described in paragraph 3.2.1 to form the amides 
53-60. 
Refluxing in POCl3 afforded the dihydroisoquinolinium salts, which were directly 
reduced to give the tetrahydroisoquinolines 61-68. Amide coupling and Bischler-
Napiralski-cyclisation worked in good to excellent yields throughout. 
When ω-bromoheptanoyl amides 69 and 70 were converted into the tetrahydro-
isoquinolines, the bromine was almost totally exchanged by chlorine (cf. Scheme C15). 
As the two products could not be separated chromatographically and both are synthetic 
equivalents for the alkylation of amines, the mixtures of chlorides 71a and 72a and the 
side products 71b and 72b were directly used for further transformations. 
 
N R2O
R1
(CH2)6BrO
O
R1
N
R2
(CH2)6Br
1. POCl3
2. NaBH4 O
R1
N
R2
(CH2)6Cl
+
51, 52
Br(CH2)6COCl
69 R1 = Bn, R2 = H
70 R1 = Me, R2 = OMe
71a (92%)
72a (85%)
71b (8%) 
72b (15%)
69, 70
71a, 71b: R1 = Bn, R2 = Ph
72a, 72b: R1 = Me, R2 = 3-methoxyphenyl  
 
Scheme C15:  Introduction of the alkylbromide chain and Bischler Napiralski cyclisation. 
 
The chlorides 71a and 72a contaminated with their corresponding bromo analogues 
71b and 72b were refluxed for three days with an excess of pyrrolidine in ethanol to 
obtain compounds 73 and 74. As a synthetic alternative, for the introduction of the 
piperidine group, the mixture of 72a and 72b together with an excess of piperidine in 
ethanol was heated for 10 min to 180 °C under microwave-assistance. The 
chloride/bromide side chain of 71a/71b was also converted into a bifunctional sidechain 
by reaction with amine 7 to afford 76 (cf. scheme C16). To complete this reaction, reflux 
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for 7 days was required. All amines were obtained in good yields (75-88%) with 
exception of compound 74 (49%). 
 
HN
CH3
S
C5H11
NEt3, EtOH, reflux O
Bn
N
Ph
(CH2)6N(CH3)(CH2)3SC5H11
71a/71b
O
R1
N
R2
(CH2)6
73 R1 = Bn; R2 = Ph; n = 1 
74 R1 = CH3; R2 = 3-methoxyphenyl; n = 1
75 R1 = CH3; R2 = 3-methoxyphenyl; n = 2
NEt3, EtOH, 
reflux or microwave
71a/71b, 72a/72b
76
HN
n
N n
7
 
Scheme C16:  Transformation of the alkyl chlorides/bromides 71a / 71 b and 72a / 72b to the 
amine side chains. 
 
As bromides are much more reactive than chlorides in alkylation reactions, an 
alternative route to THIQs with amine side chains was performed. Amine 7 was fused to 
bromide 70 prior to Bischler Napiralski cyclisation (cf. Scheme C17). The reaction 
yielded THIQ 78 in an overall yield of 63%. This synthetic route was not successful in 
the case of pyrrolidine and piperidine, as the intermediate after the nucleophilic 
substitution could not be isolated.  
 
Tetrahydroisoquinolines 49 
70
HN
CH3
S
C5H11
NEt3, ETOH, reflux N OMeMeO
(CH2)6N(CH3)(CH2)3SC5H11O
77
MeO
N
N
H3C S
C5H11
78
1. POCl3
2. NaBH4
77 OMe
7
 
 
Scheme C17:  Alternative route to a THIQ with a bifunctional side chain: Alkylation prior to 
Bischler Napiralski cyclisation 
 
The last step to the final tetrahydroisoquinlines was the cleavage of the benzyloxy and 
methoxy protecting groups. The benzyloxy groups were cleaved by heating in a mixture 
of HCl in dioxane. The two methoxy groups of the second series of compounds were 
removed by BBr3 (cf. Scheme C18). 
To obtain compounds containing sulfur atoms of different oxidation states in the side 
chain, initially a straight-forward strategy was followed to prepare the thioethers to be 
subsequently oxidized on a late step of the reaction sequence. In case of the THIQs the 
compounds were decomposed when the thioether was tried to be oxidized to the 
sulfone by MCPBA. With hydrogenperoxide as oxidation reagent the thioethers were 
successfully oxidized to sulfoxides as the very last step (cf. Scheme C18). The reaction 
at room temperature stopped after conversion to the sulfoxide. Heating should bring 
along further oxidation to the corresponding sulfone, but under these conditions the 
THIQs were unstable again. Thus, it was necessary to introduce the sulfone side chain 
from the beginning as described above (cf. Scheme C14), although this route was more 
time consuming. 
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61-65, 73, 76
HCl, dioxane
90 °C HO
N
R
79 R = CH2CH3 
80 R = (CH2)2CH3
81 R = (CH2)9SC5H11                                      
82 R = (CH2)10SC5H11                                 
83 R = (CH2)10SO2C5H11
84 R = (CH2)6N(CH2)4
85 R = (CH2)6N(CH3)(CH2)3SC5H11
H2O2, AcOH 86 R = (CH2)9SOC5H11
87 R = (CH2)10SOC5H11
66-68, 74, 75, 78
BBr3
HO
N
R
88 R = CH2CH3                              
89 R = (CH2)10SC5H11 
90 R = (CH2)10SO2C5H11
91 R = (CH2)6N(CH2)4
92 R = (CH2)6N(CH2)5
93 R = (CH2)6N(CH3)(CH2)3SC5H11
H2O2, AcOH 94 R = (CH2)10SOC5H11
OH
 
 
Scheme C18:  Deprotection and sulfur oxidation to the final THIQs 
 
 
3.2.3 N-Trifluoroacetyl and N-Phenylsulfonyl Substituted Tetrahydroisoquino-
lines 
 
Inspired by a recent publication (Chesworth et al., 2004), tetrahydroisoquinolines 
substituted with a 1-phenylsulfonyl- or a 1-trifluoroacetyl group instead of a 1-aryl 
substituent were synthesized. The N-unsubstituted phenylethylamine derivative 96 was 
synthesized starting from 3-methoxybenzaldehyde following a published procedure 
(Kashdan et al., 1982). A benzoyl substituent as well as a thioether- and sulfone side 
chain were fused to the amine by amide coupling with the corresponding acid chlorides 
described in paragraph 3.2.1. The amides were converted to the N-unsubstituted THIQs 
100-102 by Bischler Napiralski cyclisation (cf. Scheme C19).  
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MeO
O
H
MeO
CN
O
O
OEt
H2 / PdC
EtOH, H2SO4 MeO NH2
95 96
KCN
0°C        r.t.
ClCOOEt
RCOCl
MeO N
H
R
O NH
R
1. POCl3
2. NaBH4 MeO
96
97-99 100-102
97, 100 R = Ph
98, 101 R = (CH2)10SC5H11
99, 102 R = (CH2)10SO2C5H11  
 
Scheme C19:  Synthesis of 3-methoxyphenylethylamine and Bischler-Napiralski cyclisation to 
the N-unsubstituted THIQs.  
 
The trifluoroacetyl group was coupled to the amine function of 100-102 by trifluoroacetic 
anhydride. Methoxy deprotection afforded the final trifluoracetates 106-108 containing a 
phenyl substituent as well as thioether and sulfone side chains in position 1. The 
coupling reactions of 101 and 102 with phenylsulfonylchloride followed by demethylation 
afforded 111 and 112. Finally the thioether side chains were oxidized to the sulfoxides 
by hydrogenperoxide (cf. Scheme C20). 
 
ClSO2Ph
N
R
MeO
N
R
MeO
CF3
O
SO2Ph
103, 106 R = Ph
104, 107, 109, 111 R = (CH2)10SC5H11
105, 108, 110, 112 R = (CH2)10SO2C5H11
H2O2, AcOH
BBr3
BBr3
N
R
HO
CF3
O
N
R
HO
SO2Ph
100-102
103-105
109, 110
106-108
111, 112
107, 111 113, 114
THIQ-(CH2)10SOC5H11THIQ-(CH2)10SC5H11
F3C O CF3
O O
101, 102
 
 
Scheme C20:  Synthesis of N-trifluoroacetyl and N-phenylsulfonyl THIQs. 
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3.2.4 Unsuccessful Synthetic Approach to 1-Alkyl-2-aryltetrahydroisoquinolines  
 
As shown in the last paragraph, the synthesis of 1-alkyl-2-aryl-THIQs required a time 
consuming multi step reaction sequence, as the cyclisation had to be performed for 
every single sidechain. An alternative, straight forward synthetic route to 1-2-diaryl-
THIQs was recently described (Renaud et al., 2005). In this case, the key step of the 
reaction sequence is a nucleophilic attack of an aryl-lithium to a carbonyl function in 
position 1, followed by dehydratation and reduction of the dihydroisoquinolonium to the 
tetrahydroisoquinoline.  
For this study aliphatic Grignard nucleophiles were applied as synthetic equivalents for 
lithiumorganic compounds described by others. This approach may open a short 
synthetic route to a library of THIQs containing aliphatic sidechains in position 1. The 
Grignard reagents should be prepared from the corresponding alkylbromides (cf. 
paragraph 2.2.1). 
The N-aryl 3,4 dihydroisoquinolin-1-on building block was synthesized starting from 5-
methoxy-2,3-dihydroinden-1-on that was transformed to the dihydroisoquinolin-1-on 115 
in a Schmidt rearrangement (Tomita et al., 1969). The N-(4-methoxyphenyl) group was 
introduced by a Cu(I) catalyzed Ullmann-type condensation (Sugahara and Ukita, 1997) 
with the corresponding aryl bromide to afford compound 116. The attempted Grignard 
reaction of 116 with ethyl-magnesiumbromide as well as with decylmagnesium bromide 
failed (cf. Scheme C21).  
 
MeO
O
NH
O
MeO
N
O
MeO
N
R
MeO
115
116
1. RMgBr
2. H+
3. NaBH4
OMeBr
OMe OMe
CuI, K2CO3
DMF, 150°C
1. NaN3, H2SO4,
    CHCl3, 60°C
2. H2O
R = -C2H5; -C10H21
 
Scheme C21:  Unsuccessful synthetic approach to 1-alkyl-2-aryl-THIQs. 
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3.2.5 Summary of Synthesized Test-Compounds with a Tetrahydroisoquinoline 
Scaffold 
 
Tables C3 and C4 show the substitution profile of the two series of synthesized 
compounds. THIQs of series A are variably substituted in position 1 with simple alkyl 
groups as well as with long monofunctional and bifunctional chains. For each class of 1-
substiuents the N-phenyl ring is either unsubstituted or carries a 3-hydroxy function.  
 
Table C3:  Synthesized tetrahydroisoquinolines 
Series A 
                                             
N X
HO
R
 
 
 
Comp. 
 
R 
 
X 
 
79 -CH2-CH3 H 
80 -(CH2)2-CH3 H 
81 -(CH2)9-S-C5H11 H 
83 -(CH2)10-SO2-C5H11 H 
84 -(CH2)6-NC4H8 H 
85 -(CH2)6-N(CH3)(CH2)3-S-C5H11 H 
86 -(CH2)9-SO-C5H11 H 
87 -(CH2)10-SO-C5H11 H 
88 -CH2-CH3 OH 
90 -(CH2)10-SO2-C5H11 OH 
91 -(CH2)6-NC4H8 OH 
92 -(CH2)6-NC5H10 OH 
93 -(CH2)6-N(CH3)(CH2)3-S-C5H11 OH 
94 -(CH2)10-SO-C5H11 OH 
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Synthesized tetrahydroisoquinolines of series B are substituted with a trifluoroacetate or 
a phenylsulfonyl group at the nitrogen. Compound 106 carrying a phenyl group in 
position 1 and an N-trifluoroacetate group was derscribed by others as ERβ selective 
agonist (Chesworth et al., 2004). 108-114 are substituted in position 1 with a sulfoxide 
or sulfone side chain. 
 
Table C4:  Synthesized tetrahydroisoquinolines 
Series B 
                                    
N
X
HO
R2
R1
 
 
 
Comp. 
 
X 
 
R1 
 
R2 
106a CO 
 
CF3 Ph 
108 CO CF3 -(CH2)10-SO2-C5H11 
112 SO2 Ph -(CH2)10-SO2-C5H11 
113 CO CF3 -(CH2)10-SO-C5H11 
114 SO2 Ph -(CH2)10-SO-C5H11 
 
aReference compound described in literature (Chesworth et al., 2004) 
 
 
 
3.3 Pharmacological Characterization of the Tetrahydroisiquinolines 
3.3.1 Binding to Human Estrogen Receptors (ERα and ERβ) 
 
The two series of synthesized tetrahydroisoquinolines were submitted to the ER binding 
assay using the human recombinant ERα and ERβ.  
Generally, in the range of the experimental precision, the slopes of the logit-log-plots of 
the test compounds were comparable to that of the 17β-estradiol, indicating a 
competitive displacement of the tritiated endogenous ligand from the ER binding pocket. 
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The binding data for series A of the investigated tetrahydroisoquinolines are 
summarized in table C5.  
 
Table C5:  Binding affinities of tetrahydroisoquinolines to human ERα and ERβ 
 Series A 
 
                          
N X
HO
R
 
 
 
Comp. 
 
R 
 
X 
 
RBAa 
ERα 
RBAa 
ERβ 
 
79 -CH2-CH3 H 2.4 ± 0.2 2.6 ± 0.1 
80 -(CH2)2-CH3 H 3.1 ± 0.1 1.1b 
88 -CH2-CH3 OH 5.5 ± 0.2 8.8 ± 3.2 
81 -(CH2)9-S-C5H11 H 0.03b 0.02b 
86 -(CH2)9-SO-C5H11 H 0.28 ± 0.05 0.13b 
84 -(CH2)6-NC4H8 H 7.1 ± 1.3 8.2 ± 0.3 
91 -(CH2)6-NC4H8 OH 11 ± 1 1.2 ± 0.2 
92 -(CH2)6-NC5H10 OH 11.9 ± 0.2  1.08 ± 0.02 
85 -(CH2)6-N(CH3)(CH2)3-S-C5H11 H 1.4 ± 0.2 1.43 ± 0.02  
93 -(CH2)6-N(CH3)(CH2)3-S-C5H11 OH 14 ± 1 1.1 ± 0.1  
87 -(CH2)10-SO-C5H11 H 0.37 ± 0.04 0.32 ± 0.15 
94 -(CH2)10-SO-C5H11 OH 2.4 ± 0.1 0.14 ± 0.02 
83 -(CH2)10-SO2-C5H11 H 0.55 ± 0.25 1.3 ± 0.2 
90 -(CH2)10-SO2-C5H11 OH 2.9 ± 0.2 0.28 ± 0.04 
 
E2 100 100 
4-OH-Tam 11 ± 2 24b 
ICIc  8.2 ± 0.3 12 ± 1 
 
aRBA = IC50(E2) / IC50(test-comp.) · 100; values represent means of two independent 
determinations ± SEM; the concentration of the radioligand was 0.5 nM throughout; bsingle 
determination; cICI = fulvestrant (ICI 182.780) 
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Compounds 79, 80 and 88 substituted with simple alkl groups in position 1 bound to 
ERα with RBA values of 2.4 to 5 without any noteworthy selectivity over ERβ. For 
compound 88 harboring a 3’-hydroxy group, the affinity for both ER subtypes was 
increased by a factor 2 to 3 compared to the N-phenyl analogue 79. 
When these simple chains were replaced by side chains typical of aniestrogens, the 
binding affinity as well as the degree of selectivity became strongly dependent on the 
nature of the substituents included in the chain and on the presence of an additional 
hydroxy function in the 3’-position. 
Compound 81 carrying a side chain with a sulfanyl group at a distance of 9 carbon 
atoms from the core was hardly able to compete with E2 for the ER binding site. The 
affinity for both receptor subtypes dropped by a factor of 100 compared to the ethyl- and 
propyl-substituted analogues. With an RBA value of 0.3, the corresponding sulfoxide 
derivative 86 revealed a 10-fold higher binding affinity, lacking any noteworthy subtype 
selectivity. The affinities for both ER-subtypes were approximately the same, when the 
chain was prolonged by one carbon atom in compounds 83 and 87 bearing a sulfone or 
a sulfoxide group, respectively.  
If a second phenolic hydroxy group is present in position 3 of the N-phenyl (3’-position), 
the binding profiles of the tetrahydroisoquinolines carrying a sulfoxide- or sulfone side 
chain changed. The binding affinities for ERα were increased by a factor of 5 to 6 (RBA 
= 2.4-2.9) while binding to ERβ slightly decreased. Consequently, ERα selectivities 
reached from 10-fold in the case of sulfone 90 to 17-fold in the case of sulfoxide 94. 
Compounds 84, 91 and 92 with pyrrolidine and piperidine side chains were found to 
bind with RBA values of 7-12 to ERα. The binding selectivity again strongly depended 
on an additional hydroxy group at the N-phenyl ring: compound 84 with only one 
phenolic hydroxy group already revealed a marked binding affinity with RBA values for 
both ER subtypes between 7 and 8. For 91 and 92 bearing two phenolic OH-groups the 
affinities to ERα were slightly increased (RBA = 11-12) compared to 84. Both 
compounds bearing a 3’-hydroxy group bound with a selectivity of approximately 10-fold 
in favor of ERα. In this case the selectivity was mainly due to a dropping affinity at ERβ, 
when a 3'-hydroxy group was present. 
The comparison of the binding profiles of compounds 85 and 93 bearing a bifunctional 
side chain demonstrates once more, that the second hydroxy function in 3’ position of 
93 is required for a high binding affinity (RBA = 14) and a 13-fold ERα selectivity.  
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Summarizing the binding data of series A of the investigated tetrahydroisoquinolines, 
two phenomena are noticeable: generally the highest binding affinities were found, if a 
basic nitrogen was present in the side chain. The relatively high binding affinities can be 
explained by a hydrogen bond between the basic amine group and the carboxylate of 
Asp351 in the ER binding pocket. The increase in binding affinity by amine groups in the 
side chain is well known, especially for agents belonging to the class of SERMs and for 
many antiestrogens developed in our group. 
The second important observation was the fact that a meta-hydroxy group at the N-
phenyl increases the selectivity in favor of ERα. This observation confirms the result of 
a recent study on tetrahydroisoquinoline based SERMs published by others (Renaud et 
al., 2005).  
Among the synthesized compounds, the highest binding affinities (RBA = 10-14) in 
combination with selectivities of >10 fold for ERα were found for compounds 91, 92 and 
93. These affinities for ERα are comparable to the highly potent antiestrogens 
fulvestrant (RBA = 8.2) and 4-hydroxytamoxifen (RBA = 11). For compound 94 the 
affinity was somewhat decreased (RBA = 2.4), but this compound was characterized by 
a 17-fold selectivity in favor of ERα. 
 
In series B of the investigated tetrahydroisoquinolines, compound 106 revealed a high 
affinity (RBA = 14) and a 5-fold selectivity for ERβ. 106 was already investigated with a 
similar result by scientists at Pfitzer (Chesworth et al., 2004). 
The combination of an N-phenylsulfonyl or N-trifluoroacetate with sulfoxide or sulfone 
side chains in compounds 108 and 112-114 led to unselective compounds with 
consistently low binding affinities. Binding data for the compounds of series B are listed 
in table C6. 
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Table C6:  Binding affinities of tetrahydroisoquinolines to human ERα and ERβ 
 Series B 
 
                             
N
X
HO
R2
R1
 
 
 
Comp. 
 
X 
 
R1 
 
R2 
RBA 
ERα 
RBA 
ERβ 
106 CO 
 
CF3 Ph 2.5 ± 0.3 14 ± 2 
113 CO CF3 -(CH2)10-SO-C5H11 0.26a 0.4a 
108 CO CF3 -(CH2)10-SO2-C5H11 0.26 ± 0.07 0.22 ± 0.08
114 SO2 Ph -(CH2)10-SO-C5H11 0.19a 0.25a 
112 SO2 Ph -(CH2)10-SO2-C5H11 0.09 ± 0.02 0.11 ± 0.05
 
asingle determination; for additional information see table C5 
 
 
3.3.2 Functional Characterization of the THIQs in the Luciferase Assay 
 
ER positive MCF-7 breast cancer cells, that have been stably transfected with a 
luciferase reporter gene under the control of an ERE, were used for the determination of 
antiestrogenic effects of synthesized tetrahydroisoquinolines. 
The antiestrogenic activity was determined by simultaneous treatment of the cells with 
1nM E2 and the respective tetrahydroisoquinoline or reference compound (fulvestrant or 
4-hydroxytamoxifen) in various concentrations. Each compound was characterized by 
the IC50 value for the inhibition of the 1nM E2 induced luciferase expression that was 
determined by graphical regression of the respective concentration -response-plot. The 
graphs for inhibition of the luciferase activity in MCF-7/2a cells by the tested compounds 
are depicted in Figure C5.  
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Figure C5: Inhibition of the E2-induced luciferase activity by various antiestrogens 
The luciferase expression was mediated by 1nM E2 (control was set to 100 %);  
ICI = fulvestrant (ICI 182.780); 4-OH-Tam = 4-hydroxytamoxifen 
 
All investigated compounds of series A equipped with an “antiestrogenic” side chain 
revealed an inhibiting effect on the 17β-estradiol stimulated luciferase expression in a 
concentration-dependent manner. Generally, the maximum inhibition of the luciferase 
activity by the test compounds was approximately 15-20% of the E2-control. The basal 
expression of nontreated cells was typically in the range of 40% to 50%. That means 
that the compounds were capable of inhibiting the luciferase activity far below the basal 
signal, which is a characteristic effect of potent ER antagonists. This level was also the 
limit of inhibition for the reference drugs fulvestrant and 4-hydroxytamoxifen. 
As demonstrated in Figure C4 the inhibition curves for the tetrahydroisoquinolines were 
all shifted to higher concentrations compared to the potent reference antiestrogens 
fulvestrant and 4-hydroxytamoxifen. The IC50 values of all tested tetrahydroiso-
quinolines of series A are listed in table C7. 
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Table C7:  Antiestrogenic activity of tetrahydroisoquinolines with functionalized side 
chains, Series A 
 
                                  
N X
HO
R
 
 
 
Comp. 
 
R 
 
X IC50 [µM] 
 
84 -(CH2)6-NC4H8 H 2.0 
91 -(CH2)6-NC4H8 OH 1.2 
92 -(CH2)6-NC5H10 OH 2.3  
85 -(CH2)6-N(CH3)(CH2)3-S-C5H11 H 0.24 
93 -(CH2)6-N(CH3)(CH2)3-S-C5H11 OH 0.16 
87 -(CH2)10-SO-C5H11 H 0.74 
94 -(CH2)10-SO-C5H11 OH 0.47 
83 -(CH2)10-SO2-C5H11 H 0.67 
90 -(CH2)10-SO2-C5H11 OH 0.48 
86 -(CH2)9-SO-C5H11 H 0.71 
 
4-OH-Tam  0.0085 
Fulvestrant   0.010 
 
The lowest IC50 values of 160 nM and 240 nM respectively were obtained for 
tetrahydroisoquinolines 93 and 85 with the bifunctional side chain. The potencies of 
these compounds were by factor 15-25 lower than those of fulvestrant and 4-
hydroxytamoxifen, both of which were in the range of 10 nM. The IC50 values of the 
second group of synthesized THIQs, bearing long sulfoxy and sulfone side chains were 
in a range of 0.5-0.7 µM. With approximately 0.5 µM, the antiestrogenic potencies of 90 
and 94 carrying a 3-hydroxy group at the N-phenyl were slightly higher than those of the 
corresponding THIQs devoid of this hydroxy group. 
Compounds 84, 91 and 92, having a terminal pyrrolidine or piperidine group at a C6-
chain, inhibited gene transcription with IC50 values in the micromolar range. In this last 
class of THIQs, there is no correlation between the potencies in the luciferase assay 
and the binding affinities from the radiochemical assay. Pyrrolidines 84 and 91 and 
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piperidine 92 revealed throughout high affinities to the recombinant ERα, but in the 
cellular test system, they inhibited the E2- mediated gene transcription only weakly.  
The compounds, which carry a relatively short side chain bear a basic amine group that 
is protonated at physiological pH. The lipophilicity of the salts is too low to readily 
penetrate accross cell membranes, so that the intracellular concentration at the site of 
action is much lower compared to the extracellular concentration. This may be an 
explanation for the relatively low antiestrogenic potency of THIQs 84, 91 and 92, in spite 
of their high binding affinities. 
In the compounds with “bifunctional” chains, the lipophilic chain compensates the 
positive charge at the basic nitrogen to a certain degree, which possibly explains the 
relatively high potencies determined in the luciferase assay.  
 
The tested THIQs of series B were all poor inhibitors of the estrogen mediated gene 
transcription with IC50 values in the micromolar range ( > 3 µM for 112) (cf. Table C8). 
 
 
Table C8: Antiestrogenic activity of tetrahydroisoquinolines with functionalized side 
chains, Series B 
 
                           
N
X
HO
R2
R1
 
 
 
Substanz 
 
X 
 
R1 
 
R2 IC50 [µM] 
113 CO CF3 -(CH2)10-SO-C5H11 1.3 
114 SO2 Ph -(CH2)10-SO-C5H11 1.3 
112 SO2 Ph -(CH2)10-SO2-C5H11 > 3 
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3.3.3 Antiproliferative Activity  
 
The antiproliferative potencies of the synthesized tetrahydroisoquinolines in ER positive 
MCF-7 breast cancer cells were determined as a second criterion for antiestrogenic 
efficacy. The assay was performed as described by Bernhardt et al (Bernhardt et al., 
1992). The growth kinetics was determined by measuring the cell densities of treated 
and non-treated cell cultures after staining with crystal violet at five different time points. 
The characteristics of the growth curves reveal the type of growth inhibiting effect of a 
tested compound. The kinetics of growth inhibition for a number of 
tetrahydroisoquinolines and the reference fulvestrant is depicted in Figures C5 to C11. 
The IC50 values for the antiproliferative effects of selected tetrahydroisoquinolines were 
determined by analyzing the concentration-response curves at the endpoint of each 
assay. IC50 values for the antiproliferative effects of some THIQs are listed in table C9. 
The strongest inhibition of the cell proliferation was achieved with the tetrahydro-
isoquinolines 87 and 94 bearing a long sulfoxide side chain The growth kinetics 
revealed a cytostatic effect over a concentration range from 0.1 to 1 µM, while the level 
of cell density decreased in a concentration dependent manner (cf. Figure 6). At the 
endpoint, IC50 values of 95 nM and 60 nM were determined for compounds 87 and 94, 
respectively.  
Tetrahydroisoquinoline 93, bearing a bifunctional side chain was the most potent 
inhibitor of the 17β-estradiol-induced gene transcription in the lucifease assay (cf. 
paragraph 2.3.2). Surprisingly, the compound revealed a cytostatic effect only at a 
concentration of 1 µM. At 100 nM the curve is characteristic for a cytotoxic effect, as the 
cell density decreases only at the beginning, but with the progress of the incubation 
period the cell number of the cultures treated with 100 nM of 93 approximates the cell 
number of the corresponding control population. Consequently, the corrected T/C value 
shows a minimum at 140 h (cf. Figure C7). The IC50 value of 93 for the inhibition of the 
MCF-7 cell proliferation was 170 nM. A possible explanation for the lack of correlation 
between the results of the luciferase assay and the proliferation assay might be the 
difference in the incubation periods. While luciferase activity was determined after an 
incubation period of 48 hours, the time of incubation was more than 200 h in the crystal 
violet assay. The stability of the compounds is not guaranteed in an aqueous 
environment at 37 ° for such a long period of time. Compound 85 with “bifunctional” side 
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chain, but without a 3’-hydroxy group revealed a similar effect on MCF-7 cell 
proliferation than 93. The IC50 value of 85 was 160 nM. 
In contrast to compound 94, bearing a solfoxide side chain, the corresponding sulfone 
analogue 90 revealed a weak cytotoxic effect at 100 nM and a cytostatic effect at a 
concentration of 1 µM (cf. Figure C8, top). Analysis of the concentration-response curve 
at the endpoint revealed an IC50 value of 240 nM. 
Compound 91, carrying a pyrrolidine side chain, exhibited no remarkable effect at 
100 nM. At 1 µM a cytostatic effect was observed (cf. Figure C8, bottom). The relatively 
low antiproliferative potency of 91 was predictable from the gene reporter assay. The 
IC50 value of 91 with respect to growth inhibition was 180 nM. 
As ER expression in MCF-7 cells is quite unstable and can strongly differ in different 
passages, the potent antiestrogens fulvestrant (cf. Figure C9) and 4-hydroxytamoxifen 
(not shown) were used as reference compounds. The fact that both antiestrogens 
inhibited growth at nanomolar concentrations (5 and 10 nM, respectively) totally, 
demonstrates the high responsiveness of the MCF-7 breast cancer cells to hormonal 
treatment. 
 
Table C9:  Antiproliferative activity of tetrahydroisoquinolines with functionalized side 
chains 
 
                                  
N X
HO
R
 
 
 
Comp. 
 
R 
 
X IC50 [µM] 
91 -(CH2)6-NC4H8 OH 0.18a 
85 -(CH2)6-N(CH3)(CH2)3-S-C5H11 H 0.16a 
93 -(CH2)6-N(CH3)(CH2)3-S-C5H11 OH 0.17a 
87 -(CH2)10-SO-C5H11 H 0.095b 
94 -(CH2)10-SO-C5H11 OH 0.060a 
90 -(CH2)10-SO2-C5H11 OH 0.24a 
 
ICI  < 0.005b 
 
aMCF-7 passage 177; bMCF-7 passage 193 
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Figure C6:  Proliferation kinetics (left) and growth inhibition of MCF-7 cells after treatment with 
compound 87 (top) and 94 (bottom) compared to the vehicle control.  
Top: MCF-7 passage 177; bottom: MCF-7 passage 193; values represent means of at least 
14 replicates ± SD; Errors of T/C were calculated according to the Gaussian law of error 
propargation. 
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Figure C7:  Proliferation kinetics (left) and growth inhibition of MCF-7 cells after treatment 
with 85 and 93 in various concentrations compared to the vehicle treated control.  
 Top: MCF-7 passage 193; bottom: MCF-7 passage 177; for additional information see 
Figure C6 
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Figure C8:  Proliferation kinetics (left) and growth inhibition of MCF-7 cells after treatment with 
compound 90 (top) and 91 (bottom) compared to the vehicle treated control.  
MCF-7 passage 177; for additional information see Figure C6 
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Figure C9:  Proliferation kinetics (left) and growth inhibition of MCF-7 cells after treatment 
with 5 and 10 nM fulvestrant (ICI 182.780) compared to the vehicle treated 
control.  
MCF-7 passage 193; for additional information see Figure C5 
 
The observed antiproliferative effects are not necessarily due to antiestrogenic activities 
of the tested compounds, as cell proliferation is a relatively late event in the estrogen 
signaling cascade. In order to exclude any unspecific toxic effects, a additional crystal 
violet assay, using ER-negative MDA-MB-231 cells, was performed for each compound.  
The cells were incubated with the test compounds at the two highest concentrations 
applied to MCF-7 cells. As shown in Figure C10, sulfones 87 and 94 exhibited no 
antiproliferative activity on MDA-MB-231 cells at concentrations up to 1 µM. At these 
concentrations the compounds were efficient antiproliferative agents against MCF-7 
cells. As demonstrated by the treatment with 10 nM vinblastin, the MDA-MB-231 cells 
used are sensitive to classical cytostatics. This result is representative for all the other 
compounds tested in this series. Thus, the observed antiproliferative activities of the 
investigated compounds in ER-positive MCF-7 cells are very likely due to their 
antiestrogenic potencies. 
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Figure C10: Growth curves of MDA MB-231 cells in presence of tetrahydroisoquinolines 87 
and 94 compared to the vehicle control and 10 nM vinblastin. 
 
 
3.4 Separation and Characterization of Enantiomeric Tetrahydroisoquino-
lines 
 
All the synthesized tetrahydroisoquinolines are chiral due to an assymmetric sp3 carbon 
atom in position 1. As the reductive hydration of the dihydroisoquinolines to the THIQs 
with NaBH4 was not enantioselctive, the target compounds were obtained as 
racemates. As the biological assays revealed, the sidechains play a critical role for the 
biological activity of the corresponding THIQ, especially for binding affinity to the 
estrogen receptors (cf. paragraph 3.3.2).  
Published crystal structures demonstrate that one stereoisomer, namely that with the R-
configuration at C1, preferably binds to the ERα binding pocket, if the racemate of a 
THIQ-based SERM is co-crystallized with the ERα LBD (Renaud et al., 2005). 
Characteristic of these SERMs is the rigid conformation of the side chain.  
By contrast, the synthesized ER antagonists are equipped with different aliphatic, non-
rigid side chains. The study described in this paragraph reports on the separation of the 
enantiomers of some selected THIQs and their evaluation with respect to binding to the 
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human estrogen receptors ERα and ERβ. The investigation of a selection of three 
racemates aimed at the identification of individual eutomers and distomers. 
As representative tetrahydroisoquinolines 92, with a piperidine side chain, 93 with a 
bifunctional side chain and 94 with a sulfoxy side chain were chosen. All three 
compounds bear a hydroxy substituent in position 3 of the N-phenyl ring and were found 
to preferably bind to ERα.  
 
 
3.4.1 Separation of the Enantiomers 
 
Two different methods for the preparative enantiomeric separation were investigated.  
In the test compounds the tetrahydroisoquinoline-nitrogen is located in direct vicinity to 
the chiral center. A strong chiral acid such as (R)- or (S)-camphor-10-sulfonic acid 
should be capable of forming diastereomeric salts. All attempts to separate the 
enantiomers of the selected THIQs by crystallization as diastereomeric (R) or (S)-
camphor-10-sulfonic acid salts failed. The compounds either did not crystallize at all 
from mixtures of ethanol and ether or, in the case compound 92, the crystalline salt was 
a racemic mixture (analysed by chiral HPLC). 
The second method concerning the separation of the racemates of 92-94 was chiral 
HPLC. The material Eurocel 01 form Knauer proved to be an appropriate chiral selector 
for the given class of compounds. According to the manufacturer’s information, the 
chiral stationary phase consists of a silica based matrix coated with a derivatized 
polysaccharide. It is modified with the chiral selector 3,5-dimethyphenylcarbamate.  
In all separations, HPLC was performed in the reversed phase mode, using mixtures of 
methanol and 0.05 % aqueous TFA. At identical coloumn loading, the resolution of the 
two enantiomers by HPLC was strongly different in compounds 92-94 (cf. table C10). 94 
being devoid of a basic amine group showed two sharp, totally resolved peaks. The 
amine groups in compounds 92 and 93 affected a tailing that was particularly 
pronounced in the case of 92 bearing a piperidine group. At moderate column loading 
(injection of 50 µL of a 100 µM solution), the enantiomeric peaks of 92 were not totally 
resolved (Rs = 1.0) by the chiral selector. 
As only an analytical column was available in our group, a semi-preparative separation 
was performed. Multiple injections (n = 8-10) were necessary for the accumulation of 
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the substance amount required for proper biological assaying. As the ee value was 
below 80 % for enantiomer 92b after the first separation, the separation procedure was 
repeated in this case. 
Chromatograms of the chiral compounds 92-94 are depicted in Figure C11.  
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Figure C11:  Zoom in on chromatogramms of selected chiral THIIQs: left: racemate, middle: 
first eluted enantiomer after separation, right: last eluted enantiomer after 
separation.  
Stationary phase: Eurocel 01; A) mobile phase: MeOH/0.05 % TFA (aq) 50/50; B) mobile 
phase: MeOH/0.05 % TFA (aq) 70/30; C) mob. phase: MeOH/0.05 % TFA (aq) 90/10. 
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Before separation, all compounds were racemates. From the chromatograms after 
separation, the enantiomeric purity was determined by peak integration for each 
enantiomer. The circular dicromism (CD) of the individual enantiomers was determined 
at 245 nM using a CD detector directly coupled to the HPLC system. For all THIQs the 
first eluted enantiomer gave the positive CD signal. The absolute configuration was not 
accessible. 
The enantiomeric purities of all isolated enantiomers are summarized in table C10. 
 
Table C10:  Enantiomeric purities of separated THIQ-enantiomers  
 
                          
N OH
HO
R
 
  
Comp. 
 
R Rsa CDb 
 
eec [%] 
 
92a 
 
+ 
 
96.8 
 
92b 
-(CH2)6-NC5H10 1.0  
- 
 
94.9d 
 
93a 
 
+ 
 
98.4 
 
93b 
-(CH2)6-N(CH3)(CH2)3-S-C5H11 1.6  
- 
 
95.5 
 
94a 
 
+ 
 
91.2 
 
94b 
-(CH2)10-SO-C5H11 3.1  
- 
 
92.6 
 
aRs = resolution of HPLC-peaks; injection: 50 µL of a 100 µM solution; bcircular 
dichromism at 245 nM; cenantiomeric excess; dafter two successive separations 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Binding Affinities of the Enantiomers to ERα and ERβ 
 
The separated enantiomers were submitted to the ERα and ERβ binding assay 
described in paragraph 1.1. The logit-plots of the respective enantiomers of compounds 
92-94 for both receptor subtypes are depicted in Figure C11. The slope of all regression 
curves is in the range of 1, indicating a competitive displacement of the radioligand 
binding.  
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Figure C12:  Logit linearization for binding of THIQ enantiomers to ERα and ERβ;  
 means of triplicates ±SEM 
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The RBA values for the racemates and the respective single enantiomers are listed in 
table C11. For all compounds (92-94) the enantiomers giving the positive CD signal 
were identified as the eutomers concerning ER binding. They bound to both ER 
subtypes with a 3 to 6 fold higher RBA value than the corresponding distomers and with 
a slightly increased RBA value compared to the racemates.  
In a published experiment, the distomer of an 1-aryl-tetrahydroisoquinoline was reported 
to lack binding affinity up to the micromolar range (Chesworth et al., 2004). A possible 
explanation for the difference between this example from literature and the compounds 
investigated within this project is the higher degree of rotation in the aliphatic side 
chains of THIQs 92-94 compared to a rigid phenyl ring. By conformational restriction, 
the ligand is fixed to the binding pocket in only one possible conformation. In the case of 
compounds 92-94, the long aliphatic sidechains of the distomers seem to find their 
favorable orientation in the binding pocket anyhow by free rotation.  
 
Table C11:  Binding affinities of THIQ enantiomers 
 
                            
N OH
HO
R
 
 
 
Comp. 
 
R 
 
RBA 
ERα 
RBA 
ERβ 
 
rac-92 11.9 ± 0.2  1.08 ± 0.02 
 
92a 15.9 ± 0.4 1.2 ± 0.1 
92b 
-(CH2)6-NC5H10 
3.4 ± 0.4 0.22 ± 0.01 
 
rac-93 14 ± 1 1.1 ± 0.1  
 
93a 21± 1 1.7 ± 0.1 
93b 
-(CH2)6-N(CH3)(CH2)3-S-C5H11 
7.0 ± 1.9 0.28 ± 0.1 
 
rac-94 2.4 ± 0.1 0.14 ± 0.02 
 
94a 3.0 ± 0.3 0.21 ± 0.04 
94b 
-(CH2)10-SO-C5H11 
0.5 ± 0.1 0.065 ± 0.009 
 
For additional information see table C5; 
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4 Binding Affinities of 2-Phenylindoles to ERα and ERβ 
 
2-Phenylindoles as ER ligands were an important research area of our group mainly in 
the 1980s and 1990s. A large number of compounds has been synthesized and 
evaluated for biological activity aiming on new agents for the therapy of hormone 
receptor-positive breast cancer (von Angerer et al., 1984; von Angerer et al., 1990; von 
Angerer et al., 1994). ERβ as the second ER subtype was not yet discovered to that 
time, so that the binding profile of this class of compounds at both human estrogen 
receptors has not been investigated.  
Within the scope of this project a small selection of isomeric 2-phenylindoles was 
investigated with regard to affinities and selectivities for ERα and ERβ. The 
differentiated evaluation of binding affinities to the currently known two human estrogen 
receptor subtypes might offer new insight into the binding characteristics of this class of 
compounds.  
The isomeric indoles In1-In4 of series 1 are all substituted with a methyl group in 
position 1 and 3. The only difference between these compounds are the positions of the 
hydroxy groups at the indol core and the 2-phenyl-ring. The RBA values of In1-In4 for 
the human estrogen receptor subtypes and the calf ER are listed in table C12. 
 
Table C12:  Binding affinities of isomeric 2-phenylindoles (series 1) to ERα and ERβ  
 
                                    
N
R4
CH3
R1
R2
R3
CH3
 
 
 
Compound 
 
 
R1 
 
 
R2 
 
 
R3 
 
R4 
 
RBA 
calf-ERa 
RBA 
ERα 
RBA 
ERβ 
 
In1 
 
OH 
 
H 
 
OH H 
 
0.55 0.87  3.4 
In2 H OH OH H 0.6 1.3 6.6 
In3 H OH H OH 10 14  74 
In4 OH H H OH 4.6 18 95 
 
afrom calf uterus cytosol (von Angerer et al., 1984); for additional information see table C5. 
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The RBA values of In1 and In2 for ERα were in the range of 1, which is in agreement 
with the RBA values determined for the calf uterus cytosol by the original publishers of 
the compounds. In3 exhibited an approximately 10-fold higher affinity for ERα than In1 
and In2. This value also matches the corresponding value from calf ER. Exceptionally, 
the binding affinity of In4 for ERα was approximately 4-fold higher than the affinity at the 
calf ER. Generally, the RBA values of compounds In1 and In2 bearing a hydroxy group 
in the 3’ position are decreased by approximately one order of magnitude compared to 
the corresponding 4’-OH analogues. This trend became obvious for both human ER 
subtypes as well as for the calf ER.  
Characteristic of all investigated indoles of this series was the selectivity in favor ERβ by 
a factor of 4-5. For indoles In3 and In4 already exhibiting high affinities for ERα, the 
RBA values for ERβ were 75 and 95, respectively, which is very close to the 
endogenous estrogen E2. The binding affinities of In3 and In4 for ERβ are in the same 
range as the binding affinity of benzofuran B1 (cf. paragraph 2.3.1 table C2), but the 
selectivity of the indoles is by a factor of 4 lower compared to the benzofuran.  
 
A second series of 2-phenylindole-based compounds which were differently substituted 
at the indole-nitrogen, was also submitted to ERα and ERβ binding. The compounds 
were mainly synthesized and biologically characterized by Dr. T. Golob as a former 
member of our group (Golob et al., 2002). Compounds ZK119.010 (von Angerer et al., 
1990), In5 (von Angerer et al., 1984) and In8 (von Angerer et al., 1994) included in this 
second series of 2-phenylindoles have been described in earlier work of our research 
group. RBA values of the indoles of series 2 are listed in table C13. 
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Table C13:  Binding affinities of various 2-phenylindoles (series 2) to ERα and ERβ  
 
                             
N
CH3
R3
R1
R2
OH
 
 
 
Comp. 
 
R1 
 
R2 
 
R3 
RBA 
ERα 
RBA 
ERβ 
RBA 
Calf-ERa
 
In5 
 
OH 
 
H 
 
Et 25 54 
 
14 
In6 H H Et 18 7.8 3.4 
In7 H OH -(CH2)5-CO-NC4H8 4.2  3.6 12.2 
In8 OH H -(CH2)5-CO-NC4H8 21 4.6 19 
In9 H OH -(CH2)6-NC4H8 8.3 11 8.4 
ZK119.010 OH H -(CH2)6-NC4H8 25 6.0 33 
 
afrom calf uterus cytosol (Golob et al., 2002); for additional information see table C5. 
 
Within this second indol-series, compounds In5 and In6, substituted with an N-ethyl 
group are different by one hydroxy group: In5 carries a 5-OH group at the indol scaffold, 
while In6 is unsubstituted at this ring. In5 and In6 are highly affinic to ERα with similar 
RBA values of 25 and 18, respectively. In5, bearing a 5-hydroxy group, revealed a 2 
fold selectivity for ERβ, while In6 lacking a hydroxy group at the indole core preferably 
bound to ERα. In7 and In8 are isomers with a carbonyl side chain at the indole nitrogen 
varying in the position of a hydroxy group at the indole partial structure. The RBA values 
of In7 were in the range of 4 for both receptor subtypes. In8 revealed a 5-fold selectivity 
for ERα (RBA = 21) over ERβ  (RBA = 4.6).  
In9 and ZK 19.010 are the amine analogues to the amides In7 and In8. For ZK 119.010 
the RBA value (25) for ERα was again close to the value determined with the calf uterus 
cytosol as receptor source (RBA = 33). ZK119.010 revealed a 4-fold selectivity for ERα, 
which is a notable parallel to the corresponding amide analogue In8. In9 exhibits similar 
affinities for both receptor subtypes with RBA values in the range of 10.  
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5 Conclusion 
 
Two types of potential estrogen receptor ligands were synthesized and evaluated for 
binding affinity and selectivity at ERα and ERβ and for (anti)estrogenic potency.  
The first class of synthesized compounds were 2-(4-hydroxyphenyl)benzofurans with 
simple alkyl moieties as well as long functionalized side chains in position 7. Taking 
account of its binding and activity profile, the >30 fold ERβ-selective agonist (E)-2-(4-
hydroxyphenyl)-7-(prop-1-enyl)benzofuran 24 can be used as a potential tool to 
investigate subtype specific cellular effects (cf. section D). By the introduction of long 
sulfone side chains into the benzofuran 7-position, the binding affinities were 
decreased, while the ERβ-selectivity was maintained to some degree (10-fold). The 
sulfones were inactive in the luciferase assay. Compound 33 with a bifunctional side 
chain revealed an increased binding affinity compared to the benzofurans with a sulfone 
side chain. It was preferentially bound to ERα, but exhibited a weak antagonistic effect 
in the luciferase assay. The present results demonstrate again, that the development of 
potent, ERβ-selective antagonists still remains a challenge.  
 
2-Aryl-1,2,3,4-tetrahydroisoquinolines as a second class of synthesized compounds 
were known from literature as ERα-selective ligands. Within this project, the introduction 
of established side chains known to be favorable for antiestrogenic activity in position 1 
aimed on ERα selective “pure ER antagonists”. The binding affinity of the THIQs 
depended from the nature of the side chain, while a hydroxy group in position 3 of the 
N-phenyl ring was necessary for ERα-selectivity. The highest RBA values were in the 
range of 10, which is comparable to the potent antiestrogens fulvestrant and 4-
hydroxytamoxifen. In the case of three representative compounds the enantiomer which 
were eluted first and gave a positive CD were identified as the eutomers (eudysmic ratio 
3-6) after separation of the racemates by chiral HPLC. Replacement of the N-aryl 
moiety by a trifluoroacetyl or a phenylsulfonyl group lead to decreased binding affinity 
and a lack of selectivity. The synthesized THIQs with long aliphatic chains were active 
as antagonists in a gene reporter (luciferase) assay. 93 harboring a bifunctional side 
chain and a 3’-hydroxy group revealed the highest potency among the compounds 
tested with an IC50 value of 160 nM. In agreement with our previous experience, the 
compounds with pyrrolidine and piperidine side chains were the least active, in spite of 
their high binding affinities. Selected compounds were tested for their 
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antiproliferative effect on hormone-sensitive MCF-7 breast cancer cells. Interestingly, 
compounds 87 and 94, bearing a sulfoxy group in the side chain revealed the highest 
potency in the cytotoxicity assay, although they were less potent than 93 in the 
luciferase assay. 
Taken together, the THIQ scaffold proved to be suitable for the development of “pure 
ER antagonists”, while the ERα selectivity of the THIQ-based SERMs reported by 
others was retained.  
Compounds 93 and 94 are characterized by relatively high antiestrogenic potencies in 
combination with ERα selectivities of 13 and 17 fold, respectively. The compounds are 
therefore appropriate tools for the selective blockade of the ERα in order to investigate 
the subtype specificity of cellular estrogen effects (cf. section D). Furthermore, the 
THIQs with sulfoxy side chain are interesting candidates as non-steroidal “pure ER 
antagonists” for the treatment of estrogen dependent breast cancer. 
 
As a class of agents with a long history in our research group, 2-phenylindols from an 
in-house library were re-evaluated with respect to their binding affinities for human ERα 
and ERβ. Within a first series of isomeric 1-3-dimethyl-2-phenylindoles differing in the 
position of two hydroxy groups respectively, indoles In3 and In4 revealed remarkable 
binding affinities to ERβ. The RBA values of the two indoles and the endogenous ligand 
E2 were in the same order of magnitude. The indoles showed some selectivity for ERβ 
(4-5-fold) but in a much lower extent than 2-phenylbenzofurans or other ERβ selective 
ligands known from literature.  
In a second series of 2-phenylindoles, the antiestrogen ZK119.010 revealed a high RBA 
value (25) and a 4-fold selectivity for ERα. In8 as the amide analogue of ZK119.010, 
showed a very similar binding profile. These ERα-selectivities are noteworthy, but 
considerably lower than those of the tetrahydroisoquinoline-based antiestrogens 
synthesized within this project or those of 1,5-diphenylfuran-based ligands previously 
developed in our group. 
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6 Experimental  
 
6.1 Chemistry 
6.1.1 Marterials and General Methods 
 
Chemicals and solvents 
Chemicals and solvents were purchased from commercial suppliers and used without 
further purification if not otherwise noted. 
Millipore water was used throughout for the preparation of HPLC eluents. Petroleum 
ether (PE) (40-60 °C) was distilled before use. 
 
Column and thin layer chromatography 
Thin layer chromatography was performed on Merck silica gel 60 F254 TLC aluminium 
plates. For column chromatography silica gel Geduran 60 (Merck, Darmstadt, Germany; 
0.063-0.200 mm) was used.  
 
Nuclear magnetic resonance (NMR) spectroscopy  
NMR spectra were recorded on a Bruker Avance 300 spectrometer ([1H]: 300.13 MHz; 
[13C]: 75.46 MHz) (Bruker, Karlsruhe, Germany) with TMS as external standard. The 
following abbreviations are used for characterization of peaks: s = singlet; d = duplet; 
d(d) = duplet of duplet; t = triplet; d(t) = duplet of triplet; q = quartet; quin = quintet; sex = 
sextet; sept = septet; m = multiplet; br = broad; (n)J = coupling constant over n bonds. 
 
Mass spectrometry (MS) 
Mass spectrometry analysis was performed in-house by the analytical laboratory. Low 
resolution mass spectra were recorded on a Finnigan ThermoQuest TSQ 7000 (ES-MS) 
and a Finnigan SSQ 710A (EI-MS 70 eV, CI-MS). High resolution mass spectrometry 
was performed on a LTQ Orbitrap Discovery (Thermo Fisher Scientific, Waltham, MA, 
USA). 
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Melting points 
Melting points were determined with a Büchi 510 melting point apparatus and are 
uncorrected.  
 
Elemental analysis  
Elemental analyses of final benzofurans were performed in-house by the micro 
analytical laboratory 
 
Preparative HPLC 
Preparative HPLC was performed with a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps, a K-2001 detector and a RP-column (Eurospher-100 
C18, 250 × 32 mm, 5 µm, Knauer or Nucleodur-100 C18, 250 × 21 mm, 5µm, 
Macherey-Nagel, Düren, Germany) at a flow rate of 38 mL/min. Mixtures of acetonitrile 
and 0.1 % aq. TFA were used as mobile phase. Acetonitrile was removed from the 
eluates under reduced pressure (final pressure: 60 mbar) at 40 °C prior to lyophilization. 
Lyophilisation was done with a Christ alpha 2-4 LD equipped with a vacuubrand RZ 6 
rotary vane vacuum pump (Christ, Osterode a. H., Germany).  
 
Analytical HPLC 
Analytical HPLC analysis was performed on a system from Merck, composed of a L-
5000 controller, a 655A-12 pump, a 655A-40 autosampler and a L-4250 UV-VIS 
detector; the flow rate was 0.8 mL/min, the detection waveleangth 210 nm; all 
separations were run at 40 °C. Helium degassing was used throughout. If not otherwise 
indicated a Eurospher-100 C18 (250 × 4 mm, 5 µm) column (Knauer) served as RP-
stationary phase. The analysis of the benzofurans was performed on a Nucleodur 100-5 
C18 ec (250 × 4 mm, 5 µm) column (Macherey-Nagel). 
 
Chiral HPLC 
Chiral HPLC was performed on a system from Waters, composed of a 600s controller 
and pump, a Waters degasser, a temperature control module, a 717 plus autosampler 
and a 2487 UV-detector; the flow rate was 1 mL/min, the detection waveleangths were 
210 and 276 nm. A Eurocel’01 (250 × 4.6 mm; 5µm; Knauer) analytic column served as 
chiral selector. Separations were performed in reversed phase mode with mixtures of 
methanol and 0.05 % aq. TFA as mobile phase at 35 °C.  
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6.1.2 Chemical Methods and Analytical Data 
6.1.2.1 Synthesis of 2-Arylbenzofurans 
6.1.2.1.1 Synthesis of Aliphatic Side Chains 
 
1-Bromo-8-(pentylsulfanyl)octane (1) 
Under nitrogen atmosphere pentanethiol (1.56 g, 15 mmol) in dry DMF (20 mL) was 
added dropwise to a suspension of sodium hydride (60% suspension in paraffin; 0.72 g, 
18 mmol) in dry DMF (80 mL) and stirred till the gas evolution ceased. The resulting 
mixture was filled into a drop-ping funnel, slowly added to a DMF solution (35 mL; 50 
°C) of 1,8-dibromooctane (15 g, 55 mmol) and stirred at this temperature for another 
two hours. Excess sodium hydride was decomposed by the addition of water and the 
product extracted with three portions of ethyl acetate. The organic extract was washed 
with water and brine and dried over Na2SO4. The solvent was removed in vacuo. 
Unreacted starting material, desired product and the by-product 1,8-bis-(pentylsulfanyl)-
octane were separated by column chromatography (SiO2; PE/DCM 10:1, v/v). Staining 
of the TLC plates with iodine (1% on silica gel) reveals the starting material as pink spot 
and the two sulfur-containing products as yellow spots. The excess of starting material 
can be recovered quantitatively. 
Light yellow oil; yield: 1.75 g (40%)  
C13H27BrS (295.36) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 6.9Hz; -CH3), 1.20-1.50 (12H; m; -(CH2)2-CH3, 
-(CH2)4-(CH2)2-Br), 1.51-1.65 (4H; m; -CH2-CH2-S-CH2-CH2-), 1.85 (2H; 
quin; 3J = 6.9 Hz; Br-CH2-CH2-), 2.50 (4H; t; 3J = 7.3 Hz; -CH2-S-CH2-), 
3.40 (2H; t; 3J = 6.9 Hz; Br-CH2) 
 
1-Bromo-9-(pentylsulfanyl)nonane (2) 
Preparation from 1,9-dibromononane (10 g, 35 mmol) and pentanethiol (0.91 g, 
8.75 mmol) following the procedure described for 1. 
Light yellow oil; yield: 800 mg (30%)  
C14H29BrS (309.35) 
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[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 6.9 Hz; -CH3), 1.30-1.50 (14H; m; -(CH2)2-
CH3, -(CH2)5-(CH2)2-Br), 1.51-1.65 (4H; m; -CH2-CH2-S-CH2-CH2-), 1.85 
(2H; quin; 3J = 7.0 Hz; Br-CH2-CH2-), 2.50 (4H; t; 3J = 7.3 Hz; -CH2-S-
CH2-), 3.40 (2H; t; 3J = 7.0 Hz; Br-CH2-) 
 
Ethyl 3-(pentylsulfanyl)propionate (3) 
Under nitrogen atmosphere and at room temperature, pentanethiol (3.2 g, 31 mmol) in 
dry DMF (20 mL) was added dropwise to a suspension of sodium hydride (60% 
suspension in paraffin; 1.7 g, 42 mmol) in dry DMF (25 mL) and stirred till the gas 
evolution ceased. Then, a DMF solution (25 mL) of ethyl 3-bromopropionate (5 g, 
28 mmol) was added dropwise and the resulting solution was stirred at this temperature 
for another two hours. Excess sodium hydride was decomposed by the addition of water 
and the product extracted with ethyl acetate (3 x 50 mL). The organic extract was 
washed with water and brine. After drying over Na2SO4 the solvent was removed in 
vacuo. The crude product was purified by column chromatography (SiO2; PE/DCM 1:1; 
v/v). 
Colourless oil; yield: 4.3 g (75%) 
C10H20O2S (204.33) 
[1H]-NMR (CDCl3):  
δ (ppm) = 0.89 (3H; t; 3J = 7.1 Hz; -(CH2)4-CH3), 1.26 (3H; t; 3J = 7.1 Hz; 
-CH2-CH3), 1.25-1.42 (4H; m; -(CH2)2-CH3), 1.53-1.63 (2H; m; C3H7-CH2-
CH2-S-), 2.52 (2H; t; 3J = 7.4 Hz; -(CH2)3-CH2-S-), 2.58 (2H; t; 3J = 7.4 
Hz; -CH2-CO-), 2.77 (2H; t; 3J = 7.4 Hz; -S-CH2-CH2-CO), 4.11-4.18 (2H; 
q; 3J = 7.1 Hz; -O-CH2-) 
 
3-(Pentylsulfanyl)propionic acid (4) 
Ethyl 3-(pentylsulfanyl)propionate (3) (4.3 g, 21 mmol) and potassium hydroxide (2.06 g, 
37 mmol) in a mixture of EtOH/H2O (3:1 v/v, 40 mL) were refluxed for 4 h. The solution 
was cooled to room temperature and concentrated. The remaining white residue was 
dissolved in water. This aqueous phase was washed with ether (30 mL) before it was 
acidified with conc. HCl. Then, the product was extracted from the aqueous phase with 
3 portions of ether (3 x 30 mL). The combined organic extracts were washed with water 
and brine. After drying over Na2SO4 the solvent was evaporated. 
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Light yellow oil; yield: 3.7 g (100%) 
C8H16O2S (176.27) 
[1H] NMR (CDCl3):  
δ (ppm) = 0.89 (3H; t; 3J = 7.1 Hz; -(CH2)4-CH3), 1.25-1.42 (4H; m; -
(CH2)2-CH3), 1.53-1.63 (2H; quin; 3J = 7.3 Hz; C3H7-CH2-CH2-S-), 2.53 
(2H; t; 3J = 7.4 Hz; -(CH2)3-CH2-S-), 2.66 (2H; t; 3J = 7.1 Hz; -CH2-
COOH), 2.77 (2H; t; 3J = 7.1 Hz; -S-CH2-CH2-CO) 
 
N-Methyl-3-(pentylsulfanyl)propionamide (6) 
Oxalyl chloride (4 g, 31 mmol) was added dropwise to a stirred solution of 3-(pentyl-
sulfanyl)propionic acid (4) in DCM (40 mL) and the mixture was stirred for 1 h at r.t.. The 
solvent and unreacted oxalyl chloride were then removed in vacuo to obtain crude 3-
(pentylsulfanyl)propionic acid chloride (5). Crude 5 was added drop-wise to a solution of 
methylamine (40% in water; 20 mL, 210 mmol) and NaOH (1.7  g, 42 mmol) at -10 °C. 
After complete addition the reaction mixture was acidified with 15% HCl and extracted 
with DCM (3 x 50 mL). The combined organic phases were washed with water and 
brine, dried over Na2SO4 and the solvent was evaporated. The crude product was 
purified by column chromatography (SiO2; DCM/ethyl acetate 1:1, v/v). TLC plates were 
stained with iodine (1% on silica gel) to reveal the product as yellow spot. 
Orange oil; yield: 3.2 g (80%) 
C9H18NOS (189.32) 
[1H] NMR (CDCl3):  
δ (ppm) = 0.83 (3H; t; 3J = 7.1 Hz; -(CH2)4-CH3), 1.22-1.34 (4H; m; -
(CH2)2-CH3), 1.47-1.57 (2H; quin; 3J = 7.4 Hz; C3H7-CH2-CH2-S-), 2.39 
(2H; t; 3J = 7.3 Hz; -(CH2)3-CH2-S-), 2.46 (2H; t; 3J = 7.4 Hz; -CH2-CON), 
2.70-2.79 (5H; m; -S-CH2CH2CO, N-CH3) 
 
N-Methyl-3-(pentylsulfanyl)propylamine (7) 
Under dry nitrogen atmosphere, N-methyl-3-(pentylsulfanyl)propionamide 6 (1.5 g, 7.9 
mmol) in dry THF (8 mL) was added dropwise to a suspension of LiAlH4 (600 mg; 16 
mmol) in dry THF (20 mL). The reaction mixture was refluxed for 3 h and then with 
cooling in an ice-water bath hydrolysed with water (20 mL) and sat. NaHCO3 (10 mL). 
The organic components were extracted into ethyl acetate (3 x 25 mL) and this organic 
phase was washed with 3 portions of 2N HCl (3 x 25 mL). The combined acidic phases 
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were rebasified with 2N NaOH and extracted again with ethyl acetate (3 x 25 ml). The 
combined organic phases of the second extraction were washed with water and dried 
over Na2SO4. Finally the solvent was removed under reduced pressure. 
Orange oil; yield: 500 mg (36%) 
C9H21NS (175.33) 
[1H] NMR (CDCl3):  
δ (ppm) = 0.83 (3H; t; 3J = 7.1 Hz; -(CH2)4-CH3), 1.20-1.34 (4H; m; -
(CH2)2-CH3), 1.47-1.57 (2H; quin; 3J = 7.4 Hz; C3H7-CH2-CH2-S-), 1.67-
1.77 (2H; quin; 3J = 7.2 Hz; N-CH2-CH2-CH2-S), 2.37 (3H; s; N-CH3), 
2.44 (2H; t; 3J = 7.4 Hz; -(CH2)3-CH2-S-), 2.50 (2H; t; 3J = 7.3 Hz; N-
(CH2)2-CH2-S-), 2.61 (2H; t; 3J = 7.0 Hz; N-CH2) 
 
5-Carboxypentyltriphenylphosphoniumbromide (8) 
5-Bromovaleric acid (20.0 g, 110 mmol) and triphenylphosphine (26.2 g, 100 mmol) 
were mixed and heated to 85 °C. The gently stirred melt becomes solid after 1 h. The 
crude solid was dissolved in boiling chloroform/ethanol (20:1, v/v, 150 mL)). By addition 
of ether (200 mL) the pure product was precipitated. 
White solid; yield: 39 g (90%) 
C23H24BrO2P (433.31) 
Melting point: 195 °C (Lit: 205-206 °C (Bhalerao et al., 1970))  
[1H] NMR (D4-methanol):  
δ (ppm) = 1.65-1.91 (4H; m; (CH2)2-CH2-COOH), 2.37 (2H; t; 3J = 7.0 Hz; 
-CH2-COOH), 3.39-3.53 (2H; m; -CH2-P), 7.70-7.94 (15H; m; phenyl-H) 
 
6.1.2.1.2 Preparation of Aryliodides and Arylbromides 
 
Tetraethylammonium diacetoxyiodate (Doleschall and Toth, 1980) 
Under dry nitrogen atmosphere tetraethylammoniumiodide (5 g, 19.4 mmol) and 
diacetoxyiodobenzene (6.25 g, 19.4 mmol) were dissolved in abs. chloroform (25 mL) 
and stirred for 2 h at room temperature. The reaction mixture was allowed to stand over 
night. Abs. ether (150 mL) was added to the clear brown solution and the mixture was 
cooled to 0 °C under stirring. A crystalline solid was filtered of quickly under a nitrogen 
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flush, washed with abs. ether and immediately dried over phosphorous pentoxide in 
vacuo.  
Yellow crystals; yield: 10.2 g (88 %) 
C12H26NIO4 (375.25) 
[1H] NMR (CDCl3):  
δ (ppm) = 1.41 (12 H; 3 × t; N-CH2-CH3), 1.98 (6H; s, CH3-COO), 3.43 
(8H; q; N-CH2-CH3) 
 
2-Hydroxy-3-iodo-5-methoxybenzaldehyde (10) 
Under nitrogen atmosphere at -15 °C tetraethylammonium diacetoxyiodate (900 mg, 2.4 
mmol) was added to a stirred solution of 2-hydroxy-5-methoxybenzaldehyde (300 mg, 
2.0 mmol) in abs. DCM (8 mL). After stirring for 14 h at this temperature a second 
portion of the iodination reagent was added (450 mg, 1.2 mmol). After a total reaction 
time of 16 h the reaction mixture was concentrated in vacuo and the residue was 
purified by column chromatography (SiO2; PE/ethyl acetate 10/1, v/v). 
Yellow solid; yield: 200 mg (36%) 
Melting point: 98-100 °C (Lit: 102-104 °C (Hart and Mannino, 1996)) 
C8H7IO3 (278.05) 
[1H] NMR (CDCl3):  
δ (ppm) = 3.85 (3H; s; -O-CH3), 7.10 (1H; s; phenyl-H), 7.60 (1H; s; 
phenyl-H), 11.35 (1H; s; CHO) 
[13C] NMR (CDCl3):  
δ (ppm) = 56, 85 (C-I), 117, 119, 133, 153, 154, 196  
MS (CI, NH3):  m/z = 295.9 (100 % MNH4+), 278.9 (28%, MH+) 
 
3-Bromo-2-hydroxy -5-methoxybenzaldehyde (11) 
Bromine (1.36 g, 0.44 mL, 8.5 mmol) was added to a stirred solution of sodium acetate 
(0.86 g, 10.5 mmol) and 2-hydroxy-5-methoxybenzaldehyde (1.0 g, 6.6 mmol) in glacial 
acetic acid (30 mL) and the reaction mixture was stirred for 1 h. The solvent was 
removed in vacuo and the residue was dissolved in DCM (50 mL). The solution was 
washed with water (2 × 25 mL), dried over Na2SO4 and evaporated. The crude product 
was crystallised from ethanol to obtain a first product fraction. The supernant was 
evaporated and from the residue a second product fraction was isolated by column 
chromatography (SiO2; PE/ethyl acetate 10/1, v/v).  
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Yellow solid; yield: 0.95 g (62%) 
Melting point: 106 °C (Lit: 108 °C (Evano et al., 2004))  
C8H7BrO3 (231.05) 
[1H] NMR (CDCl3):  
δ (ppm) = 3.80 (3H; s; -O-CH3), 7.00 (1H; d; 5J = 3.0 Hz; phenyl-H), 7.40 
(1H; d; 5J = 3.0 Hz; phenyl-H), 11.11 (1H; s; CHO) 
 
6.1.2.1.3 Unsuccessful Iodination Methods 
 
Procedure a) (Collini et al., 2004)  
Methyl-5-methoxysalicylate (0.91 g, 5.0 mmol) and KOH (0.28 g, 5.0 mmol) were 
dissolved in methanol (5 mL). A solution of iodine (1.27 g, 5.0 mmol) in methanol (7 mL) 
was droped into the mixture while heating to 50 °C. The mixture was stirred for 2 h at 
this temperature. The solvent was removed in vavuo and the product was purified by 
column chromatography (SiO2; PE/DCM 1/2, v/v → DCM).  
 
Procedure b) (Kometani et al., 1985) 
Chloramin T (338 mg, 1.2 mmol) and NaI (180 mg, 1.2 mmol) were added to a solution 
of methyl-5-methoxysalicylate (182 mg, 1.0 mmol) in DMF (5 mL). After stirrig for 5 h the 
reaction mixture was diluted with water and acidified with conc. HCl. The formed 
precipitate was extracted into ethyl acetate. The organic phase was washed with a 
Na2S2O3 solution and brine, dried over Na2SO4 and evaporated. By crystallisation from 
ethyl acetate a solid was isolated. 
Procedures a) and b) yielded the biaryl product 12 as yellow solid 
C18H18O8 (362.33) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 3.80 (3H; s; -O-CH3), 3.95 (3H; s; -COOCH3), 7.15 (1H; s; 
phenyl-H), 7.30 (1H; s; phenyl-H) 
[13C] NMR (CDCl3): 
δ [ppm] = 52, 56, 112, 125, 127, 151, 154, 171 
MS (EI):  m/z = 362.2 
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6.1.2.1.4 Sonogashira Coupling Reaction 
 
5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-carbaldehyde (13) 
2-Hydroxy-3-iodo-5-methoxybenzaldehyde (10) (160 mg, 0.58 mmol), Pd(PPh3)2Cl2 
(12.0 mg, 0.017 mmol, 3 mol%), CuI (6.0 mg, 0.03 mmol, 5 mol%) and 4-ethinylanisol 
(86 mg, 0.65 mmol) were dissolved in a helium-degassed mixture of DMF (5 mL) and 
DEA (1 mL) and stirred for 2 h at 60 °C. The reaction mixture was then poured into a 0.1 
N HCl solution (100 mL) and extracted with three portions of ethyl acetate (3 × 50 mL). 
The combined organic phases were dried over Na2SO4 and evaporated. From the 
obtained dark residue the product was isolated by column chromatography (SiO2; 
PE/ethyl acetate 10/1, v/v). Final purification by recrystallisation from PE/ethyl acetate 
10/1, v/v. 
Pale yellow solid, yield: 100 mg (61 %) 
 
Alternatively 2-hydroxy-3-bromo-5-methoxybenzaldehyde (11) (231 mg, 1.0 mmol), 
Pd(PPh3)2Cl2 (21.0 mg, 0.03 mmol, 3 mol%), CuI (9.5 mg, 0.05 mmol, 5 mol%), NaI 
(100 mg, 0,65 mmol) and 4-ethinylanisol (165 mg, 1.25 mmol) were dissolved in a 
helium-degassed mixture of DMF (10 mL) and DEA (2 mL) and stirred for 14 h at 70 °C. 
The reaction was worked up as decribed above. 
Pale yellow solid; yield: 130 mg (46 %) 
C17H14O4 (282.30) 
Melting point: 127-128 °C (from PE/ethyl acetate) (Lit: 218-220 °C (Miller et al., 2003)) 
[1H] NMR (CDCl)3: 
δ [ppm] ) = 3.87 (3H; s; -O-CH3), 3.88 (3H; s; -O-CH3), 6.86 (1H; s; 
benzofuran-H3), 6.98-7.02 (2H; d; AA’BB’; 3J = 8.8 Hz; phenyl-H), 7.29-
7.33 (2H; m; benzofuran-H4, -H6), 7.80-7.87 (2H; d; AA’BB’; 3J = 8.8 Hz; 
phenyl-H), 10.56 (1H; s; CHO) 
MS (EI):  m/z = 282.1 
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6.1.2.1.5 Introduction of Side Chains  
 
1-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]propane-1-ol (14) 
Under nitrogen atmosphere Mg turnings (29 mg, 1.2 mmol) and ethylbromide (200 mg, 
1.8 mmol) in dry THF (4ml) were activated with iodine and subsequently stirred at 50 °C 
for 1 h, until all the Mg was converted into the Gringard reagent. 5-Methoxy-2-(4-
methoxyphenyl)benzofuran-7-carbaldehyde (13) (282 mg, 1.0 mmol) in THF (1 mL) was 
added in small portions. After stirring for 2 h at 50 °C the reaction mixture was poured 
into a 0.1 N HCl solution (20 mL) and extracted with three portions of ethyl acetate (3 × 
25 mL). The combined organic phases were washed with water and brine, dried over 
Na2SO4 and evaporated. The secondary alcohol was purified by column 
chromatography (SiO2; PE/ethyl acetate 5:1, v/v). 
Yellow solid, yield: 200 mg (64%) 
C19H20O4 (312.36) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 1.00 (3H; t; 3J = 7.4 Hz; CH3-CH2 ), 1.97-2.07 (2H; m; CH3-
CH2-), 3.85 (3H; s; -O-CH3), 3.86 (3H; s; -O-CH3), 5.13 (1H; t; 3J = 6.5 
Hz; Et-CH-OH), 6.83 (1H; s; benzofuran-H3), 6.90-6.92 (2H; m; 
benzofuran-H4, -H6), 6.96-7.00 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H), 
7.75-7.78 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
MS (EI):  m/z = 312.2  
 
1-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]butane-1-ol (15) 
Preparation from propylbromide (150 mg, 1.2 mmol) and 5-methoxy-2-(4-
methoxyphenyl)benzofuran-7-carbaldehyde (13) (200 mg, 0.71 mmol) following the 
procedure described for 14. The product was purified by column chromatography (SiO2; 
PE/ethyl acetate 5/1, v/v). 
Yellow solid, yield: 140 mg (60%) 
C20H22O4 (326.39) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.98 (3H; t; 3J = 7.3 Hz; CH3-CH2- ), 1.34-1.62 (2H; m; CH3-
CH2-) 1.90-2.02 (2H; m; -CH(OH)-CH2-), 3.85 (3H; s; -O-CH3), 3.86 (3H; 
s; -O-CH3), 5.22 (1H; t; 3J = 6.6 Hz; C3H7-CH-OH), 6.85 (1H; s; 
benzofuran-H3), 6.90-6.93 (2H; m; benzofuran-H4, -H6), 6.95-7.00 (2H; d; 
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AA’BB’; 3J = 8.9 Hz; phenyl-H), 7.73-7.78 (2H; d; AA’BB’; 3J = 8.9 Hz; 
phenyl-H) 
MS (EI):  m/z = 326.2  
 
1-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]-9-(pentylthio)nonan-1-ol (16) 
Preparation from 1-Bromo-8-(pentylsulfanyl)octane (1) (350 mg, 1.2 mmol) and 5-
methoxy-2-(4-methoxyphenyl)benzofuran-7-carbaldehyde (13) (226 mg, 0.8 mmol) 
following the procedure described for 14. The product was purified by column 
chromatography (SiO2; PE/ethyl acetate 5:1, v/v). 
Yellow oil; yield: 190 mg (47%) 
C30H42O4S (498.72) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.90 (3H; t; 3J = 7.1 Hz; CH3-CH2- ), 1.20-1.64 (18H; m; CH3-
(CH2)3-; -S-CH2-(CH2)6-) 1.91-2.02 (2H; q; 3J = 7.0 Hz; -CH(OH)-CH2-), 
2.43-2.53 (4H; m; -CH2-S-CH2-), 3.85 (3H; s; -O-CH3), 3.86 (3H; s; -O-
CH3), 5.22 (1H; t; 3J = 6.6 Hz; C3H7-CH-OH), 6.83 (1H; s; benzofuran-
H3), 6.89-6.94 (2H; m; benzofuran-H4, -H6), 6.95-7.00 (2H; d; AA’BB’; 3J 
= 8.9 Hz; phenyl-H), 7.73-7.79 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
MS (CI, NH3):  m/z = 481.3 (100%, MH+-H2O), 516.2 (30%, M+NH4+) 
 
1-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]-10-(pentylthio)decane-1-ol (17) 
Preparation from 1-bromo-9-(pentylsulfanyl)nonane (2) (430 mg, 1.38 mmol) and 5-
methoxy-2-(4-methoxyphenyl)benzofuran-7-carbaldehyde (13) (300 mg, 1.06 mmol) 
following the procedure described for 14. The product was purified by column 
chromatography (SiO2; PE/ethyl acetate 5:1, v/v). 
Yellow oil; yield: 250 mg (45%) 
C31H44O4S (512.74) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.89 (3H; t; 3J = 7.1 Hz; CH3-CH2- ), 1.20-1.64 (20H; m; CH3-
(CH2)3-; -S-CH2-(CH2)7-) 1.92-2.03 (2H; q; 3J = 7.0 Hz; -CH(OH)-CH2-), 
2.41-2.56 (4H; m (br); -CH2-S-CH2-), 3.85 (3H; s; -O-CH3), 3.86 (3H; s; 
-O-CH3), 5.20 (1H; t; 3J = 6.6 Hz; C3H7-CH-OH), 6.83 (1H; s; 
benzofuran-H3), 6.89-6.94 (2H; m; benzofuran-H4, -H6), 6.95-7.00 (2H; d; 
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AA’BB’; 3J = 8.9 Hz; phenyl-H), 7.74-7.77 (2H; d; AA’BB’; 3J = 8.9 Hz; 
phenyl-H) 
MS (EI):  m/z = 512.2  
 
6.1.2.1.6 Dehydratation 
 
(E)-5-Methoxy-2-(4-methoxyphenyl)-7-prop-1-enylbenzofuran (18) 
1-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]propane-1-ol (14) (100 mg, 
0.32 mmol) and p-toluenesulfonic acid (5.7 mg, 0.03 mmol) were dissolved in toluene 
(13 mL) and heated to 100 °C for 1 h. The reaction mixture was worked up by addition 
of 1N NaOH (10 mL) and extracted with three portions of ethyl acetate (3 × 20 mL). The 
combined organic phases were dried over Na2SO4 and evaporated. The product was 
purified by column chromatography (SiO2; PE/ethyl acetate 10/1, v/v). 
Yellow solid; yield: 70 mg (74 %) 
Melting point: 116 °C (dec.) 
C19H18O3 (294.34) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 1.99-2.04 (3H; d; 3J = 6.3 Hz; CH3-CH=CH- ),3.84 (3H; s; -O-
CH3), 3.86 (3H; s; -O-CH3), 6.61-6.70 (1H; d; 3J = 15.9 Hz; CH=CH-
phenyl), 6.71-6.84 (3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 6.86-
6.90 (1H; d; 5J = 2.5 Hz; benzofuran-H6), 6.96-7.02 (2H; d; AA’BB’; 3J = 
8.9 Hz; phenyl-H), 7.75-7.84 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
MS (CI, NH3):  m/z = 295.2 (MH+) 
 
(E)-5-Methoxy-2-(4-methoxyphenyl)-7-(but-1-enyl)benzofuran (19) 
Preparation from 1-[5-methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]butane-1-ol (15) 
(130 mg, 0.40 mmol) and p-toluenesulfonic acid (7.6 mg, 0.04 mmol) following the 
procedure described for 18.  
Yellow solid; yield: 80 mg (65 %) 
Melting point: 121-122 °C (dec.) 
C20H20O3 (308.38) 
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[1H] NMR (CDCl3): 
δ [ppm] ) = 1.18 (3H; t; 3J = 7.4 Hz; -CH2-CH3), 2.30-2.42 (2H; quin; 3J = 
7.5 Hz; CH3-CH2-CH), 3.85 (3H; s; -O-CH3), 3.87 (3H; s; -O-CH3), 6.61-
6.69 (1H; d; 3J = 16.0 Hz; -CH=CH-phenyl), 6.71-6.84 (3H; m; 
benzofuran-H3, -H4; -CH=CH-phenyl), 6.87-6.90 (1H; d; 5J = 2.5 Hz; 
benzofuran-H6), 6.95-7.02 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H), 7.75-
7.84 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
MS (EI):  m/z = 308.2 
 
(E)-5-Methoxy-2-(4-methoxyphenyl)-7-[9-(pentylthio)non-1-enyl]benzofuran (20) 
Preparation from 1-[5-methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]-9-(pentylthio)-
nonan-1-ol (16) (200 mg, 0.40 mmol) and p-toluenesulfonic acid (8 mg, 0.04 mmol) 
following the procedure described for 18.  
Yellow oil; yield: 90 mg (46%) 
C30H40O3S (480.72) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.89 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.24-1.66 (16H; m; CH3-
(CH2)3-; -S-CH2-(CH2)5-), 2.23-2.38 (2H; q; 3J = 7.0 Hz; -CH=CH-CH2-), 
2.44-2.56 (4H; m (br); -CH2-S-CH2-), 3.85 (3H; s; -O-CH3), 3.87 (3H; s; 
-O-CH3), 6.59-6.67 (1H; d; 3J = 16.0 Hz; -CH=CH-phenyl), 6.70-6.84 
(3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 6.87-6.89 (1H; d; 5J = 2.5 
Hz; benzofuran-H6), 6.95-7.02 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H), 
7.76-7.84 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
MS (EI):  m/z = 480.4  
 
(E)-5-Methoxy-2-(4-methoxyphenyl)-7-[10-(pentylthio)dec-1-enyl]benzofuran (21) 
Preparation from 1-[5-methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]-10-(pentyl-
thiodecan)-1-ol (17) (200 mg, 0.39 mmol) and p-toluenesulfonic acid (8 mg, 0.04 mmol) 
following the procedure described for 18.  
Yellow oil; yield: 145 mg (75%) 
C31H42O3S (494.73) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.89 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.24-1.67 (18H; m; CH3-
(CH2)3-; -S-CH2-(CH2)5-), 2.27-2.37 (2H; q; 3J = 7.0 Hz; -CH=CH-CH2-) 
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2.45-2.55 (4H; m (br); -CH2-S-CH2-), 3.85 (3H; s; -O-CH3), 3.87 (3H; s; 
-O-CH3), 6.59-6.67 (1H; d; 3J = 16.0 Hz; -CH=CH-phenyl), 6.70-6.84 
(3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 6.87-6.89 (1H; d; 5J = 2.5 
Hz; benzofuran-H6), 6.95-7.02 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H), 
7.76-7.84 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
 
6.1.2.1.7 Oxidation of the Side Chain Sulfur 
 
(E)-5-Methoxy-2-(4-methoxyphenyl)-7-(9-pentylsulfonylnon-1-enyl)benzofuran (22) 
A solution of meta-chloroperbenzoic acid (123 mg, 0.50 mmol) in chloroform (5 mL) was 
added dropwise to a solution of 5-methoxy-2-(4-methoxyphenyl)-7-[9-(pentylthio)non-1-
enyl]-benzofuran (20) (100 mg, 0.21 mmol) in chloroform (20 mL). After stirring for 20 
min at room temperature, the reaction mixture was poured into sat. NaHCO3 solution 
(20 mL) and stirred for 15 min. The chloroform layer was separated using a separation 
funnel. After successively washing with NaHCO3 solution, water and brine the organic 
phase was evaporated. Purification by column chromatography (SiO2; PE/ethyl acetate 
3:1, v/v).  
Light yellow oil; yield: 50 mg (49%) 
C30H40O5S (512.72) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.87 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.24-1.55 (12H; m; CH3-
(CH2)2-; -SO2-(CH2)2-(CH2)4-), 1.73-1.83 (4H; m; -CH2-CH2-SO2-CH2-
CH2-), 2.25-2.32 (2H; q; 3J = 6.9 Hz; -CH=CH-CH2-), 2.85-2.92 (4H; m 
(br); -CH2-SO2-CH2-), 3.80 (3H; s; -O-CH3), 3.82 (3H; s; -O-CH3), 6.55-
6.62 (1H; d; 3J = 16.0 Hz; -CH=CH-phenyl), 6.64-6.79 (3H; m; 
benzofuran-H3, -H4; -CH=CH-phenyl), 6.83-6.85 (1H; d; 5J = 2.5 Hz; 
benzofuran-H6), 6.93-6.96 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H), 7.73-
7.76 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
MS (EI):  m/z = 512.3 
 
(E)-5-Methoxy-2-(4-methoxyphenyl)-7-(10-pentylsulfonyldec-1-enyl)benzofuran (23) 
Preparation from 5-methoxy-2-(4-methoxyphenyl)-7-[10-(pentylthio)dec-1-enyl]-
benzofuran (21) (50 mg, 0.10 mmol) and meta-chloroperbenzoic acid (34 mg, 0.2 mmol) 
as described for 22. 
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Light yellow oil; yield: 40 mg (76%) 
C31H42O5S (526.73) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.92 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.26-1.58 (14H; m; CH3-
(CH2)2-; -SO2-(CH2)2-(CH2)4-), 1.78-1.88 (4H; m; -CH2-CH2-SO2-CH2-
CH2-) 2.29-2.36 (2H; q; 3J = 6.9 Hz; -CH=CH-CH2-), 2.89-2.95 (4H; m 
(br); -CH2-SO2-CH2-), 3.85 (3H; s; -O-CH3), 3.87 (3H; s; -O-CH3), 6.59-
6.67 (1H; d; 3J = 16.0 Hz; -CH=CH-phenyl), 6.69-6.84 (3H; m; 
benzofuran-H3, -H4; -CH=CH-phenyl), 6.87-6.89 (1H; d; 5J = 2.5 Hz; 
benzofuran-H6), 6.97-7.00  (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H), 7.77-
7.80 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H) 
MS (EI):  m/z = 526.3 
 
6.1.2.1.8 Final Cleavage of the Metoxy Protecting Groups 
 
(E)-2-(4-hydroxyphenyl)-7-(prop-1-enyl)benzofuran-5-ol (24) 
Under nitrogen atmosphere at -10 °C a solution of 5-methoxy-2-(4-methoxyphenyl)-7-
(prop-1-enyl)benzofuran (18) in abs. DCM (1 mL) was added dropwise to a stirred 
solution of BBr3 (1M stock solution in DCM, 0.85 mmol, 0.85 mL) in DCM (7 mL). After 
the adition the mixture was stirred for 90 min at room temperature. The reaction was 
terminated by slow addition of 10% NaHCO3 solution at 0 °C. After dillution with water 
the mixture was extracted with three portions of ethyl acetate (3 × 30 mL) and the 
combined organic phases were evaporated. The product was purified by column 
chromatography (SiO2; DCM/ethyl acetate 20/1, v/v) and finally crystallised from DCM. 
White solid; yield: 10 mg (22%) 
Melting point: 196 °C (dec.) 
C17H14O3 (266.29) 
[1H] NMR (D6-DMSO): 
δ [ppm] ) = 1.94-2.00 (3H; d; 3J = 6.3 Hz; CH3-CH=CH- ), 6.55-6.63 (1H; d; 
3J = 16.0 Hz; -CH=CH-phenyl), 6.65-6.78 (3H; m; benzofuran-H3, -H4; 
-CH=CH-phenyl), 6.86-6.92 (2H; d; AA’BB’; 3J = 8.7 Hz; phenyl-H), 7.02 
(1H; s; benzofuran-H6), 7.69-7.75 (2H; d; AA’BB’; 3J = 8.7 Hz; phenyl-H), 
9.11 (1H; s; -OH), 9.83 (1H; s; -OH) 
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MS (EI):  m/z = 226.3 
HR-MS (EI):  calculated:  266.0943 
 found:  266.0945 
Analysis: calculated:  C: 76.7 H: 5.3 
 found:  C: 74.9 H: 5.5 
HPLC:  Gradient: 0-35 min: MeCN/H2O 30/70 to 95/5; 35-40 min: 95/5 
RT = 20.07 min; purity: 98% 
 
(E)-2-(4-hydroxyphenyl)-7-(but-1-enyl)benzofuran-5-ol (25) 
Preparation from 5-methoxy-2-(4-methoxyphenyl)-7-(but-1-enyl)benzofuran (19) (60 mg, 
0.19 mmol) and BBr3 (1M in DCM, 1.0 mmol, 1.0 mL) following the demethylation 
method described for 24. The reaction mixture was stirred for 75 min.  
White solid; yield: 40 mg (75%) 
Melting point: 174 °C (dec.) 
C18H16O3 (280.32) 
[1H] NMR (D6-DMSO): 
δ [ppm] ) = 1.12 (3H; t; 3J = 7.4 Hz; CH3-CH2- ), 2.25-2.37 (2H; quin; 3J = 
7.4 Hz; CH3-CH2-), 6.53-6.62 (1H; d; 3J = 16.1 Hz; -CH=CH-phenyl), 6.67-
6.79 (3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 6.86-6.92 (2H; d; 3J = 
8.7 Hz; phenyl-H), 7.02 (1H; s; benzofuran-H6), 7.68-7.75 (2H; d; AA’BB’; 
3J = 8.7 Hz; phenyl-H), 9.11 (1H; s; -OH), 9.84 (1H; s; -OH) 
MS (EI):  m/z = 280.1 
HR-MS (EI):  calculated:  280.1099 
 found: 280.1104 
Analysis: calculated:  C: 77.12 H: 5.75 
 found:  C: 75.89 H: 5.85 
HPLC:  Gradient: 0-35 min: MeCN/H2O 30/70 to 95/5; 35-40 min: 95/5 
RT = 22.56 min; purity: 98% 
 
(E)-2-(4-hydroxyphenyl)-7-[9-(pentylthio)non-1-enyl]benzofuran-5-ol (26) 
Preparation from 5-methoxy-2-(4-methoxyphenyl)-7-[9-(pentylthio)non-1-enyl]-
benzofuran (20) (40 mg, 0.08 mmol) and BBr3 (1M in DCM, 0.5 mmol, 0.5 mL) following 
the demethylation method described for 24. The product was purified by column 
chromatography (SiO2; DCM/ethyl acetate 30/1, v/v) 
Experimental 95 
Light yellow solid; yield: 25 mg (69%) 
Melting point: 121-122 °C 
C28H36O3S (452.65) 
[1H] NMR (D6-DMSO): 
δ [ppm] ) = 0.84 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.20-1.55 (16H; m; CH3-
(CH2)3-; -S-CH2-(CH2)5-), 2.25-2.32 (2H; q; 3J = 6.7 Hz; -CH=CH-CH2-), 
2.41-2.46 (4H; m (br); -CH2-S-CH2-), 6.52-6.61 (1H; d; 3J = 16.0 Hz; 
-CH=CH-phenyl), 6.63-6.76 (3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 
6.86-6.89 (2H; d; AA’BB’; 3J = 8.7 Hz; phenyl-H), 7.02 (1H; s; benzofuran-
H6), 7.69-7.72 (2H; d; AA’BB’; 3J = 8.7 Hz; phenyl-H), 9.11 (1H; s; OH), 
9.84 (1H; s; OH) 
MS (EI):  m/z = 452.3 
HR-MS (EI):  calculated:  452.2385 
 found: 452.2381 
Analysis: calculated:  C: 74.3 H: 8.0 
 found:  C: 73.4 H: 8.5 
HPLC:  Gradient: 0-20 min: MeCN/H2O 60/40 to 95/5; 20-40 min: 95/5 
RT = 25.12 min; purity: 94% 
 
(E)-2-(4-hydroxyphenyl)-7-[10-(pentylthio)dec-1-enyl]benzofuran-5-ol (27) 
Preparation from 5-methoxy-2-[4-methoxyphenyl)-7-[10-(pentylthio)dec-1-enyl]-
benzofuran (21) (80 mg, 0.16 mmol) and BBr3 (1M in DCM, 0.9 mmol, 0.9 mL) following 
the demethylation method described for 24. The product was purified by column 
chromatography (SiO2; DCM/ethyl acetate 30/1, v/v) 
Light yellow solid; yield: 40 mg (54%) 
Melting point: 133-136 °C 
C29H38O3S (466.68) 
[1H] NMR (D6-DMSO): 
δ [ppm] ) = 0.84 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.21-1.57 (18H; m; CH3-
(CH2)3-; -S-CH2-(CH2)5-), 2.23-2.34 (2H; q; 3J = 6.9 Hz; -CH=CH-CH2-), 
2.40-2.48 (4H; m (br); -CH2-S-CH2-), 6.52-6.61 (1H; d; 3J = 16.0 Hz; 
-CH=CH-phenyl), 6.63-6.78 (3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 
6.84-6.92 (2H; d; AA’BB’; 3J = 8.7 Hz; phenyl-H), 7.02 (1H; s; benzofuran-
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H6), 7.67-7.74 (2H; d; AA’BB’; 3J = 8.7 Hz; phenyl-H), 9.10 (1H; s; -OH), 
9.84 (1H; s; -OH) 
MS (EI):  m/z = 466.1 
HR-MS (EI):  calculated:  466.2542 
 found: 466.2544 
Analysis: calculated:  C: 74.6 H: 8.2 
 found:  C: 73.3 H: 8.3 
HPLC:  Gradient: 0-20 min: MeCN/H2O 60/40 to 95/5; 20-40 min: 95/5 
RT = 26.70 min; purity: 97% 
 
(E)-2-(4-hydroxyphenyl)-7-[9-(pentylsulfonyl)non-1-enyl]benzofuran-5-ol (28) 
Preparation from 5-methoxy-2-(4-methoxyphenyl)-7-[9-(pentylsulfonyl)non-1-enyl]-
benzofuran (22) (50 mg, 0.1 mmol) and BBr3 (1M in DCM, 0.5 mmol, 0.5 mL) following 
the demethylation method described for 24. The product was purified by column 
chromatography (SiO2; DCM/ethyl acetate 10/1, v/v). Final Purification by preparative 
HPLC (Stat. Phase: Nucleodur 100-5 C-18, 21 mm ec, mobile Phase: acetonitrile/H2O 
65/35) 
Light yellow resin; yield: 20 mg (41%) 
C28H36O5S (484.65) 
[1H] NMR (D4-methanol): 
δ [ppm] ) = 0.92 (3H; t; 3J = 7.0 Hz; CH3-CH2-) 1.28-1.61 (12H; m; CH3-
(CH2)2-; -SO2-(CH2)2-(CH2)4-), 1.71-1.85 (4H; m; -CH2-CH2-SO2-CH2-
CH2-), 2.30-2.37 (2H; q; 3J = 6.8 Hz; -CH=CH-CH2-) 2.98-3.06 (4H; m (br); 
-CH2-SO2-CH2-), 6.55-6.63 (1H; d; 3J = 16.0 Hz -CH=CH-phenyl), 6.66-
6.79 (3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 6.83 (1H; s; 
benzofuran-H6), 6.85-6.91 (2H; d; AA’BB’; 3J = 8.8 Hz; phenyl-H), 7.66-
7.73 (2H; d; AA’BB’; 3J = 8.8 Hz; phenyl-H) 
MS (EI):  m/z = 484.3 
HR-MS (EI):  calculated:  484.2283 
 found: 484.2272 
HPLC:  Gradient: 0-30 min: MeCN/H2O 40/60 to 95/5; 30-40 min: 95/5 
RT = 23.77 min; purity: 100% 
 
 
Experimental 97 
(E)-2-(4-hydroxyphenyl)-7-[10-(pentylsulfonyl)dec-1-enyl]benzofuran-5-ol (29) 
Preparation from 5-methoxy-2-(4-methoxyphenyl)-7-(10-(pentylsulfonyl)dec-1-enyl)-
benzofuran (23) (40 mg, 0.08 mmol) and BBr3 (1M in DCM, 0.4 mmol, 0.4 mL) following 
the demethylation method described for 24. The product was purified by column 
chromatography (SiO2; DCM/ethyl acetate 30/1, v/v) 
Light yellow resin; yield: 15 mg (40%) 
C29H38O5S (498.68) 
[1H] NMR (D6-DMSO): 
δ [ppm] ) = 0.86 (3H; t; 3J = 6.9  Hz; CH3-CH2-), 1.23-1.55 (14H; m; CH3-
(CH2)2-; -SO2-(CH2)2-(CH2)5-), 1.60-1.72 (4H; m; -CH2-CH2-SO2-CH2-CH2), 
2.26-2.32 (2H; q; 3J = 6.9 Hz; -CH=CH-CH2-), 3.00-3.06 (4H; m (br), -CH2-
SO2-CH2-), 6.53-6.61 (1H; d; 3J = 16.0 Hz; -CH=CH-phenyl), 6.63-6.77 
(3H; m; benzofuran-H3, -H4; -CH=CH-phenyl), 6.85-6.91 (2H; d; AA’BB’; 3J 
= 8.7 Hz; phenyl-H), 7.02 (1H; s; benzofuran-H6), 7.67-7.74 (2H; d; 
AA’BB’; 3J = 8.7 Hz; phenyl-H), 9.11 (1H; s; -OH), 9.84 (1H; s; -OH) 
MS (EI):  m/z = 498.4 
HR-MS (EI):  calculated:  498.2440 
 found: 498.2451 
HPLC:  Gradient: 0-30min: MeCN/H2O 40/60 to 95/5; 30-40 min: 95/5 
RT = 25.44 min; purity: 99% 
 
6.1.2.1.9 Introduction of a Bifunctional Side Chain in Position 7 
 
(E)/(Z)-6-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]hex-5-enoic acid (30) 
Under nitrogen atmosphere at -15 °C n-BuLi (15% in hexane, 1.63 mmol, 1.05 mL) was 
added to a stirred solution of HN(SiMe3)2 (287 mg, 1.78 mmol) in abs. THF (1mL). The 
mixture was allowed to warm up to room temperature and after 30 min this solution was 
droped into a suspension of 5-carboxypentyltriphenylphosphoniumbromide (8) (346 mg; 
0.78 mmol) in abs. THF (3 mL) at -25 °C. The mixture was allowed to warm up slowly to 
-15 °C. Stirring for 1 h at this temperature resulted in a red suspension of phosphorous 
ylid 9. A solution of 5-methoxy-2-(4-methoxyphenyl)benzofuran-7-carbaldehyde (13) 
(200 mg, 0.71 mmol) in abs. THF (2 mL) was added slowly to the mixture at -15 °C, 
while the red colour disappeared. After 1 h the reaction mixture was worked up by 
addition of 1N HCl solution (100 mL) followed by extraction with three portions of ethyl 
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acetate (3 × 50 mL). The combined organic phases were dried over Na2SO4 and 
evaporated. Pre-purification was performed by column chromatography (SiO2; DCM 
/methanol 20/1, v/v). As the desired product 30 and the byproduct 
triphenylphosphinoxide have the same Rf value, a chromatographic separation was not 
achieved. The mixture was taken up in 0.5 N NaOH solution (100 mL) and stirred for 30 
min. Triphenylphosphinoxide was filtered of as a yellow precipitate. The filtrate was 
washed with ether (30 mL) and acidified with 2N HCl solution to pH 1. The product was 
extracted with three portions of ethyl acetate (3 × 50 mL); the organic phase was dried 
over Na2SO4 and evaporated. 
Pale yellow solid; yield: 120 mg (46 %), E/Z = 65/35 ([1H] NMR) 
C22H22O5 (366.41) 
[1H] NMR (CDCl3): 
δ [ppm] ) = 1.75-1.87 (0.74 H; q; 3J = 7.5 Hz; -CH=CH-CH2-, Z-isomer), 
1.88-1.98 (1.26 H; q; 3J = 7.4 Hz; -CH=CH-CH2-; E-Isomer), 2.33-2.52 
(4H; m; -(CH2)2-COOH), 3.83-3.88 (6H; m; -O-CH3), 5.81-5.91 (0.33 H; 
d(t); 3Jd = 11.6 Hz; 3Jt = 7.3 Hz; -CH=CH-CH2-, Z-isomer); 6.61-7.02 
(6.65 H; m; benzofuran-H3, -H4, -H6; AA’BB’ phenyl-H, -CH=CH-CH2- E-
isomer (0.65 H), phenyl-CH=CH-CH2-), 7.74-7.82 (2H; d; AA’BB’; 3J = 
8.9 Hz; phenyl-H) 
MS (EI):  m/z = 366.2 
 
(E)/(Z)-6-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]-N-[3-(pentylthio)propyl]hex-
5-enamide (31) 
(E)/(Z)-6-[5-Methoxy-2-(4-methoxyphenyl)benzofuran-7-yl]hex-5-enoic acid (30) 
(110 mg, 0.3 mmol), EDC (58 mg, 0.3 mmol), HOBT (48 mg, 0.3 mmol) and diisopropyl-
ethylamine (39 mg, 0.3 mmol) were dissolved in DCM (5mL) and stirred for 5 min. N-
Methyl-3-(pentylsulfanyl)propylamine (7) in DCM (0.5 mL) was added and the reaction 
mixture was stirred for 16 h at room temperature. DCM (30 mL) was added and the 
solution was washed with water (20 mL) and brine (20 mL), dried over Na2SO4 and 
evaporated. The product was purified by column chromatography (SiO2; DCM/ethyl 
acetate 15/1, v/v). 
Colourless oil; yield: 120 mg (78%); E/Z = 65/35 ([1H] NMR) 
C31H41NO4S (523.73) 
 
Experimental 99 
[1H] NMR (CDCl3): 
δ [ppm] ) = 0.87 (3H; m; CH3-CH2-), 1.23-2.00 (10H; m; -(CH2)3-CH3, CO-
CH2-CH2-, -N-CH2-CH2-), 2.22-2.55 (8H; m; -CH2-S-CH2-, -CH2-CH=CH-, -
CH2-CO-), 2.85, 2.93, 2.99 (3H; 3 × s; N-CH3), 3.20-3.48 (2H; m; -CH2-N), 
3.85-3.87 (6H; m; -O-CH3), 5.84-5.93 (0.35 H; d(t); 3Jd = 11.4 Hz; 3Jt = 
7.2 Hz –CH=CH-CH2-, Z-isomer), 6.62-7.00 (6.65 H; m; benzofuran-H3, 
-H4, -H6; AA’BB’ phenyl-H, phenyl-CH=CH-CH2-, E-isomer (0.65 H), 
phenyl-CH=CH-CH2-), 7.72-7.80 (2H; d; AA’BB’; 3J = 8.9 Hz; phenyl-H). 
MS (ES):  m/z = 524.2 (MH+) 
HR-MS (EI):  calculated:  523.2756 
 found: 523.2759 
 
(E)-6-[5-Hydroxy-2-(4-hydroxyphenyl)benzofuran-7-yl]-N-[3-(pentylthio)propyl]hex-5-
enamide (32) 
Under nitrogen atmosphere at -18 °C a solution of (E)/(Z)-6-[5-methoxy-2-(4-
methoxyphenyl)benzofuran-7-yl]-N-[3-(pentylthio)propyl]hex-5-enamid (31) (100 mg, 
0.19 mmol) in abs. DCM (1 mL) was added dropwise over a period of 15 min to a stirred 
solution of BBr3 (1M in DCM, 0.9 mmol, 0.9 mL) in DCM (7 mL). The reaction mixture 
turned dark immediately. After complete addition the reaction mixture was allowed to 
warm up to 10 °C and stirred for 2 h at this temperature. Then, at 0 °C, 10% NaHCO3 
solution was added and after dillution with water (30 mL) the mixture was extracted with 
three portions of ethyl acetate (3 × 50 mL). The organic phase was dried over Na2SO4 
and evaporated. The product was purified by column chromatography (SiO2; 
DCM/methanol 20/1, v/v).  
Colourless oil; yield: 60 mg (64%); E/Z = 99/1 ([1H] NMR) 
C29H37NO4S (495.67) 
[1H] NMR (D4-methanol): 
δ [ppm] ) = 0.82 (3H; m; CH3-CH2-), 1.19-1.94 (10H; m; -(CH2)3-CH3, CO-
CH2-CH2-, -N-CH2-CH2-), 2.26-2.54 (8H; m; -CH2-S-CH2-, -CH2-CH=CH-, -
CH2-CO-), 2.88, 3.03 (3H; 2 × s; N-CH3), 5.84-5.93 (0.01 H; d(t); 3Jd = 
11.4 Hz; 3Jt = 7.2 Hz –CH=CH-CH2-, Z-isomer), 6.59-6.83 (5H; m; 
benzofuran-H3, -H4, -H6, phenyl-CH=CH-CH2-, E-isomer), 6.86-6.88(2H; d; 
AA’BB’; 3J = 8.7 Hz; phenyl-H), 7.69-7.72 (2H; d; AA’BB’; 3J = 8.9 Hz; 
phenyl-H) 
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MS (ES):  m/z = 495.1  
HR-MS (EI):  calculated:  495.2443 
 found: 495.2444 
HPLC:  Gradient: 0-25min: MeCN/H2O 30/70 to 90/10; 25-40 min: 90/10 
RT = 23.64 min; purity: 97% 
 
(E)-2-(4-Hydroxyphenyl)-7-[6-[methyl[3-(pentylthio)propyl]amino]hex-1-enyl]benzofuran-
5-ol (33) 
Under dry nitrogen atmosphere a solution of (E)-6-[5-hydroxy-2-(4-hydroxyphenyl)-
benzofuran-7-yl]-N-[3-(pentylthio)propyl]hex-5-enamide (32) (50 mg, 0.1 mmol) was 
added dropwise to a suspension of lithiumaluminiumhydride (12 mg, 0.3 mmol) in abs. 
THF (1 mL). The reaction mixture was stirred for 3 h at 60 °C. The excess of 
lithiumaluminiumhydride was decomposed by slow addition of water at 0 °C. The 
product was extracted with three portions of ethyl acetate (3 × 30 mL); the combined 
organic phases were dried over Na2SO4 and evaporated. The product was purified by 
column chromatography (SiO2; ethyl acetate/methanol 7/1, v/v). 
Yellow oil; yield: 40 mg (83 %); E:Z = 94:6 ([1H] NMR) 
C29H39NO3S (481.69) 
[1H] NMR (D4-methanol): 
δ [ppm] ) = 0.88 (3H; t; 3J =7.0 Hz; CH3-CH2-), 1.22-1.41 (6H; m; -(CH2)2-
CH3, -CH=CH-CH2-CH2-), 1.45-2.81 (6H; m; -CH2-CH2-S-CH2-CH2-, -
CH=CH-(CH2)2-CH2-) 2.34 (3H; s; N-CH3), 2.35-2.41 (2H; q; 3J = 7.0 Hz; 
merged in N-CH3-peak; CH=CH-CH2-,), 2.40-2.50 (4H; m; -CH2-N-CH2-), 
2.58, 2.60 (2 × 2H; 2 × t (merged); 3J = 7.7 Hz; -CH2-S-CH2-), 5.81-5.89 
(0.06H; t(d); 3Jd = 11.4 Hz; 3Jt = 7.5 Hz; phenyl-CH=CH-CH2- Z-isomer), 
6.59-6.83 (5H; m; CH (benzofuran-H3, -H4, -H6, phenyl-CH=CH-CH2-, E-
isomer), 6.85-6.88 (2H; d; AA’BB’; 3J = 8.7 Hz; phenyl-H), 7.69-7.72 (2H; 
d; AA’BB’; 3J = 8.7 Hz; phenyl-H) 
MS (ES):  m/z = 481.2 
HR-MS (EI):  calculated:  481.2651 
 found: 481.2637 
HPLC:  Gradient: 0-25min: MeCN/0.025 % TFA (aq) 20/80 to 90/10; 25-40 min: 
90/10 
RT = 20.14 min; purity: 97% 
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6.1.2.2 Synthesis of 2-Aryl-tetrahydroisoquinolin-6-ols 
6.1.2.2.1 Synthesis of Side Chain Precursors 
 
Ethyl 10-bromodecanoate (34)  
10-bromodecanoic acid (1.0 g; 4.0 mmol) was dissolved in chloroform, ethanol (370 mg, 
8.0 mmol) and conc. H2SO4 (20 mg) were added and the mixture was refluxed for 4 h 
using a distilling trap. The chloroform solution was then washed successively with 
water, sat. Na2HCO3 solution and brine. The chloroform layer was evaporated and the 
residue was destilled in vacuo (120 °C, 1 mbar). 
Colourless oil; yield: 1.0 g (89%) 
C12H23O2Br (279.21) 
 [1H] NMR (CDCl3): 
δ(ppm) = 1.23-1.46 (13H; m; -(CH2)5 -, CH3), 1.61 (2H; quin; 3J = 7.3 Hz; 
-CH2-CH2-CO-), 1.79-1.89 (2H; quin; 3J = 7.0 Hz; -CH2-CH2-Br), 2.28 
(2H; t; 3J = 7.5 Hz; -CH2-CO-), 3.40 (2H; t; 3J = 6.9 Hz; -CH2-Br), 4.08-
4.15 (2H; q; 3J = 7.1 Hz; -O-CH2-CH3) 
 
Ethyl 11-bromoundecanoate (35)  
Preparation from 11-bromoundecanoic acid (5 g, 18.9 mmol) in the same way as 
described for 34.  
Colourless oil; yield: 5.2 g (94%) 
C13H25O2Br (293.24) 
 [1H] NMR (CDCl3): 
δ(ppm) = 1.22-1.45 (15H; m; -(CH2)6-, CH3), 1.60 (2H; quin; 3J = 7.3 Hz; 
-CH2-CH2-CO-), 1.79-1.89 (2H; quin; 3J = 7.2 Hz; -CH2-CH2-Br), 2.28 
(2H; t; 3J = 7.5 Hz; -CH2-CO-), 3.40 (2H; t; 3J = 6.9 Hz; -CH2-Br), 4.08-
4.15 (2H; q; 3J = 7.1 Hz; -O-CH2-CH3) 
 
Ethyl-10-(pentylthio)decanoate (36) 
Under nitrogen atmosphere pentanethiol (320 mg, 3.15 mmol) in dry DMF (5 mL) was 
added dropwise to a suspension of sodium hydride (60% suspension in paraffin; 
172 mg, 4.3 mmol) in dry DMF (5 mL) and the mixture was stirred till the gas evolution 
ceased. Then ethyl-10-bromodecanoate (34) in abs. DMF (5 mL) was added slowly, and 
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the reaction mixture was heated to 60 °C for 2 h. Excess sodium hydride was 
decomposed by the addition of water and the product extracted with three portions of 
ethyl acetate. The organic extract was washed with water and brine and dried over 
Na2SO4. The solvent was removed in vacuo. 
Purification by column chromatography (SiO2; PE/ethyl acetate 50/1, v/v). Staining of 
the TLC plates with iodine (1% on silica gel) revealed the product as yellow spot. 
Colourless oil; yield: 350 mg (40%) 
C17H34O2S (302.52) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.89 (3H; t; 3J = 7.0 Hz; -(CH2)4-CH3), 1.22-1.42 (17H; m; 
-(CH2)5-(CH2)2-S-(CH2)2-(CH2)2-, -O-CH2-CH3), 1.52-1.66 (6H; m; -CH2-
CH2-CO-, -CH2-CH2-S-CH2-CH2-), 2.27 (2H; t; 3J = 7.5 Hz; -CH2-CO), 
2.49 (4H; t; 3J = 7.4 Hz; -CH2-S-CH2-), 4.08-4.15 (2H; q; 3J = 7.1 Hz; O-
CH2-CH3) 
 
Ethyl-11-(pentylthio)undecanoate (37) 
Preparation from pentanethiol (1.95 g, 18.7 mmol), sodium hydride (60% suspension in 
paraffin; 612 mg, 25.5 mmol) and ethyl 11-bromoundecanoate (35) (5 g, 17.0 mmol) 
following the procedure described for 36.  
Colourless oil; yield: 2.70 g (50%) 
C18H36O2S (316.53) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.88 (3H; t; 3J = 7.1 Hz; -(CH2)4-CH3), 1.21-1.39 (19H; m; 
-(CH2)6-(CH2)2-S-(CH2)2-((CH2)2-, -O-CH2-CH3), 1.51-1.65 (6H; m; -CH2-
CH2-CO-, -CH2-CH2-S-CH2-CH2-), 2.27 (2H; t; 3J = 7.5Hz; -CH2-CO), 
2.48 (4H; t; 3J = 7.4 Hz; -CH2-S-CH2-), 4.07-4.14 (2H; q; 3J = 7.1 Hz; O-
CH2-CH3) 
 
10-Pentylthiodecanoic acid (38) 
Ethyl-10-(pentylthio)decanoate (36) (300 mg, 1 mmol) and KOH (112 mg, 2 mmol) were 
refluxed for 4 h in ethanol/water (3/1, v/v; 4 mL). The solvent was then removed in 
vacuo and the residue was dissolved in water. After acidification with 4N HCl solution 
the product was extracted with three portions of ether (3 × 50 mL). The organic extract 
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was dried over Na2SO4 and evaporated. The purity of the product was sufficient without 
further purification. 
White solid; yield: 200 mg (73%) 
C15H30O2S (274.46) 
Melting point: 45-46 °C 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.1 Hz; -(CH2)4-CH3), 1.24-1.43 (14H; m; 
-(CH2)5-(CH2)2-S-(CH2)2-(CH2)2-), 1.52-1.67 (6H; m; -CH2-CH2-CO-, -
CH2-CH2-S-CH2-CH2-), 2.34 (2H; t; 3J = 7.5 Hz; -CH2-CO), 2.49 (4H; t; 3J 
= 7.4 Hz; -CH2-S-CH2-) 
 
11-Pentylthioundecanoic acid (39) 
Preparation from ethyl-11-(pentylthio)undecanoate (37) (2.5 g, 7.9 mmol) and KOH (0.9 
g, 16 mmol) following the procedure described for 38. 
White solid; yield: 2.0 g (88%) 
C16H32O2S (288.49) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.89 (3H; t; 3J = 7.1 Hz; -(CH2)4-CH3), 1.24-1.42 (16H; m; 
-(CH2)6-(CH2)2-S-(CH2)2-(CH2)2-), 1.51-1.67 (6H; m; -CH2-CH2-CO-, -
CH2-CH2-S-CH2-CH2-), 2.34 (2H; t; 3J = 7.5 Hz; -CH2-CO), 2.49 (4H; t; 3J 
= 7.4 Hz; -CH2-S-CH2-) 
 
10-Pentylthiodecanoic acid chloride (40) 
Oxalyl chloride(120 mg, 1.2 mmol) was added to a solution of 10-pentylthiodecanoic 
acid (38) (220 mg, 0.8 mmol) in abs. DCM (2 mL) containing one drop of DMF. The 
solution was stirred for 1 h at room temperature. Solvent and excessive oxalyl chloride 
were removed in vacuo and the resulting oil was directly used for tetrahydroisoquinolin 
synthesis without further analysis. 
Light yellow oil; yield: 230 mg (100%) 
C15H29OCl (292.91) 
 
11-Pentylthioundecanoic acid chloride (41) 
Preparation from oxalyl chloride (500 mg, 5.2 mmol) and 11-pentylthioundecanoic acid 
(39) (1 g, 3.5 mmol) in the same way as described for 40.  
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Light yellow oil; yield: 1.03 g (96%) 
C16H31OCl (306.94) 
 
Ethyl-11-(pentylsulfonyl)undecanoate (42) 
Preparation from ethyl-11-(pentylthio)undecanoate (37) (370 mg, 1.17 mmol) and meta-
chloroperbenzoic acid (70 %, 605 mg) following the procedure described for 22. 
Purification by crystallisation from ethanol. 
White solid; yield: 380 mg (93%) 
C18H36O4S (348.54) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.0 Hz; -(CH2)4-CH3), 1.25-1.48 (19H; m; 
-(CH2)6-(CH2)2-S-(CH2)2-(CH2)2-, -O-CH2-CH3), 1.54-1.67 (2H; quin; -
CH2-CH2-CO-), 1.77-1.88(4H; m; -CH2-CH2-SO2-CH2-CH2-), 2.28 (2H; t; 
3J = 7.5 Hz; -CH2-CO), 2.93 (4H; t; 3J = 8.1 Hz; -CH2-SO2-CH2-), 4.08-
4.15 (2H; q; 3J = 7.1 Hz; O-CH2-CH3) 
 
11-Pentylsulfonylundecanoic acid (43) 
Preparation from ethyl-11-(pentylsulfonyl)undecanoate (42) (350 mg, 1.0 mmol) and 
KOH (200 mg, 3.5 mmol) following the procedure described for 38. 
White solid; yield: 270 mg (84 %) 
C16H32O4S (288.49) 
[1H] NMR (CDCl3) 
δ (ppm) = 0.92 (3H; t; 3J = 7.0 Hz; -(CH2)4-CH3), 1.25-1.45 (16H; m; 
-(CH2)6-(CH2)2-S-(CH2)2-(CH2)2-), 1.53-1.70 (2H; quin; 3J = 7.2 Hz; -CH2-
CH2-CO-), 1.76-1.90 (4H; m; -CH2-CH2-SO2-CH2-CH2-), 2.33 (2H; t; 3J = 
7.5 Hz; -CH2-CO), 2.91 (4H; t; 3J = 7.4 Hz; -CH2-SO2-CH2-) 
 
11-Pentylsulfonylundecanoic acid chloride (44) 
Preparation from oxalyl chloride (189 mg, 1.5 mmol) and 11-pentylsulfonyl-undecanoic 
acid (43) (300 mg, 0.94 mmol) following the procedure described for 40.  
Light yellow oil; yield: 290mg (100 %) 
C16H31O3SCl (306.93) 
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7-Bromoheptanoic acid (45) 
A solution of LiOH (400 mg, 16 mmol) in water (4 mL) was added to a stirred solution of 
etyl-7-bromoheptanoate (1.0 g, 4.22 mmol) in ethanol/THF (1/1, v/v; 8 ml) and stirred for 
4 h at room temperature. Ethanol and THF were then removed in vacuo and the residue 
was diluted with water (50 mL). After washing with ether the aqueous solution was 
acidified with 4 N HCl solution to pH 1. The product was extracted with three portions of 
ethyl acetate (3 × 50 mL); the combined organic phases were dried over Na2SO4 and 
evaporated. The purity of the remaining product was sufficient for further use. 
White solid; yield: 800 mg (91%) 
C7H13BrO2 (209.08) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.30-1.51 (4H; m; -(CH2)2-(CH2)2-COOH), 1.60-1.70 (2H; quin, 
3J = 7.3 Hz; -CH2-CH2-COOH), 1.81-1.91 (2H; quin; 3J = 7.1 Hz; -CH2-
CH2-Br), 2.36 (2H; t; 3J = 7.4 Hz; -CH2-COOH), 3.40 (2H; t; 3J = 6.7 Hz; 
-CH2-Br) 
 
7-Bromoheptanoic acid chloride (46) 
Preparation from oxalyl chloride (476 mg, 3.75 mmol) and 7-bromoheptanoic acid (45) 
(300 mg, 0.94 mmol) following the procedure described for 40.  
Light yellow oil; yield: 550 mg (98%) 
C7H12BrOCl (227.53) 
 
6.1.2.2.2 Synthesis of the N-Arylphenylethylamine Precursors 
 
3-Benzyloxyphenylacetic acid (47) 
Benzyl bromide (11.8 g, 69 mmol) and NaI (246 mg, 1.64 mmol) were added to a 
solution of 2-(3-hydroxyphenyl)acetic acid (10 g, 65.7 mmol) and KOH (9.2 g, 
164 mmol) in Ethanol (250 mL). The reaction mixture was refluxed for 6 h. Then 0.5 N 
HCl solution (300 mL) was added and the product was extracted with three portions of 
ethyl acetate (300 ml, 2 × 100 mL); the combined organic phases were dried over 
Na2SO4 and evaporated. Purification by crystallisation from ethanol. 
White crystals; yield: 13.4 g (84%) 
Melting point: 119-120 °C (Lit: 136 °C (Rapson and Robinson, 1935)) 
C15H14O3 (242.27) 
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[1H] NMR (D6 DMSO) 
δ (ppm) = 3.36 (2H; s; -CH2-COOH), 5.12 (2H; s; -O-CH2-Ph), 6.82-6.95 
(3H; m; phenyl-H), 7.21 (1H; t; 3J = 8.8 Hz; phenyl-H), 7.32-7.50 (5H; m; 
phenyl-H) 
 
2-[3-(benzyloxy)phenyl]-N-phenylacetamide (49) 
Under nitrogen atmosphere at room temperature oxalyl chloride (4.76 g, 3.2 mL, 
37.5 mmol) was added to a stirred solution of 3-benzyoxyphenylacetic acid (47) (6.06 g, 
25 mmol) in DCM (50 mL) containing one drop of DMF. The mixture was stirred until the 
gas evolution ceased. The solvent and the excess of oxalyl chloride were removed in 
vacuo. The carboxylic acid chloride was dissolved in benzene (10 mL) and added to a 
stirred solution of aniline (3.5 g, 37.5 mmol) in benzene (250 mL) containing Na2CO3 
(7.95 g, 75 mmol). The mixture was refluxed for 5 h and, after cooling to room 
temperature, carefully poured into a 0.5 N HCl solution (300 mL). The product was 
extracted with three portions of ethyl acetate (3 × 150 mL). The combined organic 
phases were washed with brine, dried over Na2SO4 and evaporated. The product was 
purified by crystallisation from acetonitrile. 
Light yellow crystals, yield: 6.2 g (78%) 
C21H19NO2 (317.38) 
[1H] NMR (CDCl3): 
δ (ppm) =3.71 (2H; s; -CH2-CO), 5.08 (2H; s; -CH2-OBn), 6.92-7.45 (14 
H; phenyl-H) 
MS (CI, NH3):  m/z = 318.1 (MH+) 
 
N,2-Bis(3-methoxyphenyl)acetamide (50) 
Preparation by coupling of 3-methoxyphenylacetic acid chloride (prepared from 
3 methoxyphenylacetic acid (5.0 g, 30 mmol) and oxalyl chloride (5.7 g, 45 mmol)) to 
meta-anisidine (5.54 g, 45 mmol). The procedure was the same as described for 49. 
The product was pre-purified by column chromatography (SiO2; PE/ethyl acetate 5/2 → 
5/3, v/v). Final purification was achieved by crystallisation from PE/ethyl acetate 5/1, v/v. 
White solid; yield: 7.3 g (89 %) 
C16H16NO3 (271.12) 
Melting point: 75-77 °C 
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[1H] NMR (CDCl3): 
δ (ppm) =3.68 (2H; s; -CH2-CO), 3.76, 3.80 (2 × 3H; 2 × s; -O-CH3), 
6.61-6.66 (1 H; d(d); 3J = 8.2 Hz; 5J = 2.0 Hz; N-phenyl-H4), 6.83-6.93 
(3H; m; 2-phenyl-H2, -H4, -H6), 7.12-7.19 (1H; t; 3J = 8.1 Hz; 2-phenyl-
H5), 7.22-7.93 (3H; m; N-phenyl-H2, -H5, -H6) 
MS (EI):  m/z = 271.1 
 
N-Phenyl-2-[3-(benzyloxy)phenyl]ethylamine (51) 
Under nitrogen atmosphere a solution of 2-[3-(benzyloxy)phenyl]-N-phenylacetamide 
(47) (2.0 g, 6.3 mmol) in abs. THF (6 mL) was added to a stirred suspension of LiAlH4 
(1.20 g, 31.5 mmol) in abs. ether (10 mL). The reaction mixture was gently refluxed for 2 
h. Under ice cooling the excess of LiAlH4 was hydrolysed with water (50 mL) and the 
product was extracted with ethyl acetate (3 × 30 mL). The organic phase was washed 
with water and brine, dried over Na2SO4 and evaporated. Purification by column 
chromatography (SiO2; PE/ethyl acetate 20/1, v/v).  
Yellow oil; yield: 1.55 g (81 %) 
C21H21NO (303.40) 
[1H] NMR (CDCl3): 
δ (ppm) = 2.91 (2H; t; 3J = 7.0 Hz; -NH-CH2-), 3.42 (2H; t; 3J = 7.0 Hz; 
phenyl-CH2-), 5.08 (2H; s; -CH2-Ph), 6.62-6.65 (2H; d, 3J = 8.5 Hz; N-
phenyl-H2, -H6), 6.74 (1H; t; 3J = 7.3 Hz; N-phenyl-H4), 6.85-6.90 (3H; m; 
2-phenyl-H2, -H4, -H6), 7.18-7.48 (8H; m; phenyl-H) 
MS (CI, NH3):  m/z = 304.1 (MH+) 
 
N,2-Bis(3-methoxyphenyl)ethylamine (52) 
Preparation from N,2-bis(3-methoxyphenyl)acetamide (50) (2.0 g; 7.38 mmol) and 
LiAlH4 (0.83 g; 22 mmol) following the procedure described for 51. Purification by 
column chromatography (SiO2; PE/ethyl acetate 10/1 → 7/1, v/v). 
Yellow-brownish oil; yield: 1.65 g (87 %) 
C16H18NO2 (257.14) 
[1H] NMR (CDCl3): 
δ (ppm) = 2.90 (2H; t; 3J = 7.0 Hz; -NH-CH2-), 3.40 (2H; t; 3J = 7.0 Hz; 
-phenyl-CH2-CH2-NH-), 3.78, 3.81 (2 × 3H; 2 × s; -O-CH3), 6.18 (1H; t; 5J 
= 2.2 Hz; N-phenyl-H2), 6.21-6.31 (2H; 2 × d(d) merged; 3J = 8.1 Hz; 5J = 
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2.2 Hz; N-phenyl-H4, -H6), 6.76-6.85 (3H; m; 2-phenyl-H2, -H4, -H6), 7.06-
7.12 (1H; t; 3J = 8.1 Hz; N-phenyl-H5), 7.21-7.28 (1H; t; 3J = 7.6 Hz; 
2-phenyl-H5) 
MS (EI):  m/z = 257.2 
 
6.1.2.2.3 Coupling of the Side Chains to the Amine Precursors 
 
N-[3-(benzyloxy)phenylethyl]-N-phenylpropionamide (53) 
Propionyl chloride (180 mg, 2.0 mmol) was added to a stirred mixture of N-phenyl-2-[3-
(benzyloxy)phenyl]ethylamine (51) (400 mg, 1.3 mmol) and Na2CO3 (420 mg, 4.0 mmol) 
in abs. benzene (15 mL). The reaction mixture was refluxed for 6 h at 80 °C and, after 
cooling to room temperature, carefully poured into a 0.5 N HCl solution. (50 mL). The 
product was extracted into ethyl acetate (3 × 50 mL) and the combined extracts were 
washed with brine, dried over Na2SO4 and evaporated. 
Purification by column chromatography (SiO2; PE/ethyl acetate 5/1, v/v).  
Colourless oil; yield: 400 mg (84 %) 
C24H25NO2 (359.46) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.05 (3H; t; 3J = 7.5 Hz; -CH2-CH3), 2.00-2.07 (2H; q; 3J = 
7.5 Hz; -CH2-CH3) 2.86 (2H; t; 3J = 7.9 Hz; -N-CH2-), 3.91 (2H; t; 3J = 
7.9 Hz; -phenyl-CH2-CH2-N-), 5.02 (2H; s; -CH2-Ph), 6.76-6.84 (3H; m; 
3-phenyl-H2, -H4, -H6), 7.05-7.08 (2H; d; 3J = 7.0 Hz; N-phenyl-H2, -H6), 
7.15-7.20 (1H; d(d); 3J1 = 8.9 Hz; 3J2 = 7.5 Hz; 3-phenyl-H5), 7.31-7.44 
(8H; m; N-phenyl-H3, -H4, -H5, -phenyl-H [benzyloxy]) 
MS (CI, NH3):  m/z = 360.1 (MH+)  
 
N-[3-(benzyloxy)phenylethyl]-N-phenylbutyramide (54) 
Preparation from butyryl chloride (210 mg, 2.0 mmol) and N-phenyl-2-[3-(benzyloxy)-
phenyl)ethylamine (51) (400 mg, 1.3 mmol) following the procedure described for 53.  
Colourless oil; yield: 400 mg (84 %) 
C25H27NO2 (373.49) 
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[1H] NMR (CDCl3): 
δ (ppm) = 0.83 (3H; t; 3J = 7.4 Hz; -CH2-CH3), 1.54-1.66(2H; s; 3J = 7.4 
Hz; -CH2-CH3), 1.97-2.05 (2H; q; 3J = 7.4 Hz; -CH2-CH2-CH3), 2.86 (2H; 
t; 3J = 7.9 Hz; -N-CH2-), 3.91 (2H; t; 3J = 7.9 Hz; -phenyl-CH2-CH2-N-), 
5.02 (2H; s; -CH2-Ph), 6.77-6.82 (3H; m; 3-phenyl-H2, -H4, -H6), 7.03-
7.08 (2H; d; 3J = 6.8 Hz; N-phenyl-H2, -H6), 7.14-7.20 (1H; d(d); 3J1 = 8.9 
Hz; 3J2 = 7.4 Hz; 3-phenyl-H5), 7.30-7.44 (8H; m; N-phenyl-H3, -H4, -H5, -
phenyl-H [benzyloxy]) 
MS (CI, NH3):  m/z = 374.1 (MH+)  
 
N-[3-(benzyloxy)phenylethyl]-10-pentylthio-N-phenyldecanamide (55) 
Preparation from 10-pentylthiodecanoic acid chloride (40) (230 mg, 0.8 mmol) and N-
phenyl-2-[3-(benzyloxy)phenyl]ethylamine (51) (160 mg, 0.53 mmol) following the 
procedure described for 53. Purification by column chromatography (SiO2; PE/ethyl 
acetate 10/1, v/v). 
Colourless resin; yield: 250 mg (85 %) 
C36H49NO2S (559.84) 
 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.1 Hz; -CH2-CH3), 1.10-1.65 (20H; m; -(CH2)3-
CH2-S-CH2-(CH2)7-), 2.00 (2H; t; 3J = 7.5 Hz; -CH2-CO), 2.46-2.52 (4H; 2 × t 
(merged); 3J = 7.4 Hz; -CH2-S-CH2-), 2.86 (2H; t; 3J = 7.9 Hz; -N-CH2-), 3.91 
(2H; t; 3J = 7.9 Hz; -phenyl-CH2-CH2-N-), 5.02 (2H; s; -CH2-Ph), 6.77-6.82 
(3H; m; 3-phenyl-H2, -H4, -H6), 7.04-7.07 (2H; d; 3J = 8.0 Hz; N-phenyl-H2, -
H6), 7.14-7.20 (1H; d(d); 3J1 = 9.0 Hz; 3J2 = 7.5 Hz; 3-phenyl-H5), 7.31-7.44 
(8H; m; N-phenyl-H3, -H4, -H5, -phenyl-H [benzyloxy]) 
MS (EI):  m/z = 559.3 
 
N-[3-(benzyloxy)phenylethyl]-11-pentylthio-N-phenylundecanamide (56) 
Preparation from 11-pentylthioundecanoic acid chloride (41) (1.02 g, 3.4 mmol) and N-
phenyl-2-[3-(benzylox)phenyl]ethylamine (51) (708 mg, 2.33 mmol) following the 
procedure described for 53. Purification by column chromatography (SiO2; PE/ethyl 
acetate 10/1, v/v). 
Colourless resin; yield: 1.00 g (80 %) 
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C37H51NO2S (573.87) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.1 Hz; -CH2-CH3), 1.11-1.62 (22H; m; -
(CH2)3-CH2-S-CH2-(CH2)8-), 2.01 (2H; t; 3J = 7.5 Hz; -CH2-CO), 2.46-
2.52 (4H; 2 × t (merged); 3J = 7.4 Hz; -CH2-S-CH2-), 2.86 (2H; t; 3J = 
7.9 Hz; -N-CH2-), 3.91 (2H; t; 3J = 7.9 Hz; -phenyl-CH2-CH2-N-), 5.02 
(2H; s; -CH2-Ph), 6.76-6.82 (3H; m; 3-phenyl-H2, -H4, -H6), 7.02-7.08 
(2H; d; 3J = 8.0 Hz; N-phenyl-H2, -H6), 7.14-7.20 (1H; d(d); 3J1 = 9.0 Hz; 
3J2 = 7.5 Hz; 3-phenyl-H5), 7.28-7.43 (8H; m; N-phenyl-H3, -H4, -H5, -
phenyl-H [benzyloxy]) 
MS (CI, NH3):  m/z = 574.4 (MH+) 
 
N-[3-(benzyloxy)phenylethyl]-11-pentylsulfonyl-N-phenylundecanamide (57) 
Preparation from 11-pentylsulfonylundecanoic acid chloride (44) (290 mg, 1.0 mmol) 
and N-phenyl-2-[3-(benzyloxy)phenyl]ethylamine (51) (200 mg, 0.7 mmol) following the 
procedure described for 53. Purification by column chromatography (SiO2; PE/ethyl 
acetate 3/1, v/v). 
White solid; yield: 360 mg (85 %) 
C37H51NO4S (605.35) 
Melting point: 64-65 °C 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.08-1.66 (14H; m; -
(CH2)2-(CH)2)2-SO2-(CH2)2-(CH2)5-), 1.70-1.89 (4H; m; -CH2-CH2-SO2-
CH2-CH2-), 2.00 (2H; t; 3J = 7.5 Hz; -CH2-CO), 2.80-2.99 (6H; m; 3J = -
CH2-SO2-CH2-, -N-CH2-), 3.90 (2H; t; 3J = 7.8 Hz; -phenyl-CH2-CH2-N-), 
5.02 (2H; s; -CH2-Ph), 6.75-6.83 (3H; m; 3-phenyl-H2, -H4, -H6), 7.02-
7.10 (2H; d; 3J = 8.0 Hz; N-phenyl-H2, -H6), 7.14-7.20 (1H; d(d); 3J1 = 9.0 
Hz; 3J2 = 7.5 Hz; 3-phenyl-H5), 7.28-7.43 (8H; m; N-phenyl-H3, -H4, -H5, -
phenyl-H [benzyloxy]) 
MS (CI, NH3):  m/z = 606.2 (MH+) 
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N-(3-Methoxyphenylethyl)-N-(3-methoxyphenyl)propionamide (58) 
Preparation from propionyl chloride (270 mg, 2.9 mmol) and N,2-bis(3-
methoxyphenyl)ethylamine (52) (500 mg, 1.9 mmol) following the procedure described 
for 53. After work-up, the purity of the product was sufficient for further use. 
Colourless oil; yield: 590 mg (97 %) 
C19H23NO3 (313.39) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.06 (3H; t; 3J = 7.3 Hz; CH3-CH2-), 2.00-2.14 (2H; q; 3J = 7.3 
hz; CO-CH2-) 2.86 (2H; t; 3J = 7.6 Hz; -NH-CH2-), 3.78, 3.79 (2 × 3H; 2 × 
s; -O-CH3), 3.89 (2H; t; 3J = 7.0 Hz; phenyl-CH2-CH2-NH-), 6.55 (1H; s; 
N-phenyl-H2), 6.62-6.80 (4H; m; N-phenyl-H6, phenyl-H2, -H4, -H6), 6.85-
6.93 (1H; d(d); 3J = 8.1 Hz; 5J = 2.4 Hz; N-phenyl-H4), 7.12-7.20 (1H; t; 
3J = 8.3 Hz; phenyl-H5), 7.27-7.33 (1H; t; merged in CDCl3 peak; 3J = 8.2 
Hz; N-phenyl-H5) 
 
N-(3-Methoxyphenylethyl)-N-(3-methoxyphenyl)-11-(pentylthio)undecanamide (59) 
Preparation from 11-pentylthioundecanoic acid chloride (41) (890 mg, 2.9 mmol) and 
N,2-bis(3-methoxyphenyl)ethylamine (52) (500 mg, 1.9 mmol) following the procedure 
described for 53. Purification by column chromatography (SiO2; PE/ethyl acetate 5/1, 
v/v). 
Colourless oil; yield: 920 mg (90 %) 
C32H49NO3S (527.80) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.89 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.12-1.43 (16 H; m; 
-(CH2)6-(CH2)2-S-(CH2)2-(CH2)2-), 1,48-1.64 (6H; m; -CH2-CH2-S-CH2-
CH2-, CO-CH2-CH2-), 2.04 (2H; t; 3J = 7.5 Hz; -CO-CH2-), 2.44-2.53 (4H; 
t; 3J = 7.4 Hz; -CH2-S-CH2-), 2.86 (2H; t; 3J = 7.6 Hz; -N-CH2-), 3.76, 
3.78 (2 × 3H; 2 × s; -O-CH3), 3.89 (2H; t; 3J = 7.0 Hz; phenyl-CH2-CH2-
N-), 6.55 (1H; t; 5J = 2.2 Hz; N-phenyl-H2), 6.63-6.79 (4H; m; N-phenyl-
H6, phenyl-H2, -H4, -H6), 6.85-6.91 (1H; d(d); 3J = 8.1 Hz; 5J = 2.0 Hz; N-
phenyl-H4), 7.13-7.20 (1H; t; 3J = 8.2 Hz; phenyl-H5), 7.26-7.33 (1H; t; 3J 
= 8.1 Hz; merged in CDCl3 peak; N-phenyl-H5) 
MS (CI, NH3):  m/z = 528.3 (MH+) 
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N-(3-Methoxyphenylethyl)-N-(3-methoxyphenyl)-11-(pentylsulfonyl)undecanamide (60) 
Preparation from 11-pentylsulfonylundecanoic acid chloride (44) (300 mg, 1.0 mmol) 
and N,2-bis(3-methoxyphenyl)ethylamine (52) (180 mg, 0.70 mmol) following the 
procedure described for 53. Purification by column chromatography (SiO2; PE/ethyl 
acetate 5/1, v/v). 
Light yellow oil; yield: 320 mg (84 %) 
C32H49NO5S (559.80) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.12-1.62 (16H; m; 
-(CH2)5-(CH2)2-SO2-(CH2)2-(CH2)2-), 1,72-1.89 (4H; m; -CH2-CH2-SO2-
CH2-CH2-), 2.04 (2H; t; 3J = 7.5 Hz; -CO-CH2-), 2.81-2.97 (6H; m; -CH2-
SO2-CH2-, -CH2-N-), 3.76, 3.78 (2 × 3H; 2 × s; -O-CH3), 3.89 (2H; t; 3J = 
7.0 Hz; phenyl-CH2-CH2-N-), 6.55 (1H; t; 5J = 2.0 Hz; N-phenyl-H2), 
6.63-6.79 (4H; m; N-phenyl-H6, phenyl-H2, -H4, -H6), 6.85-6.91 (1H; d(d); 
3J = 8.1 Hz; 5J = 2.0 Hz; N-phenyl-H4), 7.13-7.20 (1H; t; 3J = 8.2 Hz; 
phenyl-H5), 7.26-7.33 (1H; t; merged in CDCl3 peak; 3J = 8.1 Hz; N-
phenyl-H5) 
MS (CI, NH3):  m/z = 560.3 (MH+) 
 
6.1.2.2.4 Bischler Napiralski Cyclisation to the Tetrahydriisoquinolines 
 
6-(Benzyloxy)-1-ethyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (61) 
N-[3-(Benzyloxy)phenylethyl]-N-phenylpropionamide (53) (380 mg; 1.06 mmol) was 
dissolved in POCl3 (5 mL) and refluxed for 20 h. POCl3 was destilled off in vacuo at 60 
°C. Water (30 mL) and ether (30 mL) were added to the remaining resin and the mixture 
was stirred for 30 min at room temperature, until all of the material was dissolved. Then 
KI (830 mg; 5 mmol) was added to the water phase and the formed yellow precipitate 
was filtered off and dried in vacuo.  
This dihydroisoquinolinium iodide was dissolved in methanol and NaBH4 (80 mg, 
2.1 mmol) was added in small portions under gas evolution. After stirring for 1 h at room 
temperature water was added and the product was extracted with ether (3 × 50 ml); the 
organic extract was dried over Na2SO4 and evaporated. Purification by column 
chromatography (SiO2; PE/ethyl acetate 50/1, v/v). 
Light yellow resin; yield: 260 mg (71 %) 
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C24H25NO (343.46) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.00 (3H; t; 3J = 7.4 Hz, CH3-CH2-), 1.65-1.80 (1H; hept.; 3J = 
7.0 Hz; -CH-CH2-CH3 1diastereotopic H), 1.90-2.02 (1H; hept.; 3J = 7.0 
Hz; -CH-CH2-CH3 1diastereotopic H), 2.80-2.89 ´(1H; m; THIQ-H4 1 
diastereotopic H), 2.95-3.04 (1H; m; THIQ-H4 1 diastereotiopic H), 3.51-
3.66 (2H; m; THIQ-H3), 4.52 (1H; t; 3J = 7.0 Hz; -CH-), 5.05 (2H; s; -CH2-
Ph), 6.70-6.89 (5H; m; N-phenyl-H2, -H4- H6, THIQ -H5, -H7), 7.03-7.06 
(1H; d; 3J = 8.2 Hz; THIQ-H8), 7.22-7.28 (2H, d(t); merged in CDCl3-
peak; 3Jd = 7.3 Hz; 5Jt = 2.0 Hz; N-phenyl-H3, -H5), 7.31-7.46 (5H; m; 
phenyl-H) 
MS (CI, NH3):  m/z = 344.1 (MH+) 
 
6-(Benzyloxy)-1-propyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (62) 
Preparation from N-[3-(benzyloxy)phenylethyl]-N-phenylbutyramide (54) (400 mg, 1.05 
mmol) in POCl3 (5 mL) followed by reduction with NaBH4 (80 mg, 2.1 mmol). The 
procedure was the same as described for 61. 
Light yellow resin; yield: 250 mg (67 %) 
C25H27NO (357.49) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.95 (3H; t; 3J = 7.3 Hz, CH3-CH2-), 1.37-1.52 (2H; m; -CH2-
CH3), 1.60-1.73 (1H; hept.; 3J = 7.0 Hz; -CH-CH2-C2H5 1diastereotopic 
H), 1.90-2.02 (1H; hept.; 3J = 7.0 Hz; -CH-CH2- C2H5 1diastereotopic H), 
2.78-2.87 ´(1H; m; THIQ-H4- 1 diastereotopic H), 2.94-3.04 (1H; m; 
THIQ-H4 1 diastereotiopic H), 3.57-3.62 (2H; m; THIQ-H3), 4.62 (1H; t; 3J 
= 7.0 Hz; -CH-), 5.04 (2H; s; -CH2-Ph), 6.70-6.89 (5H; m; N-phenyl-H2, -
H4- H6, THIQ -H5, -H7), 7.02-7.05 (1H; d; 3J = 8.3 Hz; THIQ-H8), 7.21-
7.27 (2H, d(t); merged in CDCl3-peak ; 3Jd = 7.3 Hz; 5Jt = 2.0 Hz; N-
phenyl-H3, -H5), 7.31-7.46 (5H; m; phenyl-H) 
MS (CI, NH3):  m/z = 358.1 (MH+) 
 
6-(Benzyloxy)-1-[9-(pentylthio)nonyl]-2-phenyl-1,2,3,4-tetrahydroisoquinoline (63) 
N-[3-(Benzyloxy)phenylethyl]-10-pentylthio-N-phenyldecanamide (55) (240 mg; 
0.43 mmol) was dissolved in POCl3 (3 mL) and refluxed for 20 h. After evaporation of 
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POCl3 water was added. The dihydroisoquinolinium salt was not soluble. The product 
was extracted into ethyl acetate (3 × 50 mL); the combined organic extracts were dried 
over Na2SO4 and evaporated. The remaining resin was directly reduced with NaBH4 (42 
mg, 1.1 mmol) in ethanol as described for 61.  
Colourless resin; yield: 100 mg (43 %) 
C36H49NOS (543.85) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.91 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.23-1.71 (21H; m; 
-(CH2)7-CH2-S-CH2-(CH2)3-, -CH-CH2- 1 diastereotopic H), 1.86-1.99 
(1H; m; -CH-CH2- 1 diastereotopic H), 2.50 (4H; t; 3J = 7.4 Hz; -CH2-S-
CH2-), 2.77-2.86 ´(1H; m; THIQ-H4 1 diastereotopic H), 2.94-3.04 (1H; 
m; THIQ-H4 1 diastereotiopic H), 3.58-3.63 (2H; m; THIQ-H3), 4.59 (1H; 
t; 3J = 6.9 Hz; -CH-), 5.04 (2H; s; -CH2-Ph), 6.69-6.88 (5H; m; N-phenyl-
H2, -H4- H6, THIQ -H5, -H7), 7.00-7.05 (1H; d; 3J = 8.3 Hz; THIQ-H8), 
7.20-7.25 (2H, d(t); merged in CDCl3-peak ; 3Jd = 7.3 Hz; 5Jt = 2.0 Hz; N-
phenyl-H3, -H5), 7.31-7.46 (5H; m; phenyl-H) 
MS (CI, NH3):  m/z = 544.3 (MH+) 
 
6-(Benzyloxy)-1-[10-(pentylthio)decyl]-2-phenyl-1,2,3,4-tetrahydroisoquinoline (64) 
Preparation from N-[3-(benzyloxy)phenylethyl]-11-pentylthio-N-phenylundecanamide 
(56) (900 mg, 1.57 mmol); in POCl3 (11 mL) followed by reduction with NaBH4 (150 mg, 
4.0 mmol). The procedure was the same as described for 63. 
Colourless resin; yield: 660 mg (75 %) 
C37H51NOS (557.87) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.91 (3H; t; 3J = 7.1 Hz; -CH2-CH3), 1.20-1.75 (23H; m; 
-(CH2)8-CH2-S-CH2-(CH2)3-, -CH-CH2- 1 diastereotopic H), 1.85-1.99 
(1H; m; -CH-CH2- 1 diastereotopic H), 2.51 (4H; t; 3J = 7.4 Hz; -CH2-S-
CH2-), 2.77-2.86 ´(1H; m; THIQ-H4 1 diastereotopic H), 2.94-3.04 (1H; 
m; THIQ-H4 1 diastereotiopic H), 3.55-3.64 (2H; m; THIQ-H3), 4.59 (1H; 
t; 3J = 7.0 Hz; -CH-), 5.04 (2H; s; -CH2-Ph), 6.68-6.89 (5H; m; N-phenyl-
H2, -H4- H6, THIQ -H5, -H7), 7.01-7.04 (1H; d; 3J = 8.3 Hz; THIQ-H8), 
7.21-7.26 (2H, d(t); merged in CDCl3-peak ; 3Jd = 7.3 Hz; 5Jt = 2.0 Hz; N-
phenyl-H3, -H5), 7.30-7.47 (5H; m; phenyl-H) 
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MS (CI, NH3):  m/z = 558.2 (MH+) 
 
6-(Benzyloxy)-1-[10-(pentylsulfonyl)decyl]-2-phenyl-1,2,3,4-tetrahydroisoquinoline (65) 
Preparation from N-[3-(benzyloxy)phenylethyl]-11-pentylsulfonyl-N-phenylundecan-
amide (57) (200 mg, 0.33 mmol) in POCl3 (3 ml) followed by reduction with NaBH4 (31 
mg; 0.83 mmol). The procedure was the same as described for 63. The crude product 
was sufficiently pure without chromatographic purification. 
White solid; yield: 180 mg (92 %) 
C37H51NO3S (589.87) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.93 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.19-1.72 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.73-1.98 (6H; m; -CH2-CH2-SO2-
CH2-CH2-, -CH-CH2-), 2.51 (4H; t; 3J = 7.4 Hz; -CH2-S-CH2-), 2.77-2.87 
´(1H; m; THIQ-H4 1 diastereotopic H), 2.88-3.05 (5H; m; THIQ-H4 1 
diastereotiopic H, -CH2-SO2-CH2-), 3.54-3.61 (2H; m; THIQ-H3), 4.58 
(1H; t; 3J = 6.9 Hz; -CH-), 5.03 (2H; s; -CH2-Ph), 6.69-6.90 (5H; m; N-
phenyl-H2, -H4- H6, THIQ -H5, -H7), 7.01-7.04 (1H; d; 3J = 8.3 Hz; THIQ-
H8), 7.19-7.26 (2H, d(t); merged in CDCl3-peak ; 3Jd = 7.3 Hz; 5Jt = 2.0 
Hz; N-phenyl-H3, -H5), 7.30-7.47 (5H; m; phenyl-H) 
MS (CI, NH3):  m/z = 590.2 (MH+) 
 
1-Ethyl-6-methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (66) 
Preparation from N-(3-methoxyphenylethyl)-N-(3-methoxyphenyl)propionamide (58) 
(500 mg, 1.6 mmol) in POCl3 (12 mL) followed by reduction with NaBH4 (150 mg, 
4.0 mmol). The procedure was the same as described for 63. Purification  by column 
chromatography (SiO2; PE/ethyl acetate 20/1, v/v).  
Light yellow resin; yield: 310 mg (65%) 
C19H23NO2 (297.17) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.98 (3H; t; 3J = 7.4 Hz; CH3-CH2-), 1.62-1.77 (1H; m; -CH2-
CH- 1 diastereotopic H), 1.87-2.02 (1H; m; -CH2-CH- 1 diastereotopic 
H), 2.79-2.91 (1H; m; THIQ-H4 1 diastereotopic H), 2.93-3.05 (1H; m; 
THIQ-H4 1 diastereotopic H), 3.46-3.60 (2H; m, THIQ-H3), 3.79, 3.80 (2 
× 3H; 2 × s; -O-CH3), 4.49 (1H; t; 3J = 7.0 Hz; -CH-), 6.25-6.33 (1H; d; 3J 
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= 7.9 Hz; phenyl-H4), 6.41 (1H; s; phenyl-H2); 6.43-6.53 (1H; d; 3J = 
8.3 Hz; phenyl-H6), 6.66-6.76 (2H; m; THIQ-H5, -H7), 6.98-7.06 (1H; d; 3J 
= 8.3 Hz; THIQ-H8), 7.11-7.20 (1H; t; 3J = 8.2 Hz; phenyl-H5) 
MS (CI, NH3):  m/z = 298.1 (MH+) 
 
6-Methoxy-2-(3-methoxyphenyl)-1-[10-(pentylthio)decyl]-1,2,3,4-tetrahydroisoquinoline 
(67) 
Preparation from N-(3-methoxyphenylethyl)-N-(3-methoxyphenyl)-11-(pentylthio)-
undecanamide (59) (400 mg, 0.76 mmol) in POCl3 (6 mL) followed by reduction with 
NaBH4 (75 mg, 2.0 mmol). The procedure was the same as described for 63. 
Purification by column chromatography (SiO2; PE/ethyl acetate 30/1, v/v).  
Colourless oil; yield: 330 mg (85%) 
C32H49NO2S (511.80) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H, t; 3J = 7.0 Hz; CH3-CH2-), 1.20-1.47 (18H; m; 
-(CH2)7-(CH2)2-S-(CH2)2-(CH2)2-), 1.50-1.71 (6H; m; -CH-CH2-, -CH2-
CH2-S-CH2-CH2-), 2.50 (4H; t; 3J = 7.4 Hz; -CH2-S-CH2-); 2.77-2.89 (1H; 
m; THIQ-H4 1 diastereotopic H), 2.92-3.05 (1H; m; THIQ-H4 1 
diastereotopic H), 3.47-3.63 (2H; m, THIQ-H3), 3.78, 3.79 (2 × 3H; 2 × s; 
-O-CH3), 4.57 (1H; t; 3J = 7.0 Hz; -CH-), 6.26-6.31 (1H; d(d); 3J = 8.0 Hz; 
5J = 2.1 Hz; phenyl-H4), 6.40 (1H; t; 5J = 2.3 Hz; phenyl-H2), 6.45-6.51 
(1H; d(d); 3J = 8.2 Hz; 5J = 2.2 Hz; phenyl-H6), 6.65-6.74 (2H; m; THIQ-
H5, -H7), 6.97-7.04 (1H; d; 3J = 8.3 Hz; THIQ-H8), 7.10-7.18 (1H; t; 3J = 
8.2 Hz; phenyl-H5) 
MS (CI, NH3):  m/z = 512.3 (MH+) 
 
6-Methoxy-2-(3-methoxyphenyl)-1-[10-(pentylsulfonyl)decyl]-1,2,3,4-tetrahydroiso-
quinoline (68) 
Preparation from N-(3-methoxyphenylethyl)-N-(3-methoxyphenyl)-11-(pentylsulfonyl)-
undecanamide (60) (300 mg, 0.54 mmol) in POCl3 (5 mL) followed by reduction with 
NaBH4 (50 mg, 1.3 mmol). The procedure was the same as described for 63. 
Purification by column chromatography (SiO2; PE/ethyl acetate 5/1, v/v).  
Yellow oil; yield: 200 mg (68%) 
C32H49NO4S (543.80) 
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[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H, t; 3J = 7.0 Hz; CH3-CH2-), 1.20-1.71 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.75-1.98 (6H; m; -CH-CH2-, -CH2-
CH2-S-CH2-CH2-), 2.77-2.88 (1H; m; THIQ-H4 1 diastereotopic H), 2.89-
3.04 (5H; m; THIQ-H4 1 diastereotopic H, -CH2-SO2-CH2-), 3.48-3.64 
(2H; m, THIQ-H3), 3.78, 3.79 (2 × 3H; 2 × s; -O-CH3), 4.56 (1H; t; 3J = 
7.0 Hz; -CH-), 6.25-6.31 (1H; d(d); 3J = 8.0 Hz; 5J = 2.3 Hz; phenyl-H4), 
6.39 (1H; t; 5J = 2.3 Hz; phenyl-H2), 6.45-6.51 (1H; d(d); 3J = 8.3 Hz; 5J = 
2.3 Hz; phenyl-H6), 6.65-6.74 (2H; m; THIQ-H5, -H7), 6.98-7.03 (1H; d; 3J 
= 8.3 Hz; THIQ-H8), 7.10-7.17 (1H; t; 3J = 8.2 Hz; phenyl-H5) 
MS (CI, NH3):  m/z = 544.2 (MH+) 
 
N-[3-(benzyloxy)phenylethyl]-7-bromo-N-phenylheptanamide (69) 
Preparation from N-phenyl-2-(3-benzyloxyphenyl)ethylamine (51) (500 mg, 1.7 mmol) 
and 7-bromoheptanoic acid chloride (550 mg, 2.5 mmol) following the procedure 
described for 53. Purification by column chromatography (SiO2; PE/ethyl acetate 5/1, 
v/v) 
Light yellow oil; yield: 730 mg (89 %) 
C28H32BrNO2 (494.46) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.16-1.39 (4H; m; -(CH2)2-(CH2)2-Br), 1.50-1.63 (2H, quin; 3J = 
7.5 Hz; -CH2-CH2-CON-), 1.74-1.84 (2H; quin; 3J = 7.2 Hz; Br-CH2-CH2-), 
2.02 (2H; t; 3J = 6.8 Hz; -CH2-CON-), 2.86 (2H; t; 3J = 7.9 Hz, N-CH2-), 3.35 
(2H; t; 3J = 6.8 Hz; -CH2-Br), 3.91 (2H; t; 3J = 7.9 Hz; phenyl-CH2-), 5.02 (2H; 
s; -CH2-Ph), 6.76-6.83 (3H; m; phenyl-H2, H4, -H6), 7.04-7.07 (2H; d; 3J = 6.7 
Hz; N-phenyl-H4), 7.15-7.20 (1H; d(d); 3J1 = 8.9 Hz, 3J2 = 7.5 Hz; phenyl-H5), 
7.31-7.43 (8H; m; phenyl-H) 
 
7-Bromo-N-(3-methoxyphenethyl)-N-(3-methoxyphenyl)heptanamide (70) 
Preparation from N,2-bis(3-methoxyphenyl)ethylamine (52) (500 mg, 1.9 mmol) and 7-
bromoheptanoic acid chloride (560 mg, 2.9 mmol) following the procedure described for 
53. Purification by column chromatography (SiO2; PE/ethyl acetate 5/2, v/v) 
Light yellow oil; yield: 800 mg (92 %) 
C23H30BrNO3 (448.39) 
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[1H] NMR (CDCl3): 
δ (ppm) = 1.10-1.48 (4H; m; -(CH2)2-(CH2)2-Br), 1.50-1.65 (2H, quin; 3J = 
7.5 Hz; -CH2-CH2-CON-), 1.73-1.85 (2H; quin; 3J = 7.3 Hz; Br-CH2-CH2-
), 2.05 (2H; t; 3J = 7.4 Hz; -CH2-CON-), 2.86 (2H; t; 3J = 7.8 Hz, N-CH2-), 
3.36 (2H; t; 3J = 6.9 Hz; -CH2-Br), 3.77, 3.79 (2 × 3H; 2 × s; O-CH3), 3.90 
(2H; t; 3J = 7.9 Hz; phenyl-CH2-), 6.53-6.57 (1H; t; 5J = 2.0 Hz; N-phenyl-
H2), 6.63-6.79 (4H; m; N-phenyl-H6, phenyl-H2, -H4, -H6), 6.86-6.92 (1H; 
d(d); 3J = 8.1 Hz; 5J = 2.4 Hz; N-phenyl-H4), 7.13-7.21 (1H; t; 3J = 8.2 
Hz; phenyl-H5), 7.26-7.34 (1H; t; merged in CDCl3-peak; 3J = 8.1 Hz; N-
phenyl-H5) 
MS (CI, NH3):  m/z = 448.2 (100% ; MH+), 450.2 (91%, MH+) 
 
6-Benzyloxy-1-(6-chlorohexyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (71a) and 
6-Benzyloxy-1-(6-bromohexyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (71b) 
Preparation from N-(3-(benzyloxy)phenylethyl)-7-bromo-N-phenylheptanamide (69) 
(400 mg, 0.81 mmol) in POCl3 (7 mL) followed by reduction with NaBH4 (75 mg, 
2.0 mmol). The procedure was the same as described for 63. Purification by column 
chromatography (SiO2; PE/ethyl acetate 25/1, v/v). The NMR-spectrum revealed the 
product as a mixture of 71a (92 %) and 71b (8%) which was used for nucleophilic 
substitution with appropriate amines.  
Light yellow oil; yield: 300 mg (71a: 80%; 71b: 7%) 
71a: C28H32ClNO (434.01) 
71b: C28H32BrNO (478.47) 
[1H] NMR (CDCl3) (71a): 
δ (ppm) = 1.32-1.51 (6H; m; -(CH2)3-(CH2)2-Cl), 1.62-1.81 (3H; m; -CH2-
CH2-Cl, -CH-CH2- 1 diastereotopic H), 1.85-2.00 (1H; m; CH-CH2- 1 
diastereotopic H), 2.77-2.86 (1H; m; THIQ-H4 1 diastereotopic H), 2.94-
3.04 (1H; m; THIQ-H4 1 diastereotopic H), 3.39 (0.16H; 8%; t; 3J = 6.8 
Hz; -CH2-Br), 3.51 (1.84H; 92% t; 3J = 6.7 Hz; -CH2-Cl), 3.55-3.61 (2H; 
m; THIQ-H3), 4.59 (1H; t; 3J = 7.0 Hz; -CH-), 5.04 (2H; s; -CH2-Ph), 6.70-
6.88 (5H; m; N-phenyl-H1, -H4, -H6, phenyl-H5, -H7), 7.00-7.05 (1H; d; 3J 
= 8.3 Hz; phenyl-H8), 7.21-7.27 (2H; d(d); merged in DCCl3 peak; 3J1 = 
8.7 Hz; 3J2 = 7.3 Hz; N-phenyl-H3, -H5), 7.30-7.46 (5H; m; phenyl-H) 
MS (EI):  m/z = 434.2 (100% ; 71a), 478.2 (2%, 71b) 
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1-(6-Chlorohexyl)-6-methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (72a) 
and  
1-(6-Bromohexyl)-6-methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (72b)  
Preparation from 7-bromo-N-(3-methoxyphenethyl)-N-(3-methoxyphenyl)heptanamide 
(70) (400 mg, 0.90 mmol) in POCl3 (7 mL) followed by reduction with NaBH4 (90 mg, 
2.4 mmol). The procedure was the same as described for 63. Purification by column 
chromatography (SiO2; PE/ethyl acetate 20/1, v/v). The NMR-spectrum revealed the 
product as a mixture of 72a (85 %) and 72b (15%). This mixture was directly used for 
nucleophilic substitution with appropriate amines. 
Light yellow oil; yield: 340 mg (72a: 82%; 72b: 14%) 
72a: C23H30ClNO2 (387.94) 
72b: C23H30BrNO2 (432.39) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.28-1.51 (6H; m; -(CH2)3-(CH2)2-Cl), 1.58-1.81 (3H; m; -CH2-
CH2-Cl, -CH-CH2- 1 diastereotopic H), 1.84-2.00 (1H; m; CH-CH2- 1 
diastereotopic H), 2.76-2.89 (1H; m; THIQ-H4 1 diastereotopic H), 2.92-
3.04 (1H; m; THIQ-H4 1 diastereotopic H), 3.38 (0.31 H; 15%; t; 3J = 6.8 
Hz; -CH2-Br), 3.51 (1.69H; m; –CH2-Cl), 3.53-3.60 (2H; m; THIQ-H3), 
3.78, 3.79 (2 × 3H; 2 × s; -O-CH3), 4.57 (1H; t; 3J = 7.0 Hz; -CH-), 6.25-
6.33 (1H; d; 3J = 7.9 Hz; phenyl-H4), 6.39 (1H; s; phenyl-H2), 6.45-6.52 
(1H; d; 3J = 8.1 Hz; phenyl-H6), 6.65-6.75 (2H; m; THIQ-H5, -H7), 6.97-
7.03 (1H; d; 3J = 8.3 Hz; THIQ-H8), 7.11-7.19 (1H; t; 3J = 8.2 Hz; phenyl-
H5) 
MS (CI, NH3):  m/z = 388.2 (100% ; 72a, MH+), 432.2, 434.1 (7%, 72b, MH+) 
 
6.1.2.2.5 Introduction of the Amine Functions 
 
6-Benzyloxy-2-phenyl-1-[6-(pyrrolidin-1yl)hexyl]-1,2,3,4-tetrahydroisoquinoline (73) 
Pyrrolidine (71 mg, 1.0 mmol) was added to the mixture of 6-benzyloxy-1-(6-
chlorohexyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (71a, 92 %) and 6-benzyloxy-1-(6-
bromohexyl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (71b, 8%) (100 mg ; 0.23 mmol) in 
abs. Ethanol (2 mL). The reaction mixture was stirred for 72 h at 70 °C. After cooling to 
room temperature the mixture was poured into sat. NaHCO3 solution (50 mL) and the 
product was extracted with ethyl acetate (3 × 30 mL). The combined organic phases 
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were dried over Na2SO4 and evaporated. The product was purified by column 
chromatography. 
Yellow oil; yield: 80 mg (75%) 
C32H40N2O (468.67) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.27-1.72 (8H; m; -(CH2)4-(CH2)2-pyrrolidine), 1.73-1.82 (4H; 
m; -pyrrolidine-H3, -H4,), 1.85-2.00 (2H; m; -CH2-CH2-pyrrolidine), 2.37-
2.42 (2H; t; 3J = 7.6 Hz; -CH2-pyrrolidine), 2.44-2.52 (4H; m; pyrrolidine-
H2, -H5), 2.77-2.86 (1H; m; THIQ-H4 1 diastereotopic H), 2.93-3.03 (1H; 
m; THIQ-H4 1 diastereotopic H), 3.51-3.64 (2H; m; THIQ-H3), 4.58 (1H; t; 
3J = 7.0 Hz; -CH-), 5.03 (2H; s; -CH2-Ph), 6.68-6.88 (5H; m; N-phenyl-
H1, -H4, -H6, phenyl-H5, -H7), 6.99-7.04 (1H; d; 3J = 8.3 Hz; phenyl-H8), 
7.19-7.26 (2H; d(d); merged in DCCl3 peak; 3J1 = 8.6 Hz; 3J2 = 7.3 Hz; N-
phenyl-H3, -H5), 7.29-7.46 (5H; m; phenyl-H) 
MS (CI, NH3):  m/z = 469.3 (MH+) 
 
6-Methoxy-2-(3-methoxyphenyl)-1-(6-pyrrolidin-1-yl)hexyl-1,2,3,4-tetrahydroisoquinoline 
(74) 
Preparation from the mixture of 1-(6-chlorohexyl)-6-methoxy-2-(3-methoxyphenyl)-
1,2,3,4-tetrahydroisoquinoline (72a) and 1-(6-Bromohexyl)-6-methoxy-2-(3-methoxy-
phenyl)-1,2,3,4-tetrahydroisoquinoline (72b) (200 mg, 0.51 mmol) and pyrrolidine (106 
mg, 1.5 mmol) following the procedure described for 73. Purification by column 
chromatography (SiO2 ; DCM/methanol/TEA 80/19/1, v/v/v). 
Yellow oil; yield: 105 mg (49 %) 
C27H38N2O2 (422.29) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.23-1.72 (9H; m; -(CH2)4-CH2-pyrrolidine, -CH-CH2- 1 
diastereotopic H), 1.78-1.95 (5H; m; -pyrrolidine-H3, -H4, -CH-CH2- 1 
diastereotopic H), 2.44-2.53 (2H; t; 3J = 7.9 Hz; -CH2-pyrrolidine), 2.55-
2.65 (4H; m; pyrrolidine-H2, -H5), 2.76-2.87 (1H; m; THIQ-H4 1 
diastereotopic H), 2.91-3.04 (1H; m; THIQ-H4 1 diastereotopic H), 3.47-
3.63 (2H; m; THIQ-H3), 3.78, 3.79 (2 × 3H; 2 × s; -O-CH3), 4.56 (1H; t; 3J 
= 7.0 Hz; -CH-), 6.25-6.31 (1H; d(d); 3J = 8.0 Hz; 5J = 2.1 Hz; phenyl-H4), 
6.39 (1H; t; 5J = 2.3 Hz; phenyl-H2), 6.44-6.50 (1H; d(d); 3J = 8.3 Hz; 5J = 
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2.3 Hz; phenyl-H6), 6.65-6.74 (2H; m; THIQ-H5, -H7), 6.97-7.02 (1H; d; 3J 
= 8.3 Hz; THIQ-H8), 7.10-7.17 (1H; t; 3J = 8.2 Hz; phenyl-H5) 
MS (CI, NH3):  m/z = 423.2 (MH+) 
 
6-Methoxy-2-(3-methoxyphenyl)-1-(6-piperidin-1-yl)hexyl-1,2,3,4-tetrahydroisoquinoline 
(75) 
Preparation from the mixture of 1-(6-chlorohexyl)-6-methoxy-2-(3-methoxyphenyl)-
1,2,3,4-tetrahydroisoquinoline (72a) and 1-(6-bromohexyl)-6-methoxy-2-(3-methoxy-
phenyl)-1,2,3,4-tetrahydroisoquinoline (72b) (200 mg; 0.51 mmol) and piperidine (128 
mg; 1.5 mmol) in abs. ethanol (5mL). The reaction mixture was heated for 10 min in a 
microwave (Biotage, Grenzach-Wyhlen, Germany)) (T = 180 °C; p = 18 bar). Work-up in 
the same way as described for 73. Purification by column chromatography (SiO2; 
DCM/methanol/TEA 90/9/1, v/v/v). 
Yellow oil; yield: 200 mg (88%) 
C28H40N2O2 (436.63) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.20-1.70 (14H; m; -(CH2)4-CH2-piperidine, -CH-CH2- 1 
diastereotopic H, piperidine-H3, -H4, -H5), 1.83-2.00 (1H; m; -CH-CH2- 1 
diastereotopic H), 2.26-2.35 (2H; t; 3J = 7.8 Hz; -CH2-piperidine), 2.36-
2.49 (4H; s (br); piperidine-H2, -H6), 2.76-2.89 (1H; m; THIQ-H4 1 
diastereotopic H), 2.91-3.04 (1H; m; THIQ-H4 1 diastereotopic H), 3.47-
3.59 (2H; m; THIQ-H3), 3.78, 3.79 (2 × 3H; 2 × s; -O-CH3), 4.56 (1H; t; 3J 
= 7.0 Hz; -CH-), 6.25-6.30 (1H; d(d); 3J = 8.0 Hz; 5J = 2.1 Hz; phenyl-H4), 
6.39 (1H; t; 5J = 2.3 Hz; phenyl-H2), 6.44-6.50 (1H; d(d); 3J = 8.3 Hz; 5J = 
2.3 Hz; phenyl-H6), 6.64-6.74 (2H; m; THIQ-H5, -H7), 6.96-7.02 (1H; d; 3J 
= 8.3 Hz; THIQ-H8), 7.10-7.17 (1H; t; 3J = 8.2 Hz; phenyl-H5) 
MS (CI, NH3):  m/z = 437.3 (MH+) 
 
6-(6-Benzyloxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-N-methyl-N-[3-
(pentylthio)propyl]hexan-1-amine (76) 
Preparation from the mixture of 6-benzyloxy-1-(6-chlorohexyl)-2-phenyl-1,2,3,4-
tetrahydroisoquinoline (71a, 92 %) and 6-benzyloxy-1-(6-bromohexyl)-2-phenyl-1,2,3,4-
tetrahydroisoquinoline (71b, 8%) (150 mg ; 0.34 mmol), N-Methyl-3-(pentylthio)-
propylamine (7) (90 mg, 0.5 mmol) and TEA (50 mg, 0.5 mmol) following the procedure 
Synthesis and Biological Characterization of New ER Ligands 122 
described for 73. The reaction time was 7 days. Purification by column chromatography 
(SiO2; DCM/methanol 25/1, v/v).  
Brown-yellowish oil; yield: 150 mg (84 %) 
C37H52N2OS(572.89) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.30-1.50 (15H; m; 
-(CH2)4-(CH2)-N-, -(CH2)3-CH3, CH-CH2- 1 diastereotopic H), 1.73-1.83 
(2H; quin; 3J = 7.3 Hz; -N-CH2-CH2-CH2-S-) 1.86-2.00 (1H; m; -CH-CH2- 
1 diastereotopic H), 2.24 (3H; s; -N-CH3), 2.35 (2H; t; 3J = 7.5 Hz; -
CH2)5-CH2-N), 2.43-2.55 (6H; m; -S-(CH2)2-CH2-N-, -CH2-S-CH2-), 2.76-
2.87 (1H; m; THIQ-H4 1 diastereotopic H), 2.93-3.03 (1H; m; THIQ-H4 1 
diastereotopic H), 3.55-3.60 (2H; m; THIQ-H3), 4.58 (1H; t; 3J = 7.0 Hz; -
CH-), 5.03 (2H; s; -CH2-Ph), 6.68-6.86 (5H; m; N-phenyl-H1, -H4, -H6, 
phenyl-H5, -H7), 6.99-7.04 (1H; d; 3J = 8.3 Hz; phenyl-H8), 7.20-7.26 (2H; 
d(d); merged in DCCl3 peak; 3J1 = 8.6 Hz; 3J2 = 7.3 Hz; N-phenyl-H3, -
H5), 7.29-7.45 (5H; m; phenyl-H) 
MS (CI, NH3):  m/z = 573.5 (MH+) 
 
6.1.2.2.6 Alternative Route: Introduction of the Amine Function Prior to Cyclisation 
 
N-(3-Methoxyphenylethyl)-N-(3-methoxyphenyl)-7-[methyl[3-(pentylthio)propyl]amino]-
heptanamide (77) 
Preparation from 7-bromo-N-(3-methoxyphenethyl)-N-(3-methoxyphenyl)heptanamide 
(70) (400 mg, 0.9 mmol), N-methyl-3-(pentylthio)propylamine (7) (160 mg, 0.9 mmol) 
and TEA (90 mg; 0.9 mmol) following the procedure described for 73. Purification by 
column chromatography (DCM/methanol 20/1 → 10/1, v/v). 
Light yellow oil; yield: 370 mg (76%) 
C32H50N2O3S (542.82) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.16-1.41 (8H; m; -(CH2)2-
CH3, CO-(CH2)2-(CH2)2-), 1.47-1.64 (6H;m; -S-CH2-CH2-C3H7, CO-CH2-
CH2-, -CH2-CH2-N-), 1.80-1.94 (2H; quin; 3J = 7.0 Hz; -N-CH2-CH2-CH2-
S-), 2.04 (2H; t; 3J = 7.4 Hz; -CH2-CON-), 2.31-2.42 (3H; s (br); -N-CH3), 
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2.44-2.71 (8H; m; -CH2-S-CH2-, -CH2-N-CH2-) 2.85 (2H; t; 3J = 7.8 Hz, 
phenyl-N-CH2-), 3.76, 3.79 (2 × 3H; 2 × s; O-CH3), 3.89 (2H; t; 3J = 
7.9 Hz; phenyl-CH2-), 6.55 (1H; t; 5J = 2.0 Hz; N-phenyl-H2), 6.63-6.79 
(4H; m; N-phenyl-H6, phenyl-H2, -H4, -H6), 6.86-6.92 (1H; d(d); 3J = 8.3 
Hz; 5J = 2.4 Hz; N-phenyl-H4), 7.13-7.21 (1H; t; 3J = 8.2 Hz; phenyl-H5), 
7.26-7.33 (1H; t; merged in CDCl3-peak; 3J = 8.1 Hz; N-phenyl-H5) 
MS (ES):  m/z = 543.5 (MH+) 
 
6-[6-methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl]-N-methyl-N-[3-
(pentylthio)propyl]hexan-1-amine (78) 
Preparation from N-(3-methoxyphenylethyl)-N-(3-methoxyphenyl)-7-[methyl[3-
(pentylthio)propyl]amino]heptanamide (77) (250 mg, 0.46 mmol) in POCl3 (4 mL) 
followed by reduction with NaBH4 (75 mg, 2.0 mmol). The procedure was the same as 
described for 63. Purification by column chromatography (SiO2; DCM/MeOH 20/1 v/v). 
Light yellow oil; yield: 200 mg (83%) 
C32H50N2O2S (526.82) 
 
[1H] NMR (CDCl3): 
δ (ppm) = 0.89 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.20-1.72 (15H; m; -
(CH2)3-CH3, N-(CH2)-(CH2)4-, -CH-CH2- 1 diastereotopic H), 1.73-1.98 
(3H; m; -S-CH2-CH2-CH2-N-, -CH-CH2- 1 diastereotopic H), 2.27 (3H; s; 
N-CH3), 2.33-2.43 (2H; t; 3J = 7.5 Hz; N-CH2-), 2.45-2.57 (6H; m; N-CH2-
; -CH2-S-CH2-), 2.76-2.88 (1H; m; THIQ-H4 1 diastereotopic H), 2.91-
3.04 (1H; m; THIQ-H4 1 diastereotopic H), 3.49-3.64 (2H; m; THIQ-H3), 
3.78, 3.79 (2 × 3H; 2 × s; -O-CH3), 4.56 (1H; t; 3J = 7.0 Hz; -CH-), 6.25-
6.31 (1H; d(d); 3J = 7.9 Hz; 5J = 2.1 Hz; phenyl-H4), 6.39 (1H; t; 5J = 2.3 
Hz; phenyl-H2), 6.45-6.50 (1H; d(d); 3J = 8.3 Hz; 5J = 2.3 Hz; phenyl-H6), 
6.64-6.74 (2H; m; THIQ-H5, -H7), 6.97-7.03 (1H; d; 3J = 8.3 Hz; THIQ-
H8), 7.10-7.17 (1H; t; 3J = 8.2 Hz; phenyl-H5) 
MS (ES):  m/z = 527.4 (MH+) 
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6.1.2.2.7 Cleavage of the Benzyloxy Protecting Group  
 
1-Ethyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (79) 
Concentrated HCl (3 mL) was added to a stirred solution of 6-(benzyloxy)-1-ethyl-2-
phenyl-1,2,3,4-tetrahydroisoquinoline (61) (200 mg, 0.58 mmol) in dioxane (4 mL) and 
the reaction mixture was heated for 4 h to 95 °C. After cooling to room temperature the 
mixture was neutralised carefully with sat. NaHCO3 solution and diluted with water (25 
mL). The product was extracted with ethyl acetate (3 × 30 mL); the combined organic 
extracts were washed with brine, dried over Na2SO4 and evaporated. The product was 
purified by column chromatography (SiO2; PE/ethyl acetate 5/1, v/v). 
Yellow resin; yield: 110 mg (75%) 
C17H19NO (253.34) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.99 (3H; t; 3J = 7.4 Hz; CH3-CH2-), 1.62-1.77 (1H; m; CH3-
CH2-CH- 1 diastereotopic H), 1.88-2.03 (1H; m; CH3-CH2-CH- 1 
diastereotopic H), 2.76-2.85 (1H; m; THIQ-H4 1 diastereotopic H), 2.90-
3.00 (1H; m; THIQ-H4 1 diastereotopic H), 3.48-3.63 (2H; m; THIQ-H3), 
4.50 (1H; t; 3J = 7.0 Hz; -CH-), 6.60-7.67 (2H; m; THIQ-H5, -H7), 6.72 
(1H; t; 3J = 7.2 Hz; phenyl-H4), 6.85-6.88 (2H; d; 3J = 8.0 Hz; phenyl-H2, -
H6), 6.96-6.99 (1H; d; 3J = 8.0 Hz; THIQ-H8), 7.22-7.27 (2H; d(d); 
merged in CDCl3-peak; 3J = 7.3 Hz; 5J = 2.0 Hz; phenyl-H3, -H5) 
MS (EI): m/z = 224.1 (100%, [M - C2H5]+), 253.1 (5%) 
HPLC: Gradient: 0-25 min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 25-40 min: 
95/5 
RT = 16.18 min; purity: 91% 
 
1-Propyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (80) 
Preparation from 6-(benzyloxy)-1-propyl-2-phenyl-1,2,3,4-tetrahydroisoquinoline (62) 
(200 mg, 0.56 mmol) in dioxane (4mL) / conc. HCl (3 mL) following the procedure 
described for 79.  
Yellow resin; yield: 120 mg (80%) 
C18H21NO (267.37) 
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[1H] NMR (CDCl3): 
δ (ppm) = 0.94 (3H; t; 3J = 7.4 Hz; CH3-CH2-), 1.36-1.54 (2H; m; CH3-
CH2-), 1.58-1.70 (1H; m; CH3-CH2-CH- 1 diastereotopic H), 1.85-1.97 
(1H; m; CH3-CH2-CH- 1 diastereotopic H), 2.75-2.84 (1H; m; THIQ-H3 1 
diastereotopic H), 2.90-3.00 (1H; m; THIQ-H3 1 diastereotopic H), 3.46-
3.64 (2H; m; THIQ-H4), 4.60 (1H; t; 3J = 7.0 Hz; -CH-), 6.60-6.65 (2H; m; 
THIQ-H5, -H7), 6.72 (1H; t; 3J = 7.3 Hz; phenyl-H4), 6.85-6.89 (2H; d; 3J = 
8.0 Hz; phenyl-H2, -H6), 6.95-6.99 (1H; d; 3J = 8.1 Hz; THIQ-H8), 7.21-
7.27 (2H; d(d); merged in CDCl3-peak; 3J = 7.3 Hz; 5J = 2.0 Hz; phenyl-
H3, -H5) 
MS (EI): m/z = 224.1 (100%, [M - C3H7] +), 267.2 (4%) 
HPLC: Gradient: 0-25 min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 25-40 min: 
95/5 
RT = 18.10 min; purity: 90% 
 
1-(9-(Pentylthio)nonanyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (81) 
Preparation from 6-(benzyloxy)-1-[9-(pentylthio)nonyl]-2-phenyl-1,2,3,4-tetrahydroiso-
quinoline (63) (150 mg, 0.28 mmol) in dioxane (3 mL) / conc. HCl (2 mL) following the 
procedure described for 79; the reaction mixture was stirred for 2 h. Purification by 
column chromatography (SiO2; PE/ethyl acetate 10/1, v/v). 
Light yellow oil; yield: 80 mg (63%) 
C29H43NOS (453.29) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.20-1.72 (21H; m; 
-(CH2)7-CH2-S-CH2-(CH2)3-; CH-CH2- 1diastereotopic H), 1.83-1.99 (1H; 
m; -CH2-CH- 1 diastereotopic H), 2.47-2.53 (4H; m; -CH2-S-CH2-), 2.75-
2.84 (1H; m; THIQ-H4 1 diastereotopic H), 2.90-3.00 (1H; m; THIQ-H4 1 
diastereotopic H), 3.50-3.63 (2H; m; THIQ-H3), 4.57 (1H; t; 3J = 7.0 Hz; -
CH-), 6.59-6.66 (2H; m; THIQ-H5, -H7), 6.71 (1H; t; 3J = 7.2 Hz; phenyl-
H4), 6.82-6.89 (2H; d; 3J = 8.2 Hz; phenyl-H2, -H6), 6.94-6.99 (1H; d; 3J = 
8.1 Hz; THIQ-H8), 7.19-7.26 (2H; d(d); merged in CDCl3-peak; 3J1 = 8.8 
Hz; 3J2 = 7.2 Hz; phenyl-H3, -H5) 
MS (EI): m/z = 224.1 (100%, [M – (CH2)9SC5H11] +), 453.2 (1.5%) 
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HR-MS (EI):  calculated:  452.2987 
 found: 452.2975 
HPLC: Gradient: 0-20 min: MeCN/0.025 % TFA (aq) 50/50; to 98/2; 20-40 min: 
98/2 
RT = 27.95 min; purity: 93% 
 
1-(10-(Pentylthio)decyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (82) 
Preparation from 6-(benzyloxy)-1-(10-(pentylthio)decyl)-2-phenyl-1,2,3,4-tetrahydroiso-
quinoline (64) (200 mg, 0.36 mmol) in dioxane (4 mL) / conc. HCl (3 mL) following the 
procedure described for 79; the reaction mixture was stirred at 95 °C for 2 h, becoming 
dark brown. Purification by column chromatography (SiO2; PE/ethyl acetate 10/1, v/v).  
Light yellow oil; yield: 145 mg (86%) 
C30H45NOS (467.32) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.20-1.70 (23H; m; 
-(CH2)8-CH2-S-CH2-(CH2)3-; CH-CH2- 1diastereotopic H), 1.85-1.98 (1H; 
m; -CH2-CH- 1 diastereotopic H), 2.47-2.53 (4H; m; -CH2-S-CH2-), 2.73-
2.85 (1H; m; THIQ-H4 1 diastereotopic H), 2.88-3.01 (1H; m; THIQ-H4 1 
diastereotopic H), 3.51-3.59 (2H; m; THIQ-H3), 4.57 (1H; t; 3J = 7.0 Hz; -
CH-), 6.58-6.66 (2H; m; THIQ-H5, -H7), 6.71 (1H; t; 3J = 7.2 Hz; phenyl-
H4), 6.81-6.90 (2H; d; 3J = 8.2 Hz; phenyl-H2, -H6), 6.94-6.99 (1H; d; 3J = 
8.1 Hz; THIQ-H8), 7.19-7.26 (2H; d(d); merged in CDCl3-peak; 3J1 = 8.8 
Hz; 3J2 = 7.2 Hz; phenyl-H3, -H5) 
MS (CI, NH3): m/z = 468.4 (MH+) 
 
1-(10-(Pentylsulfonyl)decyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (83) 
Preparation from 6-(benzyloxy)-1-[10-(pentylsulfonyl)decyl]-2-phenyl-1,2,3,4-tetrahydro-
isoquinoline (65) (120 mg, 0.20 mmol) in dioxane (3 mL) / conc. HCl (1.5 mL) following 
the procedure described for 79; the reaction mixture was stirred at 95 °C for 2 h, 
becoming dark brown. Purification by column chromatography (SiO2; PE/ethyl acetate 
3/1, v/v). Final purification by preparative HPLC (Eurospher; gradient: 0-
7 min:MeCN/0.05 % TFA 50/50 to 98/2, 7-25 min: 98/2). 
Yellow resin; yield: 12 mg (12%) 
C30H45NO3S (499.75) 
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[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.17-1.70 (18H; m; 
-(CH2)7-CH2-SO2-CH2-(CH2)3-), 1.73-1.98 (6H; m; -CH2-CH2-SO2-CH2-
CH2-, -CH2-CH-), 2.75-2.99 (6H; m; -CH2-SO2-CH2-, THIQ-H4), 3.43-3.63 
(2H; m; THIQ-H3), 4.55 (1H; t; 3J = 7.0 Hz; -CH-), 6.60-6.76 (3H; m; 
THIQ-H5, -H7, phenyl-H4), 6.82-6.86 (2H; d; 3J = 8.2 Hz; phenyl-H2, -H6), 
6.94-6.97 (1H; d; 3J = 8.0 Hz; THIQ-H8), 7.20-7.26 (2H; d(d); merged in 
CDCl3-peak; 3J1 = 8.8 Hz; 3J2 = 7.2 Hz; phenyl-H3, -H5) 
MS (EI): m/z = m/z = 224.1 (100%, [M – (CH2)10SO2C5H11] +), 499.1 (1.2%)  
HR-MS (EI):  calculated:  499.3120 
 found: 499.3106 
HPLC: Gradient: 0-20 min: MeCN/0.025 % TFA (aq) 50/50 to 98/2; 20-40 min: 
98/2 
RT = 19.45 min; purity: 98% 
 
2-Phenyl-1-(6-pyrrolidin-1-yl)hexyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (84) 
Preparation from 6-benzyloxy-2-phenyl-1-(6-(pyrrolidin-1yl)hexyl)-1,2,3,4-tetrahydro-
isoquinoline (73) (70 mg, 0.20 mmol) in dioxane (1.5 mL) / conc. HCl (1 mL) following 
the procedure described for 79; the reaction mixture was stirred at 95 °C for 2 h, 
becoming dark brown. Purification by column chromatography (SiO2; DCM/ 
methanol/TEA 100/5/1 → 100/10/1, v/v/v). Final purification by preparative HPLC 
(Eurospher; gradient: 0-15 min:MeCN/0.05 % TFA 25/75 to 35/65). 
Yellow oil; yield: 30 mg (53%) 
C25H34N2O · C2HF3O2 (492.57) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.16-1.62 (8H; m; CH-(CH2)4-), 1.68-1.88 (6H; m; -CH2-CH2-
pyrrolidine, pyrrolidine-H3, -H4), 2.40 (2H; t; 3J = 7.9 Hz, -CH2-
pyrrolidine), 2.44-2.55 (4H; m; pyrrolidine-H2, -H5) 2.65-2.76 (1H; m; 
THIQ-H4 1 diastereotopic H), 2.81-2.92 (1H; m; THIQ-H4 1 
diastereotopic H), 3.44-3.51 (2H; m; THIQ-H3), 4.48 (1H; t; 3J = 6.9 Hz; -
CH-), 6.48-6.54 (2H; m; THIQ-H5, -H7), 6.64 (1H; t; 3J = 7.2 Hz; phenyl-
H4), 6.74-6.80 (2H; d; 3J = 8.1 Hz; phenyl-H2, -H6), 6.83-6.87 (1H; d; 3J = 
8.9 Hz; THIQ-H8), 7.14-7.19 (2H; d; 3J = 8.7 Hz; phenyl-H3, -H5) 
MS (EI): m/z = 224.1 (100%, [M – (CH2)6NC4H8] +), 378.2 (1.5%) 
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HR-MS (EI):  calculated:  378.2671 
 found: 378.2665 
HPLC: Gradient: 0-30min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 30-40 min: 
95/5 
RT = 12.39 min; purity: 98% 
 
1-[N-methyl-N-[3-(pentylthio)propyl]amino]hexyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-
6-ol (85) 
Preparation from 6-[6-(benzyloxy)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl]-N-methyl-
N-[3-(pentylthio)propyl]hexan-1-amine (76) (140 mg, 0.24 mmol) in dioxane (3 mL) / 
conc. HCl (1.5 mL) following the procedure described for 79; the reaction mixture was 
stirred at 95 °C for 2.5 h,. Purification by column chromatography (SiO2; DCM/ methanol 
15/1, v/v/). 
Orange oil; yield: 60 mg (52%) 
C30H46N2OS (482.76) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.84 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.15-1.66 (15H; m; 
-(CH2)3-CH3, -CH-CH2-(CH2)4-, CH-CH2- 1 diastereotopic H), 1.72-1.90 
(3H; m; -N-CH2-CH2-CH2-S- , CH-CH2- 1 diastereotopic H), 2.26 (3H; s; 
N-CH3), 2.36-2.54 (8H; m; -CH2-S-CH2-, -CH2-N-CH2-), 2.67-2.76 (1H; 
m; THIQ-H4 1 diastereotopic H), 2.83-2.93 (1H; m; THIQ-H4 1 
diastereotopic H), 3.42-3.56 (2H; m; THIQ-H3), 4.49 (1H; t; 3J = 6.9 Hz; -
CH-), 6.53-6.60 (2H; m; THIQ-H5, -H7), 6.65 (1H; t; 3J = 7.2 Hz; phenyl-
H4), 6.76-6.82 (2H; d; 3J = 8.1 Hz; phenyl-H2, -H6), 6.84-6.90 (1H; d; 3J = 
8.9 Hz; THIQ-H8), 7.15-7.20 (2H; d(d); 3J1 = 8.7 Hz; 3J2 = 7.3 Hz; phenyl-
H3, -H5) 
MS (EI): m/z = 224.1 (100%, [M – (CH2)10N(CH3)(CH2)3SC5H11] +), 482.2 (3.1%) 
HR-MS (EI):  calculated:  482.3331 
 found: 482.3326 
HPLC: Gradient: 0-20 min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 20-30 min: 
95/5 
RT = 19.99 min; purity: 99% 
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1-[9-(Pentylsulfinyl)nonanyl]-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (86) 
At 10 °C a H2O2-solution (30%; 30 µL, 0.2 mmol) was added to a solution of 1-[9-
(pentylthio)nonanyl]-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (81) (30 mg, 
0.056 mmol) in glacial acetic acid. The reaction mixture was allowed to warm up to 
room temperature and stirreed for 20 min. Then the solution was poured into sat. 
NaHCO3 solution, followed by extraction with etyl acetate (3 × 30 mL). The organic 
extracts were washed with water and brine, driesd over Na2SO4 and evaporated. The 
product was purified by column chromatography (SiO2; DCM/methanol 20/1, v/v). 
Light yellow resin; yield: 30 mg (97%) 
C29H43NO2S (469.29) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.15-1.94 (22H; m; 
-(CH2)8-CH2-SO-CH2-(CH2)3-), 2.55-2.97 (6H; m; -CH2-SO-CH2-, THIQ-
H4), 3.42-3.62 (2H; m; THIQ-H3), 4.54 (1H; t; 3J = 6.7 Hz; -CH-), 6.63-
6.73 (3H; m; THIQ-H5, -H7, phenyl-H4), 6.79-6.87 (2H; d; 3J = 8.2 Hz; 
phenyl-H2, -H6), 6.90-6.96 (1H; d; 3J = 8.0 Hz; THIQ-H8), 7.19-7.26 (2H; 
d(d); merged in CDCl3-peak; 3J1 = 8.7 Hz; 3J2 = 7.3 Hz; phenyl-H3, -H5) 
MS (EI): m/z = 224.1 (100%, [M – (CH2)9SOC5H11] +), 452.2 (1.4%, [M – OH]+), 
469.2 (0.4%) 
HR-MS (EI):  calculated:  469.3015 
 found: 469.3003 
HPLC: Gradient: 0-25min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 25-40 min: 
95/5 
RT = 24.30 min; purity: 98% 
 
1-(10-(Pentylsulfinyl)decyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol (87) 
Preparation from 1-[10-(pentylthio)decyl]-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol 
(82) (130 mg, 0.28 mmol) and H2O2 (30%; 60 µL, 0.5 mmol) following the procedure 
described for 86. Purification by column chromatography (SiO2; DCM/methanol 20 /1, 
v/v). 
Light yellow resin; yield: 120 mg (89%) 
C30H45NO2S (483.75) 
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[1H] NMR (CDCl3): 
δ (ppm) = 0.87 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.10-1.90 (24H; m; 
-(CH2)9-CH2-SO-CH2-(CH2)3-), 2.53-2.93 (6H; m; -CH2-SO-CH2-, THIQ-
H4), 3.37-3.60 (2H; m; THIQ-H3), 4.59 (1H; t; 3J = 7.5  Hz; -CH-), 6.60-
6.68 (3H; m; THIQ-H5, -H7, phenyl-H4), 6.77-6.80 (2H; d; 3J = 8.3 Hz; 
phenyl-H2, -H6), 6.88-6.91 (1H; d; 3J = 8.3 Hz; THIQ-H8), 7.16-7.21 (2H; 
d(d); merged in CDCl3-peak; 3J1 = 8.7 Hz; 3J2 = 7.3 Hz; phenyl-H3, -H5) 
MS (EI): m/z = 224.1 (100%, [M – (CH2)10SOC5H11] +), 466.2 (2.2%, [M – OH]+), 
483.1 (0.7%) 
HR-MS (EI):  calculated:  483.3171 
 found: 483.3160 
HPLC: Gradient: 0-30min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 30-40 min: 
95/5 
RT = 33.01 min; purity: 99% 
 
6.1.2.2.8 Cleavage of the Methoxy Protecting Groups 
 
1-Ethyl-2-(3-hydroxyphenyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (88) 
Preparation from 1-ethyl-6-methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline 
(66) (100 mg, 0.33 mmol) and BBr3 (1M stock solution in DCM; 1.7 mL; 1.7 mmol) 
following the demethylation-procedure described for 24. The reaction mixture was 
stirred for 4 h at room temperature. The product was purified by column 
chromatography (SiO2; PE/ethyl acetate 5/2, v/v) and finally by preperative HPLC 
(Eurospher; gradient: 0-15 min: acetonitrile/0.05 % TFA 55/45 to 80/20). 
Yellow-brownish resin; yield: 40 mg (45 %) 
C17H19NO2 (269.14) 
[1H] NMR (D4-methanol): 
δ (ppm) = 0.95 (3H; t; 3J = 7.4 Hz; CH3-CH2-), 1.57-1.73 (1H; sept; 3J = 
7.2 Hz; -CH2-CH- 1 diastereotopic H), 1.80-1.97 (1H; sept; 3J = 7.2 Hz; -
CH2-CH- 1 diastereotopic H), 2.69-2.81 (1H; m; THIQ-H4 1 
diastereotopic H), 2.82-2.95 (1H; m; THIQ-H4 1 diastereotopic H), 3.39-
3.58 (2H; m, THIQ-H3), 4.42 (1H; t; 3J = 7.0 Hz; -CH-), 6.10-6.16 (1H; 
d(d); 3J = 8.0 Hz; 5J = 2.1 Hz; phenyl-H4), 6.33 (1H; t; 5J = 2.2 Hz; 
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phenyl-H2), 6.34-6.40 (1H; d(d); 3J = 8.3 Hz; 5J = 2.2 Hz; phenyl-H6), 
6.54-6.66 (2H; m; THIQ-H5, -H7), 6.90-7.02 (2H; m; THIQ-H8, phenyl-H5) 
MS (EI): m/z = 240.1 (100%, [M – C2H5]+), 269.2 (8.3%) 
HR-MS (EI):  calculated:  269.1416 
 found: 269.1412 
HPLC: Gradient: 0-25min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 25-40 min: 
95/5 
RT = 11.92 min; purity: 98% 
 
2-(3-Hydroxyphenyl)-1-[10-(pentylthio)decyl]-1,2,3,4-tetrahydroisoquinolin-6-ol (89) 
Preparation from 6-methoxy-2-(3-methoxyphenyl)-1-[10-(pentylthio)decyl]-1,2,3,4-
tetrahydroisoquinoline (67) (120 mg ; 0.23 mmol) and BBr3 (1M stock solution in DCM; 
1.2 mL; 1.2 mmol) following the demethylation-procedure described for 24. The reaction 
mixture was stirred for 3 h at room temperature. The product was purified by column 
chromatography (SiO2; PE/ethyl acetate 5/2, v/v). 
Colourless oil; yield: 75 mg (68 %) 
C30H45NO2S (483.75) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.4 Hz; CH3-CH2-), 1.12-1.47 (18H; m; 
-(CH2)7-(CH2)2-S-(CH2)2-(CH2)2-), 1.50-1.69 (6H; m ;-CH2-CH2-S-CH2-
CH2-; -CH-CH2-), 2.45-2.54 (4H; t; 3J = 7.4 Hz; -CH2-S-CH2-), 2.72-2.95 
(2H; m; THIQ-H4), 3.40-3.57 (2H; m, THIQ-H3), 4.53 (1H; t; 3J = 6.9 Hz; -
CH-), 6.15-6.25 (1H; d; 3J = 7.2 Hz; phenyl-H4), 6.28-6.50 (2H; m; 
phenyl-H2, -H6), 6.57-6.66 (2H; m; THIQ-H5, -H7), 6.89-6.97 (1H; d; 3J = 
8.1 Hz; THIQ-H8), 7.03-7.11 (1H; t; 3J = 8.1 Hz; phenyl-H5) 
MS (CI, NH3): m/z = 484.3 (MH+) 
 
2-(3-Hydroxyphenyl)-1-[10-(pentylsulfonyl)decyl]-1,2,3,4-tetrahydroisoquinolin-6-ol (90) 
Preparation from 6-methoxy-2-(3-methoxyphenyl)-1-[10-(pentylsulfonyl)decyl]-1,2,3,4-
tetrahydroisoquinoline (68) (150 mg, 0.28 mmol) and BBr3 (1M stock solution in DCM; 
1.4 mL; 1.4 mmol) following the demethylation-procedure described for 24. The reaction 
mixture was stirred for 4 h at room temperature. The product was purified by column 
chromatography (SiO2; PE/ethyl acetate 5/2, v/v) and finally by preperative HPLC 
(Eurospher; gradient: 0-12min: MeCN/0.05 % TFA (aq) 55/45 to 85/15). 
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Light yellow oil; yield: 75 mg (52%) 
C30H45NO4S (515.75) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.91 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.10-1.48 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2), 1.52-1.71 (1H; m; -CH-CH2- 1 
diastereotopic H), 1.72-1.97 (5H; m; -CH-CH2- 1 diastereotopic H, -CH2-
CH2-SO2-CH2-CH2-), 2.75-3.00 (2H; m; THIQ-H4, -CH2-SO2-CH2-), 3.43-
3.64 (2H; m, THIQ-H3), 4.53 (1H; t; 3J = 6.0 Hz; -CH-), 6.44-6.53 (1H; d; 
3J = 7.9 Hz; phenyl-H4), 6.54-6.72 (4H; m; phenyl-H2, -H6, THIQ-H5, -H7), 
6.83-6.92 (1H; d; 3J = 8.4 Hz; THIQ-H8), 7.04-7.15 (1H; t; 3J = 8.1 Hz; 
phenyl-H5) 
MS (ES): m/z = 516.4 (MH+) 
HR-MS (EI):  calculated:  515.3069 
 found: 515.3057 
HPLC: Gradient: 0-15 min: MeCN/0.025 % TFA (aq) 55/45 to 95/5; 15-30 min: 
95/5 
RT = 10.92 min; purity: 99% 
 
2-(3-Hydroxyphenyl)-1-[6-(pyrrolidin-1-yl)hexyl)]-1,2,3,4-tetrahydroisoquinolin-6-ol (91) 
Preparation from 6-methoxy-2-(3-methoxyphenyl)-1-[6-(pyrrolidin-1-yl)hexyl]-1,2,3,4-
tetrahydroisoquinoline (74) (60 mg, 0.14 mmol) and BBr3 (1M stock solution in DCM; 0.7 
mL; 0.7 mmol) following the demethylation-procedure described for 24. The reaction 
mixture was stirred for 4 h at room temperature. The product was purified by column 
chromatography (SiO2; DCM/methanol/TEA 100/20/1, v/v/v) and finally by preperative 
HPLC (Eurospher; gradient: 0-12 min: MeCN/0.05 % TFA 55/45 to 85/15). 
Yellow oil; yield: 48 mg (55 %) 
C25H34N2O2 · C2HF3O2 (509.57) 
[1H] NMR (D4-methanol): 
δ (ppm) = 1.18-2.20 (10 H; m; -(CH2)5-CH2-pyrrolidine), 2.87-3.19 (8H; 
m; -CH2-pyrrolidine; pyrrolidine-H2, -H5; THIQ-H4), 3.33-3.51 (2H; m; 
THIQ-H3), 4.23 (1H; t; 3J = 7.5 Hz; -CH-), 6.69-6.82 (3H; m; phenyl-H), 
6.94-7.21 (4H; m; phenyl-H) 
MS (CI, NH3): m/z = 395.3 (MH+) 
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HR-MS (EI):  calculated:  394.2620 
 found: 394.2610 
HPLC: Gradient: 0-25min: MeCN/0.025 % TFA (aq) 20/80 to 40/60; 25-30 min: 
40/60 to 95/5; 30-40 min: 95/5 
RT = 15.35 min; purity: 99% 
 
2-(3-Hydroxyphenyl)-1-[6-(piperidin-1-yl)hexyl]-1,2,3,4-tetrahydroisoquinolin-6-ol (92) 
Preparation from 6-methoxy-2-(3-methoxyphenyl)-1-[(6-piperidin-1-yl)hexyl]-1,2,3,4-
tetrahydroisoquinoline (75) (150 mg; 0.34 mmol) and BBr3 (1M stock solution in DCM; 
1.7 mL; 1.7 mmol) following the demethylation-procedure described for 24. The reaction 
mixture was stirred for 4 h at room temperature. The product was purified by column 
chromatography (SiO2; DCM/methanol/TEA 100/20/1, v/v/v) and finally by crystallisation 
from DCM/methanol 20/1 v/v. 
White solid; yield: 100 mg (72 %) 
C26H36N2O2 (408.28) 
Melting point:  176-178 °C 
[1H] NMR (D4-methanol): 
δ (ppm) = 1.28-1.97 (16H; m; -(CH2)5-CH-, piperidine-H3, -H4, -H5), 2.65-
3.28 (8H; m; -CH2-piperidine; piperidine-H2, -H6; THIQ-H4), 3.46-3.55 
(2H; m; THIQ-H3), 4.55 (1H; t; 3J = 6.9 Hz; -CH-), 6.10-6.18 (1H; d(d); 3J 
= 7.8 Hz; 5J = 1.9 Hz; phenyl-H4), 6.34 (1H, t, 5J = 2.2 Hz; phenyl-H2), 
6.36-6.43 (1H; d(d); 3J = 8.2 Hz; 5J = 2.1 Hz; phenyl-H6),  6.52-6.62 (2H; 
m; THIQ-H5, -H7), 6.91-7.03 (2H; m; THIQ-H8, phenyl-H5) 
MS (CI, NH3): m/z = 409.2 (MH+) 
HR-MS (EI):  calculated:  408.2777 
 found: 408.2765 
HPLC: Gradient: 0-20 min: MeCN/0.025 % TFA (aq) 20/80 to 50/50; 20-30 min: 
50/50 to 95/5; 30-40 min: 95/5 
RT = 13.62 min; purity: 98% 
 
2-(3-Hydroxyphenyl)-1-[6-[N-methyl-N-[3-(pentylthio)propyl]amino]hexyl]-1,2,3,4-
tetrahydroisoquinolin-6-ol (93) 
Preparation from 6-[6-methoxy-2-(3-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl]-
N-methyl-N-[3-(pentylthio)propyl]hexan-1-amine (78) (100 mg; 0.19 mmol) and BBr3 
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(1M stock solution in DCM; 1.0 mL; 1.0 mmol) following the demethylation-procedure 
described for 24. The reaction mixture was stirred for 3 h at room temperature. The 
product was purified by column chromatography (SiO2; DCM/methanol 10/1, v/v) and 
finally by preperative HPLC (Eurospher; gradient: 0-13 min: MeCN/0.05 % TFA (aq) 
35/65 to 60/40). 
Light yellow resin; yield: 50 mg (43 %) 
C30H45N2O2S · C2HF3O2 (612.78) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.88 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.14-1.63 (15H; m; 
-(CH2)3-CH3, N-(CH2)-(CH2)4-, -CH-CH2- 1 diastereotopic H), 1.72-1.98 
(3H; m; -S-CH2-CH2-CH2-N-, -CH-CH2- 1 diastereotopic H), 2.38-2.62 
(9H; m; N-CH3, 1 × -N-CH2-, -CH2-S-CH2-), 2.64-2.89 (4H; m; N-CH2-; 
THIQ-H4), 3.34-3.46 (2H; m; THIQ-H3), 4.44 (1H; t; 3J = 7.0 Hz; -CH-), 
6.18-6.25 (1H; d; 3J = 7.5 Hz; phenyl-H4), 6.30-6.35 (1H; d; 3J = 8.3 Hz; 
phenyl-H6), 6.40 (1H; s; phenyl-H2), 6.55-6.66 (2H; m; THIQ-H5, -H7), 
6.76-6.84 (1H; d; 3J = 8.1 Hz; THIQ-H8), 6.98-7.07 (1H; t; 3J = 8.0 Hz; 
phenyl-H5) 
MS (CI, NH3): m/z = 498.2 (MH+) 
HR-MS (EI):  calculated:  497.3202 
 found: 497.3196 
HPLC: Gradient: 0-25min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 25-40 min: 
95/5 
RT = 18.40 min; purity: 99% 
 
2-(3-Hydroxyphenyl)-1-[(10-pentylsulfinyl)decyl]-1,2,3,4-tetrahydroisoquinolin-6-ol (94) 
Preparation from 2-(3-hydroxyphenyl)-1-[(10-pentylthio)decyl]-1,2,3,4-tetrahydroiso-
quinolin-6-ol (89) (60 mg; 0.12 mmol) and H2O2 (30%; 40 µL, 0.3 mmol) following the 
procedure described for 86. Purification by column chromatography (SiO2; 
DCM/methanol 20/1, v/v). The product was purified by column chromatography (SiO2; 
DCM/methanol 25/1, v/v). 
Light yellow resin; yield: 50 mg (83%) 
C30H45NO3S (499.31) 
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[1H] NMR (CDCl3): 
δ (ppm) = 0.91 (3H; t; 3J = 7.4 Hz; CH3-CH2-), 1.08-1.96 (24H; m; 
-(CH2)9-CH2-SO-CH2-(CH2)3-), 2.55-2.88 (6H; m; 3J = 7.4 Hz; -CH2-SO-
CH2-, THIQ-H4), 3.35-3.57 (2H; m, THIQ-H3), 4.51 (1H; t; 3J = 6.8 Hz; -
CH-), 6.17-6.48 (3H; m; phenyl-H2, -H4, -H6), 6.58-6.69 (2H; m; THIQ-H5, 
-H7), 6.85-6.93 (1H; d; 3J = 8.1 Hz; THIQ-H8), 7.00-7.09 (1H; t; 3J = 8.2 
Hz; phenyl-H5) 
MS (EI): m/z = 499.3 (1.16%), 240.1 (100%; [M – (CH2)10SOC5H11 
HR-MS (EI):  calculated:  499.3120 
 found: 499.3107 
HPLC: Gradient: 0-25 min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 25-40 min: 
95/5 
RT = 24.17 min; purity: 98% 
 
6.1.2.3 Synthesis of N-trifluoroacetyl and N-Phenylsulfonyltetrahydroisoquinolin-6-ols 
6.1.2.3.1 Synthesis of N-unsubstituated THIQs 
 
O-(Ethoxycarbonyl)-3-methoxymandelonitrile (95) (Kashdan et al., 1982) 
3-Methoxybenzaldehyde (20 g, 147 mmol) and ethyl chloroformate (17.6 g, 162 mmol) 
were dissolved in THF (30 mL) and the solution was cooled to 0 °C. A solution of KCN 
(10.6 g, 162 mmol) in water (40 mL) was added and the mixtute was stirred for 4 h at 
this temperature and another 16 h at room temperature. Then the reaction mixture was 
poured into water (200 mL) and the product was extracted with ether (3 × 100 mL). The 
combined organic extracts were washed with brine, dried over Na2SO4 and evaporated. 
The crude product was destilled in vacuo (bp: 115-120 °C; 0.3 mbar).  
Colourless oil; yield: 26.5 g (75%) 
C12H13NO4 (235.08) 
[1H] NMR (CDCl3): 
δ (ppm) = 1.33 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 3.83 (3H; s; -O-CH3), 
4.20-4.37 (2H; m; 2 diastreotopic Hs; O-CH2-CH3), 6.23 (1H; s; -CH-CN), 
6.96-7.02 (1H; d(d); 3J = 8.3 Hz; 5J = 2.5 Hz; phenyl-H4), 7.05 (1H; t; 5J = 
2.3 Hz; phenyl-H2), 7.08-7.13 (1H; d; 3J = 8.0 Hz; phenyl-H6), 7.36 (1H; t; 
3J = 8.0 Hz; phenyl-H5) 
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2-(3-Methoxyphenyl)ethylamine (96) (Kashdan et al., 1982) 
A solution of O-(ethoxycarbonyl)-3-methoxymandelonitrile (95) (5.8 g, 25 mmol) in abs. 
ethanol (75 mL) was added dropwise into a stirred mixture of Pd/C (0.38 g; 10 mol%) 
and conc. H2SO4 (1.75 mL; 32.5 mmol) while hydrogen was bubbling through the 
solution. Stirring and bubbling was continued for 12 h. Pd/C was filtered of and the 
solvent was destilled of in vacuo. The residue was taken up in water (100 mL) and the 
mixture was neutralised with 4M NaOH under ice.cooling. The organic components 
were extracted into ether (3 × 50 mL); the organic phase was washed with brine, dried 
over Na2SO4 and evaporated. The crude product was purified by Kugelrohr-destillation 
under reduced pressure (bp = 65-68 °C; 0.1 mbar). 
Light yellow oil; yield: 1.2 g (32 %) 
C9H13NO (151.21) 
[1H] NMR (CDCl3): 
δ (ppm) = 2.75 (2H; t; 3J = 7.0 Hz; -CH2-NH2), 2.93 (2H; t; 3J = 7.1 Hz; -
CH2-phenyl), 3.78 (3H; s; -O-CH3), 6.63-6.85 (3H; m; phenyl-H), 7.20 
(1H; t; 3J = 8.0 Hz; phenyl-H5) 
 
N-(3-Methoxyphenylethyl)benzamide (97) 
Preparation from benzoyl chloride (170 mg; 1.2 mmol) and 2-(3-methoxyphenyl)-
ethylamine (96) (151 mg; 1.0 mmol) following the procedure described for 53. 
Purification by column chromatography (SiO2; DCM/ethyl acetate 15/1, v/v). 
Colourless resin; yield: 180 mg (70 %) 
C16H17NO2 (255.31) 
[1H] NMR (CDCl3): 
δ (ppm) = 2.90 (2H; t; 3J = 7.3 Hz; phenyl-CH2-), 3.69 (2H; t; 3J = 7.3 Hz; 
-CH2-N), 3.80 (3H; s; -O-CH3), 6.78-6.87 (3H; m; phenyl-H), 7.20-7.27 
(1H; m; phenyl-H5), 7.36-7.55 (3H; m; -CO-phenyl-H), 7.68-7.75 (2H; d; 
3J = 8.2 Hz; -CO-phenyl-H2, -H6) 
MS (CI, NH3): m/z = 256.2 (100%; MH+), 273.3 (49%; MNH4+) 
 
 
N-(3-Methoxyphenylethyl)-11-pentylthioundecanamide (98) 
Preparation from 11-pentylthioundecanoic acid chloride (41) (300 mg; 1.0 mmol) and 2-
(3-methoxyphenyl)ethylamine (96) (100 mg; 0.66 mmol) following the procedure 
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described for 53. Purification by column chromatography (SiO2; DCM/methanol 50/1, 
v/v). 
Colourless oil; yield: 250 mg (90 %) 
C25H41NO2S (421.22) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.89 (3H; t; 3J = 7.1 Hz; CH3-CH2-), 1.20-1.42 (16H; m; 
-(CH2)6-(CH2)2-S-(CH2)2-(CH2)2-), 1.50-1.63 (6H; m; -CO-CH2-CH2-, -
CH2-CH2-S-CH2-CH2-), 2.11 (2H; t; 3J = 7.5 Hz; -CH2-CO-), 2.43-2.56 
(4H; t; 3J = 7.0 Hz; -CH2-S-CH2-) 2.79 (2H; t; 3J = 6.9 Hz; phenyl-CH2-), 
3.47-3.56 (2H; d(t); 3J1 = 6.8 Hz; 3J2 = 6.1 Hz; -CH2-NH-), 3.80 (3H; s; -
O-CH3), 6.72-6.80 (3H; m; phenyl-H), 7.19-7.25 (1H; m; phenyl-H5) 
MS (CI, NH3): m/z = 422.2 (100%; MH+), 439.4 (9%; MNH4+) 
 
N-(3-Methoxyphenylethyl)-11-pentylsulfonylundecanamide (99) 
Preparation from 11-pentylsulfonylundecanoic acid chloride (44) (600 mg; 1.8 mmol) 
and 2-(3-methoxyphenyl)ethylamine (96) (250 mg; 1.65 mmol) following the procedure 
described for 53. Purification by crystallisation from toluene. 
White crystals; yield: 520 mg (71 %) 
Melting point: 109-110 °C 
C25H43NO4S (453.68) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.0 Hz; CH3-CH2-), 1.21-1.49 (16H; m; 
-(CH2)6-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.52-1.64 (2H; m; -CO-CH2-CH2-, -
CH2-CH2-S-CH2-CH2-), 2.11 (2H; t; 3J = 7.5 Hz; -CH2-CO-), 2.43-2.56 
(4H; t; 3J = 7.0 Hz; -CH2-S-CH2-) 2.79 (2H; t; 3J = 6.9 Hz; phenyl-CH2-), 
2.89-2.97 (4H; t; 3J = 8.1 Hz; -CH2-SO2-CH2-), 3.47-3.55 (2H; d(t); 3J1 = 
6.8 Hz; 3J2 = 6.0 Hz; -CH2-NH-), 3.80 (3H; s; -O-CH3), 6.71-6.81 (3H; m; 
phenyl-H), 7.19-7.26 (1H; t; merged in CDCl3 peak; 3J = 7.9 Hz; phenyl-
H5) 
MS (CI, NH3): m/z = 454.2 (100%; MH+), 471.2 (24%; MNH4+) 
 
6-Methoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline (100) 
N-(3-methoxyphenylethyl)benzamide (97) (180 mg, 0.7 mmol) was refluxed in POCl3 
(0.3 mL) / toluene (14 mL) for 16 h. Solvent and POCl3 were removed in vacuo and the 
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residue was dissolved in DCM (25 mL). The solution was washed with sat. Na2HCO3 
solution and brine, dried over Na2SO4 and evaporated. The crude 3-4-
dihydroisoquinoline was directly reduced with NaBH4 (200 mg; 5.2 mmol) in methanol 
(10 mL). The work-up procedure was the same as described for 63 with DCM as 
extraction-solvent. The crude product was purified by column chromatography (SiO2; 
DCM/methanol/TEA 1000/50/1, v/v/v). 
White solid; yield: 120 mg (72 %) 
C16H16NO (238.30) 
[1H] NMR (CDCl3): 
δ (ppm) = 2.75-2.90 (1H; m; -CH2-phenyl 1 diastereotopic H), 2.97-3.12 
(2H; m; N-CH2-CH2-phenyl 1 diastereotopic H of each), 3.21-3.30 (1H; 
m; -CH2-N- 1 diastereotopic H), 3.78 (3H; s; -O-CH3), 5.06 (1H; s; -CH-
phenyl-), 6.60-6.69 (3H; m; THIQ-H), 7.24-7.35 (5H; m; phenyl-H) 
MS (CI, NH3): m/z = 240.2 (MH+) 
 
6-Methoxy-1-[10-(pentylthio)decyl]-1,2,3,4-tetrahydroisoquinoline (101) 
Preparation from N-(3-methoxyphenylethyl)-11-pentylthioundecanamide (98) (300 mg, 
0.8 mmol) in POCl3 (0.4mL) / toluene (15 mL) followed by reduction with NaBH4 (200 
mg; 5.2 mmol) in methanol (10 mL). The procedure was the same as described for 100. 
Purification by column chromatography (SiO2; DCM/methanol/TEA 1000/70/1, v/v/v). 
White solid; yield: 260 mg (83 %) 
C25H41NOS (405.31) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.1 Hz; -CH2-CH3), 1.23-1.64 (22H; m; 
-(CH2)8-CH2-S-CH2-(CH2)3-), 1.70-1.92 (2H; m; -CH-CH2-), 2.50 (4H; t; 3J 
= 7.4 Hz; -CH2-S-CH2-), 2.74-2.97 (2H; m; -CH2-phenyl 2 diastereotopic 
Hs), 3.01-3.10 (1H; m; -CH2-NH- 1 diastereotopic H), 3.26-3.35 (1H; m; -
CH2-NH- 1 diastereotopic H), 3.78 (3H; s; -O-CH3), 4.00-4.06 (1H; m; -
CH-), 6.60-6.64 (1H; d; 5J = 2.6 Hz; THIQ-H5), 6.71-6.77 (1H; d(d); 3J = 
8.6 Hz; 5J = 2.7 Hz; THIQ-H7), 7.02-7.07 (1H; d; 3J = 8.6 Hz; THIQ-H8) 
MS (EI): m/z = 162.1 (100%, [M – (CH2)10-S-C5H11]+), 405.4 (1%) 
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6-Methoxy-1-[(10-pentylsulfonyl)decyl]-1,2,3,4-tetrahydroisoquinoline (102) 
Preparation from N-(3-methoxyphenylethyl)-11-pentylsulfonylundecanamide (99) 
(500 mg, 0.8 mmol) in POCl3 (0.6mL) / toluene (25 mL) followed by reduction with 
NaBH4 (280 mg; 7.3 mmol) in methanol (20 mL). The procedure was the same as 
described for 100. Purification by column chromatography (SiO2; DCM/methanol/TEA 
1000/100/1, v/v/v). 
Light yellow solid; yield: 450 mg (93 %) 
Melting point: 55-56 °C 
C25H43NO3S (437.68) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.23-1.50 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.76-1.90 (6H; m; -CH-CH2-, -CH2-
CH2-SO2-CH2-CH2-), 2.67-2.85 (2H; m; -CH2-phenyl 2 diastereotopic 
Hs), 2.91-3.04 (4H; m; -CH2-SO2-CH2-, -CH2-NH- 1 diastereotopic H), 
3.20-3.29 (1H; m; -CH2-NH- 1 diastereotopic H), 3.78 (3H; s; -O-CH3), 
3.90-3.97 (1H; m; -CH-), 6.60-6.63 (1H; d; 5J = 2.6 Hz; THIQ-H5), 6.70-
6.75 (1H; d(d); 3J = 8.5 Hz; 5J = 2.7 Hz; THIQ-H7), 7.02-7.07 (1H; d; 3J = 
8.6 Hz; THIQ-H8) 
MS (CI, NH3): m/z = 483.1 (MH+) 
 
6.1.2.3.2 Introduction of a N-Trifluoroaceyl Group and Cleavage of the Methoxy 
Protecting Group 
 
2,2,2-Trifluoro-1-(6-methoxy-1-phenyl-1,2,3,4tetrahydroisoquinolin-2-yl)ethanon (103) 
At 0 °C under nitrogen a solution of trifluoroacetic acid anhydride (132 mg, 0.63 mmol) 
in abs. DCM (1 mL) was added to a solution of 6-methoxy-1-phenyl-1,2,3,4-tetrahydro-
isoquinoline (100) (100 mg, 0.63 mmol) in abs DCM (5 mL) / TEA (0.2 mL). The reaction 
mixture was stirred at this temperature for 1.5 h. Then water was added and the DCM-
phase was separated. The aqueous phase was extracted with two portions of DCM; the 
combined organic phases were washed with water and brine, dried over Na2SO4 and 
evaporated. The product was purified by column chromatography (SiO2; PE/ ethyl 
acetate 15/1, v/v). 
Colourless resin; yield: 130 mg (92% 
C18H16F3NO2 (335.32) 
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[1H] NMR (CDCl3): 
δ (ppm) = 2.76-2.85 (1H; m; -CH2-phenyl 1 diastereotopic H), 2.97-3.11 
(1H; m; -CH2-phenyl 1 diastereotopic H), 3.37-3.49 (1H; m; -CH2-N- 1 
diastereotopic H), 3.83-3.94 (1H; m; -CH2-N- 1 diastereotopic H), 3.77 
(3H; s; -O-CH3), 6.66-6.70 (1H; m; -CH-phenyl-), 6.72-6.77 (2H; m; 
THIQ-H5, -H7), 6.90-6.95 (1H; d; 3J = 8.5 Hz; THIQ-H8), 7.14-7.28 (5H; 
m; phenyl-H) 
MS (CI, NH3): m/z = 336.3 (9%; MH+), 353.3 (100% MNH4+) 
 
2,2,2-Trifluoro-1-[6-methoxy-1-[10-(pentylthio)decyl]-1,2,3,4-tetrahydroisoquinolin-2-
yl]ethanone (104) 
Preparation from 6-methoxy-1-[10-(pentylthio)decyl]-1,2,3,4-tetrahydroisoquinoline 
(101) (200 mg; 0.5 mmol) and trifluoroacetic acid anhydride (157 mg; 0.75 mmol) 
following the procedure described for 103. Purification by column chromatography 
(SiO2; PE/ ethyl acetate 20/1, v/v). 
Colourless resin; yield: 170 mg (68%) 
C27H42F3NO2S (501.29) 
[1H] NMR (CDCl3): 
δ (ppm) = = 0.85 (3H; t; 3J = 7.1 Hz; -CH2-CH3), 1.13-1.41 (18H; m; 
-(CH2)7-(CH2)2-S-(CH2)2-(CH2)2-), 1.46-1.61 (4H; m; -CH2-CH2-S-CH2-
CH2-) 1.70-1.82 (2H; m; -CH-CH2-), 2.45 (4H; t; 3J = 7.4 Hz; -CH2-S-
CH2-), 2.73-3.20 (2H; m; -CH2-phenyl 2 diastereotopic Hs), 3.51-3.61 
(1H; m; -CH2-NH- 1 diastereotopic H), 3.90-4.10 (1H; m; -CH2-NH- 1 
diastereotopic H), 3.74 (3H; s; -O-CH3), 5.41-5.47 (1H; m; -CH-), 6.57-
6.64 (1H; d; 5J = 2.6 Hz; THIQ-H5), 6.71-6.76 (1H; d(d); 3J = 8.5 Hz; 5J = 
2.6 Hz; THIQ-H7), 6.98-7.02 (1H; d; 3J = 8.6 Hz; THIQ-H8) 
MS (CI, NH3): m/z = 502.2 (39%; MH+), 519.3(100%; MNH4+) 
 
2,2,2-Trifluoro-1-[6-methoxy-1-[10-(pentylsulfonyl)decyl]-1,2,3,4-tetrahydroisoquinolin-2-
yl]ethanone (105) 
Preparation from 6-methoxy-1-[10-(pentylsulfonyl)decyl]-1,2,3,4-tetrahydroisoquinoline 
(102) (80 mg; 0.2 mmol) and trifluoroacetic acid anhydride (58 mg; 0.27 mmol) following 
the procedure described for 103. Purification by column chromatography (SiO2; PE/ 
ethyl acetate 3/1, v/v). 
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White solid; yield: 80 mg (83%) 
C27H42F3NO4S (533.69) 
[1H] NMR (CDCl3): 
δ (ppm) = = 0.92 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.20-1.49 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.75-1.90 (6H; m; -CH2-CH2-SO2-
CH2-CH2-, -CH-CH2-), 2.78-3.09 (6H; m; -CH2-phenyl 2 diastereotopic 
Hs, -CH2-SO2-CH2-),), 3.54-3.67 (1H; m; -CH2-NH- 1 diastereotopic H), 
3.78 (3H; s; -O-CH3), 3.95-4.06 (1H; m; -CH2-NH- 1 diastereotopic H), 
5.45-5.52 (1H; m; -CH-), 6.62-6.65 (1H; d; 5J = 2.5 Hz; THIQ-H5), 6.75-
6.81 (1H; d(d); 3J = 8.5 Hz; 5J = 2.6 Hz; THIQ-H7), 7.02-7.07 (1H; d; 3J = 
8.6 Hz; THIQ-H8) 
MS (CI, NH3): m/z = 534.2 (2.2%; MH+), 551.2(100%; MNH4+) 
 
2,2,2-Trifluoro-1-[6-hydroxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-2-yl]ethanon (106) 
Preparation from 2,2,2-trifluoro-1-(6-methoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-2-
yl)ethanon (103) (100 mg, 0.3 mmol) and BBr3 (1M stock solution in DCM; 0.9 mL; 0.9 
 mmol) following the demethylation procedure described for 24. The reaction mixture 
was stirred for 2 h. Purification by column chromatography (PE/ethyl acetate 3/1 v/v) 
Light yellow resin; yield: 60 mg (62 %) 
C17H14F3NO2 (321.29) 
[1H] NMR (CDCl3): 
δ (ppm) = 2.74-2.85 (1H; m; -CH2-phenyl 1 diastereotopic H), 2.95-3.13 
(1H; m; -CH2-phenyl 1 diastereotopic H), 3.39-3.55 (1H; m; -CH2-N- 1 
diastereotopic H), 3.88-4.00 (1H; m; -CH2-N- 1 diastereotopic H), 6.69-
6.82 (3H; m; -CH-phenyl, THIQ-H5, -H7), 6.89-6.95 (1H; d; 3J = 8.5 Hz; 
THIQ-H8), 7.15-7.38 (5H; m; phenyl-H) 
MS (EI): m/z = 321.1 
HPLC: Gradient: 0-25 min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 25-40 min: 
95/5 
RT = 20.63 min; purity: 99% 
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2,2,2-Trifluoro-1-[6-hydroxy-1-[10-(pentylthio)decyl]-3,4-dihydroisoquinolin-2-
yl]ethanone (107) 
Preparation from 2,2,2-trifluoro-1-[6-methoxy-1-[10-(pentylthio)decyl]-1,2,3,4-tetra-
hydroisoquinolin-2-yl]ethanone (104) (170 mg, 0.35 mmol) and BBr3 (1M stock solution 
in DCM; 1 mL; 1.0 mmol) following the demethylation procedure described for 24. The 
reaction mixture was stirred for 2 h. Purification by column chromatography (PE/ethyl 
acetate 5/1 v/v) 
Colourless oil; yield: 80 mg (48%) 
C26H40F3NO2S (487.27) 
[1H] NMR (CDCl3): 
δ (ppm) = = 0.90 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.20-1.46 (18H; m; 
-(CH2)7-(CH2)2-S-(CH2)2-(CH2)2-), 1.51-1.65 (4H; m; -CH2-CH2-S-CH2-
CH2-) 1.70-1.90 (2H; m; -CH-CH2-), 2.50 (4H; t; 3J = 7.4 Hz; -CH2-S-
CH2-), 2.74-3.05 (2H; m; -CH2-phenyl 2 diastereotopic Hs), 3.53-3.66 
(1H; m; -CH2-NH- 1 diastereotopic H), 3.94-4.04 (1H; m; -CH2-NH- 1 
diastereotopic H), 5.42-5.50 (1H; m; -CH-), 6.57-6.62 (1H; d; 5J = 2.3 Hz; 
THIQ-H5), 6.67-6.74 (1H; d(d); 3J = 8.3 Hz; 5J = 2.6 Hz; THIQ-H7), 6.95-
7.02 (1H; d; 3J = 8.4 Hz; THIQ-H8) 
MS (CI, NH3): m/z = 403.2 (100%; [MNH4 – C5H11]+), 488.3 (10%; MH+), 505.2 (41%; 
MNH4+) 
 
2,2,2-Trifluoro-1-[6-hydroxy-1-[10-(pentylsulfonyl)decyl]-1,2,3,4-tetrahydroisoquinolin-2-
yl]ethanone (108) 
Preparation from 2,2,2-trifluoro-1-[6-methoxy-1-[10-(pentylsulfonyl)decyl]-1,2,3,4-
tetrahydroisoquinolin-2-yl)ethanone (105) (60 mg, 0.11 mmol) and BBr3 (1M stock 
solution in DCM; 0.35 mL; 0.35 mmol) following the demethylation procedure described 
for 24. The reaction mixture was stirred for 2 h. Purification by column chromatography 
(PE/ethyl acetate 5/1 v/v) 
Colourless resin; yield: 45 mg (79%) 
C26H40F3NO4S (519.66) 
[1H] NMR (CDCl3): 
δ (ppm) = = 0.92 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.18-1.50 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.70-1.90 (6H; m; -CH2-CH2-SO2-
CH2-CH2-, -CH-CH2-), 2.75-3.03 (6H; m; -CH2-phenyl 2 diastereotopic 
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Hs, -CH2-SO2-CH2-), 3.55-3.67 (1H; m; -CH2-NH- 1 diastereotopic H), 
3.93-4.04 (1H; m; -CH2-NH- 1 diastereotopic H), 5.41-5.49 (1H; m; 
-CH-), 6.57-6.64 (1H; d; 5J = 2.4 Hz; THIQ-H5), 6.67-6.73 (1H; d(d); 
3J = 8.3 Hz; 5J = 2.6 Hz; THIQ-H7), 6.90-7.02 (1H; d; 3J = 8.4 Hz; THIQ-
H8) 
MS (CI, NH3): m/z = 520.3 (1%; MH+), 537.2 (100%; MNH4+) 
HR-MS (EI):  calculated:  519.2630 
 found: 519.2622 
HPLC: Gradient: 0-20 min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 40 min: 95/5 
RT = 23.07 min; purity: 96% 
 
6.1.2.3.3 Introduction of a Phenylsulfonyl Group and Cleavage of the Methoxy 
Protecting group 
 
6-Methoxy-1-[10-(pentylthio)decyl]-2-(phenylsulfonyl)-1,2,3,4.tetrahydroisoquinoline 
(109) 
Phenylsulfonylchloride (88 mg, 0.5 mmol) was added to a stirred suspension of 6-
methoxy-1-[10-(pentylthio)decyl]-1,2,3,4-tetrahydroisoquinoline (101) (60 mg, 
0.15 mmol) in THF (3 mL) / pyridine (2 mL) / TEA (120 µL) and the reaction mixture was 
stirred for 2 h at room temperature. Then the solvent was removed in vacuo and the 
residue was dissolved in DCM. The DCM solution was washed with brine; dried over 
Na2SO4 and evaporated. The product was purified by column chromatography (SiO2; 
PE/ ethyl acetate 20/1 → 10/1, v/v). 
Colourless oil; yield: 70 mg (85%) 
C31H47NO3S2 (545.84) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.21-1.50 (18H; m; 
-(CH2)7-(CH2)2-S-(CH2)2-(CH2)2-), 1.52-1.82 (6H; m; -CH2-CH2-S-CH2-
CH2-, -CH-CH2-), 2.47-2.55 (6H; m; CH2-phenyl, -CH2-S-CH2-), 3.39-
3.51 (1H; m; -CH2-NH- 1 diastereotopic H), 3.71 (3H; s; -O-CH3), 3.80-
3.90 (1H; m; -CH2-NH- 1 diastereotopic H), 4.87-4.95 (1H; m; -CH-), 
6.36-6.39 (1H; d; 5J = 2.5 Hz; THIQ-H5), 6.66-6.71 (1H; d(d); 3J = 8.5 Hz; 
5J = 2.6 Hz; THIQ-H7), 6.92-6.97 (1H; d; 3J = 8.5 Hz; THIQ-H8), 7.27-
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7.35 (2H; t; 3J = 7.5 Hz; phenyl-H3, -H5), 7.39-7.46 (1H; t; 3J = 7.4 Hz; 
phenyl-H4), 7.68-7.73 (2H; d; 3J = 7.9 Hz; phenyl-H2, -H6) 
MS (CI, NH3): m/z = 461.2 (100%; [MNH4 – SC5H11]+), 546.2 (46%; MH+), 563.2 (86%; 
MNH4+) 
 
6-Methoxy-1-[10-(pentylsulfonyl)decyl]-2-(phenylsulfonyl)-1,2,3,4.tetrahydroisoquinoline 
(110) 
Preparation from 6-methoxy-1-((10-pentylsulfonyl)decyl)-1,2,3,4-tetrahydroisoquinoline 
(102) (100 mg; 0.23 mmol) and phenylsulfonyl chloride (88 mg; 0.5 mmol) following the 
procedure described for 109. The product was purified by column chromatography 
(SiO2; PE/ ethyl acetate 5/1 → 2/1, v/v). 
Colourless oil; yield: 120 mg (91%) 
C31H47NO5S2 (577.29) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.20-1.52 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.55-1.91 (6H; m; -CH2-CH2-SO2-
CH2-CH2-, -CH-CH2-), 2.41-2.50 (2H; m; CH2-phenyl), 2.90-2.99 (4H; t; 
3J = 8.2 Hz; CH2-SO2-CH2-), 3.39-3.51 (1H; m; -CH2-NH- 1 
diastereotopic H),; 3.71 (3H; s; -O-CH3), 3.79-3.89 (1H; m; -CH2-NH- 1 
diastereotopic H), 4.88-4.95 (1H; m; -CH-), 6.35-6.38 (1H; d; 5J = 2.6 Hz; 
THIQ-H5), 6.66-6.71 (1H; d(d); 3J = 8.4 Hz; 5J = 2.6 Hz; THIQ-H7), 6.92-
6.97 (1H; d; 3J = 8.5 Hz; THIQ-H8), 7.27-7.35 (2H; t; 3J = 7.5 Hz; phenyl-
H3, -H5), 7.38-7.45 (1H; t; 3J = 7.4 Hz; phenyl-H4), 7.67-7.72 (2H; d; 3J = 
7.9 Hz; phenyl-H2, -H6) 
MS (CI, NH3): m/z = 438.1 (100%; [MH – SO2Ph]+), 578.2 (2.3%; MH+), 595.2 (57%; 
MNH4+) 
 
1-(10-(Pentylthio)decyl)-2-(phenylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (111) 
Preparation from 6-methoxy-1-[10-(pentylthio)decyl]-2-(phenylsulfonyl)-1,2,3,4-tetra-
hydroisoquinoline (109) (80 mg, 0.15 mmol) and BBr3 (1M stock solution in DCM; 0.45 
mL; 0.45 mmol) following the demethylation procedure described for 24. The reaction 
mixture was stirred for 2 h. Purification by column chromatography (PE/ethyl acetate 3/1 
v/v) 
Colourless resin; yield: 55 mg (69 %) 
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C30H45NO3S2 (531.81) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.90 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.20-1.50 (18H; m; 
-(CH2)7-(CH2)2-S-(CH2)2-(CH2)2-), 1.51-1.83 (6H; m; -CH2-CH2-S-CH2-
CH2-, -CH-CH2-), 2.39-2.56 (6H; m; CH2-phenyl, -CH2-S-CH2-), 3.37-
3.50 (1H; m; -CH2-NH- 1 diastereotopic H), 3.78-3.89 (1H; m; -CH2-NH- 
1 diastereotopic H), 4.85-4.93 (1H; m; -CH-), 6.30-6.34 (1H; d; 5J = 2.1 
Hz; THIQ-H5), 6.57-6.64 (1H; d(d); 3J = 8.3 Hz; 5J = 2.4 Hz; THIQ-H7), 
6.85-6.92 (1H; d; 3J = 8.3 Hz; THIQ-H8), 7.27-7.36 (2H; t; 3J = 7.5 Hz; 
phenyl-H3, -H5), 7.38-7.47 (1H; t; 3J = 7.4 Hz; phenyl-H4), 7.66-7.74 (2H; 
d; 3J = 7.3 Hz; phenyl-H2, -H6) 
MS (CI, NH3): m/z = 447.2 (100%; [MNH4 – SC5H11]+), 532.2 (59%; MH+), 549.2 (96%; 
MNH4+) 
 
1-[10-(Pentylsulfonyl)decyl]-2-(phenylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (112) 
Preparation from 6-methoxy-1-[10-(pentylsulfonyl)decyl]-2-(phenylsulfonyl)-1,2,3,4-tetra-
hydroisoquinoline (110) (80 mg, 0.14 mmol) and BBr3 (1M stock solution in DCM; 0.45 
mL; 0.45 mmol) following the demethylation procedure described for 24. The reaction 
mixture was stirred for 3 h. Purification by column chromatography (DCM/methanol 30/1 
v/v). 
Colourless resin; yield: 50 mg (63 %) 
C30H45NO5S2 (563.81) 
[1H] NMR (CDCl3): 
δ (ppm) = 0.92 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.18-1.52 (18H; m; 
-(CH2)7-(CH2)2-SO2-(CH2)2-(CH2)2-), 1.58-1.91 (6H; m; -CH2-CH2-SO2-
CH2-CH2-, -CH-CH2-), 2.38-2.47 (2H; m; CH2-phenyl), 2.90-2.99 (4H; t; 
3J = 8.1 Hz; CH2-SO2-CH2-), 3.38-3.52 (1H; m; -CH2-NH- 1 
diastereotopic H), 3.76-3.89 (1H; m; -CH2-NH- 1 diastereotopic H), 4.85-
4.93 (1H; m; -CH-), 6.30-6.35 (1H; d; 5J = 2.2 Hz; THIQ-H5), 6.58-6.64 
(1H; d(d); 3J = 8.3 Hz; 5J = 2.4 Hz; THIQ-H7), 6.85-6.92 (1H; d; 3J = 
8.3 Hz; THIQ-H8), 7.27-7.36 (2H; t; 3J = 7.5 Hz; phenyl-H3, -H5), 7.38-
7.46 (1H; t; 3J = 7.4 Hz; phenyl-H4), 7.66-7.74 (2H; d; 3J = 7.9 Hz; 
phenyl-H2, -H6) 
MS (CI, NH3): 564.2 (1%; MH+), 581.3 (58%; MNH4+) 
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HR-MS (EI):  calculated:  563.2739 
 found: 563.2727 
HPLC: Gradient: 0-20min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 20-40 min: 
95/5 
RT = 22.95 min; purity: 96% 
 
6.1.2.3.4 Oxidation of the Side Chain Sulfur to the Sulfoxide Function 
 
2,2,2-Trifluoro-1-[6-hydroxy-1-[10-(pentylsulfinyl)decyl]-1,2,3,4-tetrahydroisoquinolin--2-
yl]ethanone (113) 
Preparation from 2,2,2-trifluoro-1-[6-hydroxy-1-[10-(pentylthio)decyl]-1,2,3,4-tetrahydro-
isoquinolin-2-yl]ethanone (107) (60 mg, 0.12 mmol) and H2O2 (30%; 30µL, 0.25 mmol) 
following the procedure described for 86. The product was purified by column 
chromatography (SiO2; DCM/methanol 20/1, v/v).  
Colourless resin; yield: 55 mg (91%) 
C26H40F3NO3S (503.27) 
[1H] NMR (CDCl3):  
δ (ppm) = = 0.91 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.18-1.54 (18H; m; 
-(CH2)7-(CH2)2-SO-(CH2)2-(CH2)2-), 1.69-1.89 (6H; m; -CH2-CH2-SO-
CH2-CH2-, -CH-CH2-), 2.58-3.01 (6H; m; -CH2-SO-CH2-, -CH2-phenyl), 
3.56-3.68 (1H; m; -CH2-NH- 1 diastereotopic H), 3.89-4.00 (1H; m; -CH2-
NH- 1 diastereotopic H), 5.38-5.40 (1H; m; -CH-), 6.59-6.63 (1H; d; 5J = 
2.0 Hz; THIQ-H5), 6.70-6.75 (1H; d(d); 3J = 8.2 Hz; 5J = 2.0 Hz; THIQ-
H7), 6.93-6.99 (1H; d; 3J = 8.4 Hz; THIQ-H8) 
MS (CI, NH3):  504.2 (100%; MH+) 
HR-MS (EI):  calculated:  503.2681 
 found: 503.2676 
HPLC: Gradient: 0-20 min: MeCN/0.025 % TFA (aq) 50/50 to 95/5; 20-40 min: 
95/5 
RT = 19.70 min; purity: 98% 
 
1-[10-(Pentylsulfinyl)decyl]-2-(phenylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-6-ol (114) 
Preparation from 1-[10-(pentylthio)decyl]-2-(phenylsulfonyl)-1,2,3,4-tetrahydroiso-
quinolin-6-ol (111) (50 mg, 0.09 mmol) and H2O2 (30%; 35 µL, 0.20 mmol) following the 
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procedure described for 86. The product was purified by column chromatography (SiO2; 
DCM/methanol 20/1, v/v). 
Colourless resin; yield: 30 mg (67%) 
C30H45NO4S2 (547.81) 
[1H] NMR (CDCl3):  
δ (ppm) = 0.91 (3H; t; 3J = 7.0 Hz; -CH2-CH3), 1.14-1.53 (18H; m; 
-(CH2)7-(CH2)2-SO-(CH2)2-(CH2)2-), 1.58-1.88 (6H; m; -CH2-CH2-SO-
CH2-CH2-, -CH-CH2-), 2.30-2.55 (2H; m; CH2-phenyl), 2.56-2.79 (4H; m; 
CH2-SO-CH2-), 3.42-3.54 (1H; m; -CH2-NH- 1 diastereotopic H), 3.68-
3.79 (1H; m; -CH2-NH- 1 diastereotopic H), 4.83-4.92 (1H; m; -CH-), 
6.32-6.39 (1H; d; 5J = 2.2 Hz; THIQ-H5), 6.58-6.66 (1H; d(d); 3J = 8.3 Hz; 
5J = 2.0 Hz; THIQ-H7), 6.83-6.90 (1H; d; 3J = 8.3 Hz; THIQ-H8), 7.28-
7.36 (2H; t; 3J = 7.7 Hz; phenyl-H3, -H5), 7.38-7.46 (1H; t; 3J = 7.4 Hz; 
phenyl-H4), 7.67-7.74 (2H; d; 3J = 7.7 Hz; phenyl-H2, -H6) 
MS (CI, NH3):  504.2 (100%; MH+) 
HR-MS (EI):  calculated:  547.2790 
 found: 547.2783 
HPLC: Gradient: 0-20 min: MeCN/0.025 % TFA (aq) 20/80 to 95/5; 20-35 min: 
95/5 
RT = 23.90 min; purity: 97% 
 
6.1.2.4 Unsuccessful Approach to 1-Alkyl-2-aryltetrahydroisoquinolines  
6.1.2.4.1 Preparation of 6-Methoxy-2-(4-methoxyphenyl)-3,4-dihydroisoquinolin-1-on 
(116) 
 
6-Methoxy-3,4-dihydro-2H-isoquinolin-1-one (115) 
At 60 °C NaN3 (0.65 g; 10 mmol) was added slowly to a stirred solution of 5-methoxy-
2,3-dihydroinden-1-one (1.62 g, 10 mmol) and conc. H2SO4 (6.0 mL, 110 mmol) in 
toluene (20 mL). A strong gas evolution started. After 1.5 h the gas evolution ceased. 
Then a second portion of NaN3 (160 mg, 2.5 mmol) was added and the the mixtute was 
stirred for another hour at given temperature. The reaction mixture was cooled down 
and the toluene layer was discarded. The acidic phase was poured into ice water (150 
mL) and neutralized with sat. NaHCO3 solution. The organic components were 
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extracted with three portions of DCM (3. ×.100 mL); the combined organic extracts were 
dried over Na2SO4 and evaporated. Purification by column chromatography (SiO2; 
DCM/methanol 20/1, v/v) followed by crystallisation from acetone.  
Light yellow crystals; yield: 1.24 g (70%) 
Melting point: 136 °C (Lit: 139-140 °C (Tomita et al., 1969))  
C10H11NO2 (177.20) 
[1H] NMR (CDCl3): 
δ (ppm) = 2.96 (2H; t; 3J = 6.6 Hz; DHIQ-H3), 3.55 (2H; d(t); 3Jt = 6.8 Hz; 
3Jd = 2.8 Hz; DHIQ-H4), 3.85 (3H; s; -O-CH3), 6.69-6.72 (1H; d; 3J = 2.5 
Hz; DHIQ-H5), 6.83-6.89 (1H; dd; 3J = 8.7 Hz; 5J = 2.6 Hz; DHIQ-H7), 
7.99-8.04 (1H; d; 3J = 8.6 Hz; DHIQ-H8) 
 
6-Methoxy-2-(4-methoxyphenyl)-3,4-dihydroisoquinolin-1-on (116)  
A solution of 4-bromoanisol (1.25 g, 6.7 mmol), CuI (0.255 g, 1.34 mmol), K2CO3 (0.185 
g, 1.34 mmol) and 6-methoxy-3,4-dihydro-2H-isoquinolin-1-one (115) (0.327 g, 1.34 
mmol) in abs. DMF (2 mL) was stirred 70 h at 100 °C. After cooling to room temperature 
the reaction mixture was worked up by the addition of diluted NH3 solution (100 mL) and 
the organic components were extracted with three portions of ethyl acetate (3 × 50 mL). 
The combined organic phases were washed with brine, dried over Na2SO4 and 
evaporated. Purification by column chromatography (SiO2; DCM/methanol 80/1, v/v) 
Light yellow crystals; yield: 280 mg (74 %) 
Melting point: 132-133 °C 
C17H17NO3 (283.33) 
[1H] NMR (CDCl3): 
δ (ppm) = 3.09 (2H; t; 3J = 6.5 Hz; DHIQ-H3), 3.82 (3H; s; -O-CH3), 3.86 
(3H; s; -O-CH3), 3.92 (2H; t; 3J = 6.5 Hz; DHIQ-H4), 6.69-6.72 (1H; d; 5J 
= 2.5 Hz; DHIQ-H5), 6.85-6.90 (1H; d(d); 3J = 9.0 Hz; 5J = 2.5 Hz; DHIQ-
H7), 6.90-6.95 (2H; d; AA’BB’; 3J = 9.0 Hz; phenyl-H), 7.25-7.30 (2H; d; 
AA’BB’; 3J = 9.0 Hz; phenyl-H), 8.07-8.12 (1H; d; 3J = 8.6 Hz; DHIQ-H8) 
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6.1.2.4.2 Attempted Grignard Reaction of 6-Methoxy-2-(4-methoxyphenyl)-3,4-dihydro-
isoquinolin-1-on (116) with Alkylmagnesiumbromides. 
 
The Grignard reaction was performed as described for compound 14. For 
ethylmagnesiumbromide and decylmagnesiumbromide no reaction with 3-4-
dihydroisoquinolin-1-on 116 was observed (TLC).  
 
6.1.2.5 Semipreparative Separation of Selected Tetrahydroisoquinolines by Chiral 
HPLC  
 
Compounds 92, 93 and 94, obtained as racemates from chemical synthesis were 
submitted to a chiral HPLC separation to obtain the pure enantiomers on a 
semipreperative scale. The HPLC system used is listed under materials and general 
methods. The resolution (Rs) of the two peaks corresponding to the respective 
enantiomers was estimated according to:  
 
Rs = 2 · (RT2 - RT1) / (wb1 + wb2), where RT2 > RT1 and wb1,2 = baseline peak widths.  
 
For this purpose 100 µL of a 50 µM solution of each compound (92-94) were injected. A 
Jasco CD1595 detector (Jasco, Gross-Umstadt, Germany) was used to assign CD 
signals to the enantiomers. For preparative separation, the pure enantiomers were 
accumulated by collecting the cerrespondung peaks from multiple injections. The 
injection volume for each preparative separation was 100 µL. Further separation 
conditions for each compound are depicted in table C14.  
After separation the enantiomers were dissolved in ethanol p.a (200-400 µL); small 
samples of these stock solutions were submitted to an enantiomeric purity check by the 
chiral HPLC method mentioned above. Another sample of each stock solution was 
analyzed using a C-18 RP-HPLC column (Eurospher; see materials and methods) to 
determine the concentrations of the enantiomers in the prepared solutions. Solutions of 
the corresponding racemates with known concentrations were used as standards. The 
absolute concentrations were determined by peak-integration and comparison to the 
standards. Appropriate dillutionds of the stock solutions were then used in the binding 
assay. 
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Table C14: Conditions for semipreparative separation of enantiomers 
Comp. 
Gradient 
methanol/0.05% TFA 
peaks 
Concentration of 
injected solution 
92 
0 min: 40/60 
20 min: 50/50 
92a: 5.9 min 
92b: 9.5 min 
0.5 mM 
93 
0 min: 65/35 
25 min: 75/25 
93a: 7.5 min 
93b: 11.5 min 
1 mM 
94 
isocratic 
90/10 
94a: 6.3 min 
94b: 8.7 min 
1 mM 
*two successive separations 
 
 
 
6.2 Pharmacology 
6.2.1 Radiometric Binding Assay  
Preparation of recombinant human estrogen receptor (ER) proteins 
The recombinant full-length human receptor proteins ERα and ERβ (Invitrogen, 
Karlsruhe, Germany) were delivered as a solution in binding buffer in concentrations of 
2600 nM and 1800 nM respectively. In order to prevent frequent freeze- and thaw 
cycles the whole protein solution was aliquoted in portions of 6.92 µL in the case of ERα 
and 10.0 µL in the case of ERβ and stored at –80 °C.  
Prior to use the aliquots of ERα and ERβ were diluted up to 1mL with ER binding buffer 
(10 mM Tris-HCl pH 7.5, 10% glycerol, 2 mM DTT, 1% BSA) by gentle pipetting. 
Another dilution step (gentle pipetting, no vortexing to prevent protein aggregation) with 
ER binding buffer up to 20 mL provided the receptor concentration of 0.9 nM, that was 
used in the binding assay.  
Preparation of HAP slurry 
10 g of hydroxylappatite (HAP fast flow; Merck-Calbiochem, Darmstadt, Germany) was 
mixed vigorously with 60 mL of an equilibration buffer (50 mM Tris-HCl, pH 7.4). After 
10 minutes the supernatant was decanted and the process repeated ten more times 
using 60 mL of the equilibration buffer. The HAP slurry was equilibrated at 4 °C 
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overnight before being adjusted to 50% (v/v) with the equilibration buffer. The slurry is 
stable at +4 °C over several months.  
Preparation of compound solutions 
For each compound a 10 mM stock solution in ethanol p.a. was prepared and stored at 
-20 °C. By 1/100 dilution 100 µM solutions in pure ethanol were prepared. For ≤10 µM 
concentrated solutions that were directly used in the assay, ER binding buffer 
containing maximal 10% (v/v) ethanol was used as solvent. All buffer containing 
solutions were prepared freshly on the day of the experiment. 
The commercialy available [3H]17β-estradiol stock solution (GE Healthcare, München, 
Germany) was diluted to a 200 nM solution in ethanol p.a. that was stored at -20 °C. For 
the assay the 200 nM solution was freshly diluted 1/100 in binding buffer. 
The binding experiment 
Each test compound and reference compound was tested twice (independently) in six 
different concentrations. The experiment was performed in triplicate for each 
concentration. As control for the concentration of the radioligand and as standard to 
calculate the relative binding affinity, a binding curve for 17β-estradiol (Sigma, 
München, Germany) was generated in each experiment. 
The assay was performed in 1.5 mL cups (Sarstedt, Nümbrecht, Germany) according to 
scheme F1. The respective final concentrations of a test compound were achieved by 
appropriate dilution of the prepared solutions. 
All reaction vessels were incubated for 16-20 hours at 4 °C with shaking. To bind the 
ligand-receptor-complex, 100 µL of HAP slurry was added to each vial. The 
suspensions were incubated 15 min while vortexing three times. After addiditon of 1mL 
wash buffer (40 mM Tris-HCl, pH 7.4; for ERα the buffer additionaly contained 100 mM 
KCl), the vials were vigorously vortexed and centrifuged at 4000 rpm for 10 min. The 
supernatant was discarded by suction. This washing step was once repeated. After the 
second wash the HAP pellet was resuspended in 400 µL of EtOH and pipetted into a 
minivial containing 3 mL of scintillation fluid (Roth, Karlsruhe, Germany). The bound 
radioactivity was counted in a LS6500 liquid scintillation beta counter (Beckmann 
Instruments, München, Germany). 
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Table C15: Pipetting scheme for the binding assay 
 
solutions 
Unspec. Binding 
[µL] 
Control 
[µL] 
Sample 
[µL] 
 
binding buffer  
 
50 
 
na 
Testcompoundb   50-n 
0.9 nM receptor proteinc 100 100 100 
1µM 17β-estradiold  50   
2nM [3H]-17β-estradiole  50 50 50 
 
1n is the volume of binding buffer to make a defined final concentration of the testcompound and 
a volume of 200 µL; bvariable concentrations; final concentrations by appropriate dilution; cfinal 
concentration: 0.45 nM; dfinal concentration: 250 nM; efinal concentration: 0.5 nM 
 
Data analysis 
From the difference of the total binding and the unspecific binding the specific binding 
for each concentration of tested compounds was calculated.  
For the determination of the IC50 values a logit-log-transformation for at least 4 
datapoints in the range of [20 % ≤ (spec. bound radioactivity) ≤ 80 %] was performed.  
The logit was calculated as follows: 
 
  
logit  =  log {displacement [%] / (100% - displacement [%])} 
 
 
The logit values were ploted semilogarithmic as a function of the concentration and 
linearized by linear regression. The IC50 values were derived from the intersections of 
the straight lines with the x-axis. 
For estimation of the relative binding affinities (RBA) the IC50 values of tested 
compounds were compared with that of 17-β-estradiol: 
 
 
RBA  =  IC50 (17β-estradiol) / IC50 (test compound) · 100 
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6.2.2 Luciferase Assay 
The MCF-7/2a cell line 
The MCF-7/2a cell line is an estrogen receptor positive MCF-7 sub line that was stably 
transfected with the luciferase reporter plasmid ‘EREwtc luc’ (F. Hafner, University of 
Regensburg). The cells were used as a tool for the determination of estrogenic and 
antiestrogenic activities of test compounds in vitro. 
Cell culture 
The MCF-772a cell line was cultivated in Dublecco’s modified eagle medium (DMEM, 
Invitrogen) without phenol red, supplemented with 5 vol% sterile FCS (25 mL), a 
solution of L-glutamine (Merck; 29.2 mg/mL in sterile PBS; 5 mL per 500 mL) and 
neomycin (Geneticin®, G-418; Merck; 175 µg / mL added from a 35 mg/mL solution in 
sterile PBS).  
The cells grow as monolayer in 75 cm2 culture flasks (Becton Dickinson, Franklin Lakes, 
NY, USA) in a humidified , 5% CO2 containing atmosphere at 37 °C. 
Once a week or shortly before the cells had grown confluent the cells were passaged 
1/10 by routine trypsination using 3 mL of a trypsin/EDTA, solution (Boehringer, 
Mannheim, Germany) per culture flask. 
Performance of the luciferase assay 
Cells were seeded on 24 well plates (Becton Dickinson) in 0.5 mL of DMEM without 
FCS and incubated for 48 h or until the cells reached a density of about 40-50%.  
The medium was removed by suction and replaced by fresh medium containing the 
corresponding concentrations of test compound (0.5 mL/well). In the antagonist mode 
the medium additionaly contained 1nM estradiol as stimulation agent (added as 1µM 
ethanolic stock solution to the used medium). The solutions of the test compounds in 
medium were prepared by 400-fold dilution of ethanolic solutions of the compounds. 
The assay was performed in triplicate for each concentration. For each assay a vehicle 
control (contained only the respective volume of solvent) and a 17β-estradiol (1nM) 
control was performed in triplicate. The potent antiestrogens fulvestrant (ICI 182.780; 
gift of Prof. Dr. M. Schneider; Schering AG, Berlin, Germany) and 4-hydroxytamoxifen 
(Sigma) were used as references for antiestrogenic activity. 
After an incubation period of 48-50 hours, the medium was removed and washed twice 
with PBS (0.5 mL/well).  
Synthesis and Biological Characterization of New ER Ligands 154 
Cell lysis and luminescent measurement were performed by two alternative methods:  
a) By using a commercial firefly luciferase asay kit (Biotium, Hayward, CA, USA) 
following the manufacturer’s protocol 
b) By using a self-prepared buffer system and commercially available D-luciferin 
(potassium salt; Molecular Imaging Products Company, Ann Arbor, MI, USA)  
The majority of the assays were performed according to method b). Method a) mainly 
served as control for the optimization of method b). 
 
The buffers and solutions for method b) were prepared as follows:  
Lysis buffer: 25 mM Tricine (N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; Sigma; 
pH 7.8); 10% (v/v) Glycerol; 2 mM ethyleneglycoltetraacetic acid (EGTA); 1% (v/v) 
TritonTM X-100 (Serva, Heidelberg, Germany); 5 mM MgSO4 × 7H2O, 1 mM dithiotreitol 
(DTT; Sigma; added directly before use). 
Luciferase assay buffer: 25 mM Tricine (pH 7.8); 5 mM MgSO4 × 7H2O; 2 mM EGTA; 
2 mM ATP (Boehringer, Mannheim, Germany); When indicated, 50µM or 100 µM 
coenzyme A (CoA; Sigma) were supplemented. 
D-Luciferin stock solution: A stock solution of 10 mg/mL was prepared in tricine buffer 
(pH 7.8) containing 10 mM DTT. Aliquots of 100 µL were stored at -70 °C 
 
60 µL of lysis buffer was added to each well and incubated for 20 min under shaking. 
The unsoluble remains of the cells agglomerated and formed a pellet. 30 µL of the 
supernatant were pipetted into a polystyrene tube. A solution of D-luciferin in luciferase 
assay buffer (0.2 mg/mL; prepared by 1:50 dilution of the D-luciferin stock solution) was 
automaticly injected by a Lumat LB 9501 luminometer (Berthold, Bad Wildbad, 
Germany) and the luminescence was integrated over 10 s. The result is given in RLU 
(relative light units).  
Normalisation of the luminescence by total protein content 
The results of the luminescence measurement were corrected by the total protein 
content of each sample, which was quantified by Bradford’s protein assay (Bradford, 
1976).  
95 µl millipore water and 5 µL of cell lysate were pipetted into a polystyrene cuvette 
(Sarstedt 67742) followed by the addition of 1 mL of Bradford dye reagent (Bio Rad 
Laboratories, Munich, Germany; 5-fold concentrate, dilluted with millipore water). After 
10 min the UV-absorbance of each sample was measured at 595 nm in a UV 
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spectrophotometer Uvikon 930 (Kontron, Düsseldorf, Germany). To assign the 
absorption values to the corresponding protein contents a calibration curve using HSA 
(human serum albumin; Behringwerke, Marburg, Germany) standards in a range of 1-12 
µg protein was recorded. 5µL of plain lysis buffer was added to each HSA-sample to 
exclude any adulteration by the buffer ingredients.  
Data analysis 
The luminescence was normalized by the protein content for each sample 
(RLU/mgprotein). The relative luciferase activity is given as the percent ratio of the 
respective corrected luciferase activity relative to the luciferase activity induced by 1 nM 
estradiol that is per definition 100%. 
The IC50 values were derrived from the semilogarithmic plot of the relative luciferase 
activity as a function of the molar concentration. 
 
6.2.3 Determination of Antiproliferative Activity 
Human breast cancer cell lines 
For the determination of antiproliferative activity of synthesized antiestrogens, two 
different human breast cancer cell lines were used: 
• MCF-7 cells grow estrogen dependently and were therefore used to demonstrate 
estrogen receptor mediated antiproliferative effects of synthesized compounds. 
• MDA-MB-231-cells grow hormone independently and were used to test the 
synthesized compounds with respect to unspecific cytotoxic or cytostatic effects.  
Both cell lines were purchased from the American Type Culture Collection, (ATCC; 
Manassas, VA, USA) 
Cell culture 
Both cell lines were grown in 75 cm2 culture flasks (Becton Dickinson) in a humidified, 
5% CO2 containing atmosphere at 37 °C. MCF-7 cells were cultivated in phenol red 
containing EMEM (Eagle’s minimunm essential medium, Sigma), supplemented with 
2.2 g of sodium bicarbonate per liter. MDA-MB-231 cells were cultivated in phenol red 
containing McCoy’s 5A medium (Sigma) supplemented with 2.2 g of sodium 
bicarbonate per liter. In both cases 5 vol % of sterile FCS was added prior to usage. 
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Cytotoxicity assay 
The antiproliferative activity of synthesized compounds and reference compounds 
fulvestrant (ICI 182.780) and 4-hydroxytamoxifen was determined by the crystal violet 
assay (Bernhardt et al., 1992). 
Cells were seeded in 100 µL of the respective medium at a density of 10 (MDA-MB-
231) or 15 (MCF-7) cells per microscopic field (320×, Diavert microscope, Leitz, 
Wetzlar, Germany) in 96 well flat bottomed microtitration plates (Greiner, 
Frickenhausen, Germany). After 48 hours the medium was carefully removed by suction 
and replaced by fresh medium (200 µL/well) containing different concentrations of test 
compounds, added as 1000 fold concentrated ethanolic solutions. Two vertical rows (16 
wells) were arranged for one concentration of a test compound. Control wells (16 wells 
per plate) contained pure medium with 0.1 vol% ethanol. Positive controls contained 10 
µM cisplatin or 10 nM vinblastin.  
The cells of one untreated plate were fixed immediately after drug addition to determine 
the initial cell density. The cells of the treated plates were fixed after various incubation 
times. For fixation the culture medium was shaken off and replaced by 100 µL of a 2% 
glutardialdehyde solution (prepared by dillution of a 25% aqueous solution; Merck) in 
PBS. After 20 min the fixative was replaced by 180µL of PBS and the plates were 
stored at 4 °C. 
At the end of the experiment the cells of all plates were stained simultaneously with 0.02 
% crystal violet solution (N-hexamethylpararosanilin HCl in water, 100 µL per well, 25 
min incubation). After decanting, remaining dye was removed by repeating washings 
with deionized water followed by an incubation step (20 min) with water at room 
temperature. Water was discarded and the plates were patted dry on a cellulose sheet. 
Cell bound dye was extracted by addition of 200 µL 70 % ethanol and incubated for 3 h 
at room temperature with permanent shaking. Absorbance was measured at 578 nm 
using a BioTEK EL309 autoreader (Bad Friedrichshall, Germany) and the average and 
standard deviation values were calculated. Absorbance values outside of the 
confinence interval (95%) were not considered for the calculations. 
 
As unit for the growth inhibiting effect, the corrected T/C values were calculated 
according to: 
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T/Ccorr. [%]  =  (T-T0) / (C-T0) · 100 % 
 
 
T: optical density of tested cultures treated with a test compound 
T0: optical density of cells at the time of compound addition (initial cell density) 
C: optical density of vehicle treated cultures (control) 
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D  Expression, Function and Cross-Talk of Estrogen and 
NPY Y1 Receptors in Human Breast Cancer Cells  
 
1 Introduction 
 
NPY, a 36 amino acid peptide, is one of the most abundant peptides in the central and 
peripheral nervous system of mammals, involved in numerous (patho)physiological 
processes such as food intake, regulation of blood pressure, hormone secretion, anxiety 
and memory function (Pedrazzini et al., 2003). 
In humans NPY exerts its biological effects by interaction with at least four distinct G- 
protein coupled receptors designated Y1, Y2, Y4, and Y5 (Michel et al., 1998). The NPY 
Y1 receptor (Y1R) subtype was the first NPY binding receptor to be cloned (Larhammar 
et al., 1992). Its constitutive expression and functionality in human erythroleukemia 
(HEL) cells (Motulsky and Michel, 1988) and in SK-N-MC neuroblastoma cells 
(Aakerlund et al., 1990) is well established. Y1 and Y2 receptors were recently reported 
to be expressed in several human cancers and were proposed as potential tumor 
markers (Körner and Reubi, 2007). Mammary carcinomas revealed a 85 % incidence of 
Y1R expression, whereas Y2R was shown to be the less expressed subtype (Reubi et 
al., 2001). An estrogen-induced expression of NPY Y1R mRNA in MCF-7 breast cancer 
cells was shown in a differential screening study (Kuang et al., 1998). Later 
investigations confirmed the up-regulation of the Y1R mRNA after estrogen treatment, 
and suggested a role of the Y1R in cell signaling and proliferation (Amlal et al., 2006). 
Derived from the (R)-argininamide BIBP3226 (Rudolf et al., 1994), [3H]-UR-MK114 (cf. 
Figure D1) was recently synthesized and characterized as a highly potent and selective 
NPY Y1R antagonist (Keller et al., 2008). The development of this novel Y1R-selective 
tritium labeled antagonist enabled us to quantify Y1R protein expression in a radioligand 
binding assay using adherent live cells. In the present study different subclones of MCF-
7 breast cancer cells with varying estrogen receptor (ER) content were analyzed with 
respect to a possible correlation between ER and Y1R expression. Furthermore, the 
influence of ER agonists and antagonists on expression of the functional Y1R protein 
was investigated with focus on concentration-response relationships and ER subtype 
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specificity. The applicability of the Y1R as endogenous gene reporter for the functional 
characterization of estrogens and antiestrogens was evaluated in MCF-7 cells.  
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Figure D1: Structure of the NPY Y1R-selective radioligand [3H]-UR-MK114  
 
To investigate the functional activity of the Y1 receptor in MCF-7 breast cancer cells, the 
effect of NPY on intracellular calcium levels and on adenylyl cyclase activity were 
studied with appropriate assays. Further investigations were addressed to a possible 
Y1R-mediated effect of NPY on the proliferation of MCF-7 cells and on ER-mediated 
transcriptional activity in a transfected MCF-7/2a subline expressing an estrogen- 
responsive luciferase reporter (see section C).  
 
 
2 Results and Discussion 
2.1 Characterization of Breast Cancer Cells with Respect to Antiestrogen 
Sensitivity, ER and NPY Y1R Expression 
 
Cultured MCF-7 breast cancer cells are known to show variable sensitivities against 
estrogen and antiestrogen treatment. Three different MCF-7 subclones (designated 
MCF-7 (a-c)) were separately cultivated in our laboratory, showing distinct differences in 
growth kinetics and response against the antiestrogen 4-hydroxytamoxifen. As the 
differential antiestrogen sensitivity was supposed to depend on the level of ER 
expression, and as Y1R expression was estrogen-induced, we analyzed the three 
different MCF-subclones for expression of the Y1R and ER proteins using appropriate 
radioligand binding assays. 
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The estrogen receptor content was determined from cytosols of breast cancer cells by a 
binding assay using the radioligand [3H]-17β-estradiol. Representative curves for 
estrogen receptor saturation binding in the presence of increasing concentrations of 
[3H]-17β-estradiol are depicted in Figure D2. ER content was estimated from the Bmax 
values of the saturation curves and related to the total protein content of the 
corresponding cytosols.  
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Figure D2:  Representative saturation curves for unspecific and specific binding of [3H]-17-β-
estradiol to a cytosol of MCF-7 (a) breast cancer cells. 
 
Growth kinetics of the three identically treated MCF-7 subclones and MDA-MB-231 cells 
in the presence and absence of 4-hydroxytamoxifen and the corresponding 
radiometrically determined ER contents are depicted in Figure D3.  
MCF-7 (a) was identified as a subclone with strong response to 4-OH-tamoxifen 
treatment and the highest ER expression (95 fmol/mgprotein) among the studied MCF-7 
subclones. The two other subclones, MCF-7 (b) and MCF-7 (c) revealed considerably 
decreased sensitivities against 4-hydroxytamoxifen, whereas the extent of drug 
resistance correlated with a decrease of the ER contents (30 and 46 fmol/mg, 
respectively). The latter MCF-7 subclones were also characterized by a faster growth of 
the untreated control cultures compared to the MCF-7 (a) subclone. As expected, in 
MDA-MB-231 cells the ER expression was below the limit of detection (10 fmol per mg 
of protein) and cell proliferation did not respond to 4-hydroxytamoxifen. 
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Figure D3: Growth kinetics of MCF-7 (subclones a-c) and MDA-MB-231 breast cancer cells in 
the presence of 4-hydroxytamoxifen (○ 10 nM; ∆ 100 nM; □ 1 µM) compared to its 
vehicle (●).  
Cell densities were determined via absorbance at 578 nm (A578) after crystal violet staining. 
Values represent means of at least 14 replicates ± standard deviations; Shown growth 
kinetics of each MCF-7 subclone are representative for two to three independently 
conducted experiments; *radiometricly determined from corresponding cytosols.  
 
As 17β-estradiol binds to ERα and ERβ with nearly the same dissociation constant (Kd), 
the radioligand binding experiments do not allow a discrimination between the 
expression of the ER subtypes. Therefore, ER subtype distribution in the studied MCF-7 
(a-c) cells was analysed on the protein level by Western blot analysis using specific 
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antibodies and on the mRNA level by amplification of specific cDNA fragments within 
the ERα and ERβ genes after RT-PCR. Representative results are depicted in Figure 
D4. 
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Figure D4:  ER subtype distribution in MCF-7 and MDA-MB-231 breast cancer cells;  
 A: Western Blot analysis of ERα and ERβ in different MCF-7 subclones (a-c) and 
MDA-MB-231 breast cancer cells; B: RT-PCR analysis of ERα and ERβ mRNA 
expression in different MCF-7 subclones and MDA-MB-231 cells; c1: MCF-7 (c) 
passage 50; c2: MCF-7 (c) passage 10; For MCF-7 (a) a similar result was 
obtained. 
 
In Western blot analyses the antibody against ERα detected a single sharp band 
corresponding to the expected molecular weight of 72 kD in all MCF-7 subclones, 
whereas immunoreactivity was missing in MDA-MB-231 cells. The ERβ−selective 
antibody detected a band of the expected molecular weight (53 kD) in MCF-7 subclones 
and, surprisingly, also in homogenates of MDA-MB-231 cells. Consistently, the ERβ 
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was detected immunochemically by Filardo et al. in MDA-MB-231 cells using a different 
antibody (Filardo et al., 2000). In case of the MCF7 (b) and MCF-7 (c) subclones a 
second band corresponding to 46 kD became obvious, which might represent an 
isoform of ERβ (cf. Figure D4 (A)). The detection of a strong band in MDA-MB-231 
cytosols corresponding to ERβ was in disagreement with the results of radioligand 
binding assays, where there was no specific binding of [3H]-17β-estradiol. The question 
arises, why the ERβ was detected in a cell line, which is considered a prime example of 
ER-negative i. e. hormone insensitive breast cancer. A possible explanation is the 
expression of a non-functional ERβ maybe misfolded protein having an epitope, which 
is recognized by the antibody.  
In accordance with Western blot analyses a high expression of the ERα mRNA was 
detected in MCF-7, but not in MDA-MB-231 cells. The strong band at the predicted 
position in the agarose gel indicates a specific cDNA fragment within the ERα gene 
after RT-PCR. On the contrary, weak bands indicate a low expression of the ERβ 
mRNA in all investigated cell lines and subclones. However, expression of the mRNA is 
not necessarily indicative of translation, correct folding and trafficking of a protein. A role 
of ERβ in estrogen signalling, in particular in cross-talk signalling with the Y1R, that will 
be discussed in the following paragraphs cannot be excluded. Appropriate subtype 
selective ligands acting as agonists or antagonists at the estrogen receptor should give 
insight into ER subtype specific functions. 
 
The expression of the intact Y1R protein was determined by a radioligand binding assay 
on living cells that allows the simultaneous processing in the multiwell format. The 
recently developed non-peptidic BIBP3226 derived radioligand [3H]-UR-MK114 used for 
this purpose has advantages over labeled peptides such as high stability towards 
enzymatic degradation, fast association kinetics and convenient non-expensive 
preparation (Keller et al., 2008). Typical curves for total, unspecific and specific binding 
of [3H]-UR-MK114 to MCF-7 cells are shown in Figure D5 (A). The radioligand revealed 
no Y1R specific binding sites in ER negative MDA-MB-231 (cf. Figure D5 (B)), HCC1806 
and HCC1937 (data not shown) breast cancer cells.  
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Figure D5:  Representative curves for saturation binding of [3H]-UR-MK114 to whole MCF-7 
(A) and MDA-MB-231 (B) cells; Values represent means of triplicates ± SEM.  
 
Table D1 summarizes the ER and Y1R contents of the investigated cell lines obtained 
from radioligand binding assays and the relative ERα and ERβ subtype expression 
determined by densitometric analysis of the corresponding Western blots. A graphical 
overview of the expression profile of ERs and Y1Rs by the investigated MCF-7 
subclones a-c is given in Figure D6. 
 
Table D1:  Comparison of ER status, ER subtype expression and NPY Y1R status in 
MCF-7 and MDA-MB-231 breast cancer cells 
 
Cell line 
 
ER statusa 
[fmol/mgprotein] 
 
ERαb 
% OD/mg 
 
ERβb 
% OD/mg 
 
Y1R statusc 
[103 sites/cell] 
 
a 
 
95 ± 8 
 
100 
 
100 
 
38 ± 10 
b 30 ± 5 70 69 98 ± 9 
 
MCF-7 
c 46 ± 3 81 53 91 ± 4 
 
MDA-MB-231 
 
negative 
 
negative 
 
96 
 
negative 
 
SK-N-MC 
 
n.d. 
 
n.d. 
 
n.d. 
 
50d 
 
Determined from acytosol in a [3H]-17β-estradiol saturation binding assay; bcytosol by Western 
blotting; OD/mg = optical density per mg of protein cintact cells in a radioligand binding assay 
using [3H]-UR-MK114; d(Entzeroth et al., 1995; Keller et al., 2008) 
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Figure D6:  Comparison of the relative NPY Y1 R basal expression and the total ER expression 
by MCF-7 (a-c) subclones.  
 
Interestingly, the Y1R expression appears to be inversely correlated with ER expression 
in identically cultured subclones of MCF-7 breast cancer cells: with approximately 
40,000 sites per cell the basal Y1R protein density in MCF-7 (a) cells was found to be in 
the same range as in SK-N-MC neuroblastoma cells (Entzeroth et al., 1995; Keller et 
al., 2008), whereas it was by more than a factor two higher in the antiestrogen 
insensitive MCF-7 (b) and MCF-7 (c) subclones (≈ 90,000-100,000 receptors per cell). 
Based on this result, future studies might reveal a possible link between tamoxifen 
resistance and Y1R expression in hormone sensitive breast cancers. 
 
2.2 Effect of (Anti)estrogens on Y1R Expression in Human Breast Cancer 
Cells 
 
Two previous reports suggest an estrogen induced Y1R up-regulation in certain human 
breast cancer cells (Kuang et al., 1998; Amlal et al., 2006). By submitting (anti)estrogen 
pretreated cultured cells to a Y1R radioligand binding assay we aimed to gain detailed 
information on estrogen responsiveness of the Y1R expression on the level of the 
functional receptor protein, as previous data have been limited to the mRNA level. Our 
studies were especially focused on concentration response relationships and ER 
subtype specificity. 
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2.2.1 Characterization of the Estrogen-Induced Y1R Up-regulation at the Protein 
Level 
 
Figure D7 (A) shows representative saturation binding curves for the specific binding of 
the [3H]-UR-MK114 to MCF-7 cells pretreated with E2 (1 nM) or its vehicle for 48 h. To 
facilitate the analysis of Y1R regulation, the specifically bound radioactivity at a 
radioligand concentration of 12 nM was compared, whereupon the expression levels are 
given as a percentage of the control treated with 1 nM 17β-estradiol. At this radioligand 
concentration, the saturation curves reveal an approximation of the specifically bound 
radioactivity to the Bmax value. The number of occupied binding sites at 12 nM is 
therefore representative for Y1R expression.  
An increase in Y1R protein expression by somewhat more than 100 % was observed, 
when cells were treated wit 1 nM 17β-estradiol for 48 hours. The ratio between estrogen 
treated and untreated cells was not significantly increased when the time of incubation 
was prolonged to 72 hours (data not shown). Consequently, 45 to 50 hours were 
considered as an appropriate incubation period for the treatment of MCF-7 cells with 
(anti)estrogens in all following experiments. Such a time period is typical for genomic 
processes. In T-47-D breast cancer cells an up-regulation of the Y1R after estrogen 
treatment occurred as well, but the basal expression was on a 20-fold lower level 
compared to MCF-7-cells (cf. Figure D7 B). For the MCF-7 and T-47-D cell lines our 
results are in accordance with the recently reported estrogen triggered Y1R mRNA up-
regulation (Amlal et al., 2006). 
The strong difference between total and non-specific binding in autoradiography 
demonstrates a very high Y1R density in sections of solid tumor xenografts established 
from MCF-7 (b) cells in nude mice (cf. Figure D7 (C)). An estrogen level comparable to 
that of premenopausal women was guaranteed by implantats, releasing 17β-estradiol to 
enable the growth of MCF-7 tumors in nude mice (Bernhardt et al., 1992) . The high 
Y1R density in tumor xenografts from estrogen-substituted animals makes an estrogen-
induced Y1R up-regulation very likely to occur in vivo too. 
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Figure D7:  Saturation binding curves of [3H]-UR-MK114 to MCF-7 (A, n = 2) and T47-D (B, n = 
3) cells after preincubation with 1nM 17β-estradiol or its vehicle  
 C: Total and non-specific binding of [3H]-UR-MK114 to adjacent tumor sections of a 
subcutaneous MCF-7 (b) mammary carcinoma from a NMRI (nu/nu) mouse with 
estrogen substitution. 
 
The basal Y1 R expression was compared when growing MCF-7 cells in two different 
culture media. Phenol red containing EMEM and phenol red free DMEM were either 
supplemented with normal fetal calf serum (FCS) or steroid depleted ct-FCS (charcoal 
treated FCS). As shown in Figure D8 (A) the basal Y1R expression was significantly 
decreased in ct-FCS containing media compared to the respective untreated FCS 
containing media. The pH indicator phenol red was reported to bring along 
contaminants with weak estrogenic activity (Bindal et al., 1988) and might therefore 
contribute to basal Y1R expression. In the present study the Y1R baseline expression 
was not significantly different, when cells were maintained in phenol red free DMEM and 
EMEM with phenol red, respectively. Consequently an effect of phenol red 
contaminants on Y1R expression was excluded, contrary to the finding of Amlal and 
coworkers (Amlal et al., 2006). The basal Y1R expression is estrogen induced anyhow, 
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as it was significantly down-regulated to approximately 25% of the basal level when 
17β-estradiol was co-incubated with the “pure ER antagonist” fulvestrant (100 nM) (cf. 
Figure D8 (B)).  
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Figure D8: A: Dependence of the basal NPY Y1R expression by MCF-7 (b) cells from culture 
medium and supplemented fetal calf serum (FCS or steroid depleted ct-FCS)  
 In case of blank DMEM cells were grown in ct-FCS containing medium and estradiol or its 
vehicle was added in FCS-free medium; *p<0.01 compared with DMEM + ct-FCS and blank 
DMEM; ** p< 0.01 compared with EMEM + ct-FCS (n= 4; mean ± SD). 
B: Effect of the “pure antagonist” fulvestrant (ICI) on estrogen induced Y1R 
expression: fulvestrant co-incubated with 17β-estradiol for 48 h effects a down-
regulation of the Y1R beyond the baseline expression in EMEM+ct-FCS.  
Values represent mans of n independent experiments ± SEM, each conducted at least in 
triplicate; *p<0.001 compared to vehicle. 
 
An inhibition of the intrinsic ER activity by potent ER antagonists was also observed in 
the luciferase assay as described in paragraph C.3.3.2. As the presence of estrogenic 
compounds in the medium supplements ct-FCS and phenol red was excluded, we 
suggest a ligand-independent ER activation mechanism being responsible for the 
relatively high baseline Y1R expression. Ligand independent ER activation can be 
mediated by a number of cross-talk signaling pathways including proteinkinase A and C 
or growth factor mediated pathways. In previous studies it was shown that full ER 
antagonists such as fulvestrant are capable of blocking many cross-talk activation 
cascades (Driggers and Segars, 2002). 
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2.2.2 Concentration Dependent Y1R Induction by ER Agonists and its Inhibition 
by ER Antagonists: The Y1R as an Endogenous Gene Reporter for 
(Anti)estrogenic Activity in MCF-7 Cells 
 
The experiments described in this paragraph aimed on the detailed investigation of 
estrogen-induced effects on Y1R expression in MCF-7 cells concerning concentration 
response relationships and ER subtype specificity.  
MCF-7 breast cancer cells grown in 48 well plates were simultaneously treated with 
different concentrations of various (anti-)estrogens for 45-50 hours. For each set of 
identically treated cells total and unspecific Y1R radioligand binding were determined by 
applying 12 nM [3H]-UR-MK114 alone or in combination with a high excess of pNPY, 
respectively. This processing allowed the analysis of a relative high number of 
(anti)estrogen pretreated cell cultures in one assay with respect to its relative 
expression of Y1Rs. To exclude adulterations of the determined Y1R expression due to 
anti-proliferative effects of antiestrogens or growth-stimulating effects of estrogenic 
agents, all specific binding values were normalized by the total protein content derived 
from an independently performed protein assay (Bradford). Figure D9 shows 
concentration-response curves for the relative Y1R induction by a selection of ER 
agonists.  
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Figure D9:  Concentration–response curves for the induction of the NPY Y1 receptor by 
various ER agonists above the basal level 
 The Y1R up-regulation induced by 1 nM estradiol was set to 100 %.  
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17β-estradiol was applied in the picomolar to nanomolar concentration-range, showing 
a sigmoidal concentration–response relationship with an EC50 value of approximately 
20 pM. The maximum Y1R protein expression was observed in the sub-nanomolar 
range of 17β-esteradiol, whereas a biphasic mechanism was excluded as no further 
effects were detected up to 50 nM (data not shown). This is the first time that an up-
regulation of the Y1R at physiologically relevant concentrations of 17β-estradiol has 
been demonstrated at the protein level. These results are in accordance with the work 
of Amlal et al. (Amlal et al., 2006) reporting an elevation of Y1R mRNA expression albeit 
at supra-physiological estradiol concentrations (10 and 100 nM). The EC50 value 
determined via Y1R up-regulation is in the same range as published data that were 
determined via progesterone receptor mRNA up-regulation in MCF-7 cells (44 pM; c.f. 
(Allan et al., 2001)) and by a gene reporter (lucifease) assay in our laboratory (40 pM). 
 
In further experiments, appropriate agonists were used as pharmacological tools, 
providing information on the subtype specificity of observed effects. The high efficacy 
and potency of the ERα selective agonist PPT suggests a predominant role of the ERα 
subtype in Y1R regulation, as PPT is devoid of any activity at ERβ (Stauffer et al., 2000). 
The EC50 value is in good agreement with that reported for ERα from a co-transfection 
assay (≈ 0.1 nM cf. (Stauffer et al., 2000)). Genistein, a phytoestrogen, was previously 
reported to be a full agonist at ERα and a partial (50 %) agonist at ERβ thereby 
preferably binding to the ERβ subtype (Barkhem et al., 1998). Genistein up-regulated 
the Y1R by 70% with an EC50 value of 100 nM. This result matches with the reported 
data for ERα rather than ERβ, underlining that Y1R induction is ERα specific. The ERβ 
selective benzofuran 24 synthesized within the scope of this thesis (cf. paragraph C.2) 
showed 100 % Y1R induction compared to 17β-estradiol, but only at micromolar 
concentrations. As compound 24 exhibited a high binding affinity for ERβ the observed 
effect is most likely mediated by ERα. 
EC50 values and efficacies for Y1R up-regulation by the investigated ER agonists are 
summarized in Table D2. 
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Table D2: EC50 values and intrinsic activities for the Y1R up-regulation by various ER 
agonists 
 
O
OH
CH3
HO
NN
CH3
HO
HO OH
PPT
24O
OH
HO
O
OH
Genistein
 
 
Comp. 
 
Selecticity 
ERα/ERβa 
EC50 [nM] 
Y1R up-regulation 
Efficacy  
 
EC50 [nM] 
references 
 
E2 
 
1 
 
0.016 ± 0.006b 
 
100 
 
0.044c; 0.04d 
PPT 400e 0.25 ± 0.03b 107 ERα: 0.1 nM; ERβ: >1 µMe 
Genistein 0.05 98 72 ERα: 38; ERβ: 9f 
24 0.03 1100 100 >1000d 
 
areferred to relative binding affinity (RBA) for recombinant ERα and ERβ bmean of two 
independent determinations ± SEM; c(Allan et al., 2001); ddetermined by the luciferase assay 
using the MCF-7/2a subline;  e(Stauffer et al., 2000); f(Barkhem et al., 1998) 
 
The observed effects of selective agonists suggest a dominant role of the ERα subtype 
in Y1R regulation, but a contribution of ERβ to this signaling cannot be totally excluded 
from these experiments. One uncertain factor is the relatively high basal expression of 
the Y1R that was shown to be strongly decreased by the unselective ER antagonist 
fulvestrant (cf. Figure D8). We assumed a ligand independent ER activation mechanism 
being responsible for this basal Y1R induction that might be mediated by both ERα and 
ERβ. Therefore, the effect of the moderately ERα selective 1,2,3,4-tetrahydro-
isoquinoline (THIQ)-based “pure antagonists” synthesized within the scope of this thesis 
(cf. section C) was investigated.  
The representative curves for the inhibition of the estradiol-induced (1 nM) Y1R protein 
expression by selected ER antagonists are depicted in Figure D10. Table D3 
summarizes the IC50 values determined from the concentration dependent inhibition of 
the 17β-estradiol-induced Y1R expression. 
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Figure D10:  Concentration–response curves for the inhibition of the 17β-estradiol (1nM) 
mediated Y1R expression by selected antiestrogens. 
 Each value represents Y1R specific binding (mean of at least tiplicates) that was 
normalized by the corresponding protein content (mean of at least 6 control wells) ± 
propargated error. The Y1R content in presence of 1nM 17β-estradiol was set to 100% 
 
 
Table D3: IC50 values of ER antagonists for the inhibition of the estrogen-tinduced Y1R 
expression in MCF-7 cells compared to inhibition of luciferase activity in 
MCF-7/2a cells. 
                        
N
SC
OH
HO  
 
 
Compound 
 
SCa 
Selectivityb 
ERα/ERβ 
 
Y1R expr. 
IC50 [nM]c 
Luciferase 
IC50 [nM]d 
 
fulvestrant 
 
 
 
0.70 
 
4.7 ± 1.3 
 
10 
 
93 
 
-(CH2)6-N(CH3)-(CH2)3-S-C5H11
 
13 
 
92 ± 5 
 
160 
94 -(CH2)10-SO-C5H11 17 103 ± 22 470 
aside chain; breferred to RBA values for human recombinant receptors; cmeans of two 
independent determinations ± SEM; ddetermined in transfected MCF-7/2a cells 
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As a potent, non-selective ER antagonist, fulvestrant (ICI 182.80) strongly inhibited the 
Y1R expression to 15 % of the maximum (1 nM E2 triggered) level with an IC50 value of 
5 nM when co-incubated with 1 nM E2. This result is in accordance with data obtained 
in a gene reporter (luciferase) assay with the transfected MCF-7/2a subline in our 
laboratory (IC50 = 10 nM). 
The ERα-selective THIQ-based antagonists 93 and 94 inhibited the Y1R expression to 
the same extent as fulvestrant revealing ERα as the main subtype mediating a ligand 
independent as well as a 17β-estradiol-induced Y1R basal expression. The IC50 values 
of the THIQs are in the range of 100 nM.  
Generally, the EC50 and IC50 values obtained from the radioligand binding assay are in 
agreement with literature data or values obtained from a gene reporter (luciferase) 
assay in our laboratory. The results suggest the exploitation of the Y1R both as a tumor 
marker and as an endogenous, easily detectable gene reporter for the determination of 
(anti)estrogenic activity of new compounds in MCF-7 cells, a standard model in breast 
cancer research.  
Several estrogen-responsive genes, such as the progesterone receptor (PR) gene that 
are constitutively expressed in MCF-7 cells have been used as endogenous gene 
reporters of estrogenic activity in previous studies (Jorgensen et al., 2000; Allan et al., 
2001; Lim et al., 2005). Methods based on the detection of endogenous estrogen 
responsive genes on mRNA level - such as RT-PCR - are poorly applicable in 
screenings of compound libraries, which is a major drawback compared to artificial gene 
reporters such as the luciferase expression system established in our workgroup. 
Within the present study the Y1R was characterized as the first GPCR that is estrogen 
responsively overexpressed by MCF-7 cells and can be addressed by a small labeled 
ligand. Being located in the plasma membrane, the Y1R protein can be quantified by a 
robust and fast radioligand binding assay on whole cells. By processing in multiwell 
(e.g. 48-well) plates, the method is applicable for screenings providing a throughput of 
several hundred samples. The radioligand [3H]-UR-MK114 is economic in preparation 
and use, as low concentrations (12 nM) are sufficient for saturating the Y1R binding 
sites. These aspects, and the fact that obtained EC50 and IC50 values were reproducible 
and match with data from established gene reporter assays, suggest the endogenous 
Y1R expression system as an alternative to artificial estrogen responsive expression 
systems such as the luciferase reporter. The work with non-transfected MCF-7 cells 
offers further advantages such as easy availability of the cells, higher genetic stability 
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and possibly higher physiological relevance of the obtained results compared to 
engineered cells.  
Nevertheless, further experiments are necessary for the validation of the assay and its 
establishment as a general accepted functional test system for (anti)estrogens. 
Alternatively to the radiolabeling approach, fluorescently labeled Y1R ligands recently 
developed in our workgroup (to be reported) might also be useful tools for the fast 
quantification of estrogen induced Y1R expression in MCF-7 cells. 
 
2.3 Functional Characterization of the NPY Y1 Receptor in MCF-7 Cells 
 
To investigate the functionality of the Y1R expressed in MCF-7 breast cancer cells, the 
coupling of the receptor to calcium mobilization and inhibition of adenylylcyclase (AC) 
activity was determined by appropriate assays established in our workgroup.  
Furthermore, effects of NPY on MCF-7 cell proliferation and on ER mediated 
transcriptional activity were investigated in the crystal violet assay and the luciferase 
gene reporter assay, respectively. 
 
2.3.1 NPY Y1R- Mediated Mobilization of Intracellular Calcium 
 
The intracellular calcium level was determined by a fluorescent calcium assay 
established for HEL cells in our workgroup using the selective calcium chelator fura-2 
(Gessele, 1998). 
With 10 nM porcine NPY (pNPY) an increase in the intracellular calcium level was 
induced by a factor of four. In the presence of the Y1R antagonist BIBP3226 the signal 
was abrogated by ≈ 80 %, showing the Y1R specificity of the signaling. As expected, the 
calcium signal was strongly reduced after receptor down-regulation by fulvestrant. 
Interestingly, in spite of a marked up-regulation of the Y1R, the effect did not respond to 
pre-incubation with 17β-estradiol (cf. Figure D11). This might be due to a receptor 
reserve after the estrogen induced up-regulation or a limitation by the intracellular 
calcium stores. 
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Figure D11:  Intracellular calcium release after stimulation with 10 nM pNPY in MCF-7 cells 
preatreated with estradiol, estradiol + fulvestrant (ICI) or their vehicle; a similar 
result was obtained in another independent experiment. 
 
 
2.3.2 NPY-Induced Inhibition of Adenylyl Cyclase (AC) Activity  
 
Adenylyl cyclase (AC) catalyses the transformation of adenosin triphosphate (ATP) to 
the second messenger 3’-5’-cyclic adenosine monophosphate (cAMP). Therefore, the 
level of intracellular cAMP is a monitor of AC activity. In MCF-7 cells the cAMP content 
was determined by an enzymatic assay (Sugiyama and Lurie, 1994) that was 
established in our workgroup by Dr. Gessele (Gessele, 1998). The assay relies on the 
equimolar formation of NADPH during the last step of an enzymatic reaction sequence 
consuming cAMP from cell extracts. Finally, the NADPH concentration can be 
measured flurimetrically and allows the stoichiometric calculation of the cAMP amount 
consumed in the enzymatic reaction. Experimental and theoretical details on this 
method are described by Gessele. 
MCF-7 breast cancer cells were submitted to the enzymatic cAMP assay to explore the 
functional coupling of the Y1R to the inhibition of AC activity. As the intracellular cAMP 
content is normally very low, the AC had to be stimulated by the activators IBMX and 
forskolin in order to enable a detectable NPY induced inhibition of cAMP formation. 
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Figure D12 shows the concentration-dependent increase in the cAMP level after 
forskolin treatment and its inhibition by pNPY in MCF-7 cells. 
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Figure D12:  A: cAMP formation in MCF-7 cells after stimulation of the cells with different 
concentrations of forskolin and IBMX and inhibition with 1nM pNPY; B: 
concentration-response curve for the inhibition of adenylyl cyclase by pNPY; cells 
were stimulated with 1 µM forskolin; the concentration of IBMX was 50 µM 
throughout. 
 
The concentration dependent inhibition of AC activity by pNPY revealed an IC50 value of 
approximately 1 nM, which is in agreement with data obtained from SK-N-MC cells. This 
finding demonstrates a functional coupling of the Y1R to the cAMP pathway. Due to 
limited availability of certain enzymes, the assay was inapplicable for extensive 
investigations. Future studies using an alternative cAMP assay might show the Y1R 
specificity of the signaling with help of selective antagonists (BIBP3226 and derivatives). 
Investigations of (anti)estrogen induced effects on the Y1R mediated cAMP response 
are another interesting perspective. 
 
2.3.3 Effect of NPY on Cell Proliferation and Estrogen Receptor Activity 
 
The high expression and functionality of the Y1R in MCF-7 breast cancer cells gives rise 
to speculations on a possible role of NPY on tumor growth. Recently, published data 
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suggest an involevement of NPY in the growth of Y1R expressing cancer cell lines. NPY 
was reported to inhibit the proliferation of SK-N-MC cells (Reubi et al., 2001; Kitlinska et 
al., 2005), of certain prostate cancer cells (Ruscica et al., 2006) and MCF-7 cells (Amlal 
et al., 2006). Growth stimulating effects were observed in another Y1R expressing 
prostate cancer cell line (Ruscica et al., 2006) and - contrary to the findings of Kitilinska 
et al. and Reubi et al. - in SK-N-MC cells (Shorter and Pence, 1997). 
By the kinetic crystal violet assay we observed no significant effects of pNPY on the 
proliferation of MCF-7 cells at concentrations of 10 and 100 nM, respectively. At these 
pNPY concentrations full receptor occupation and maximum functional response was 
guaranteed. The inconsistent effects of NPY on cell proliferation obtained by different 
laboratories might be due to different experimental conditions. In the present study -
contrary to Amlal et al. - the supplemented serum was not inactivated to guarantee an 
environment closer to physiological situation. Growth kinetics were compared in the 
presence or absence of 17β-estradiol coming to a similar result. Representative curves 
are depicted in Figure D13 (A).  
Amlal et al. report an inhibition of the estrogen-induced MCF-7 cell proliferation by NPY. 
This finding suggests a direct impact of the Y1R mediated cytoplasmic signaling on ER 
activity. Y1R signaling might cross-talk with the ER activated transcription through the 
PKC/MAPK pathway, which has been described as one possible mechanism of ligand 
independent ER phosphorylation.  
To explore such an indirect Y1R-mediated effect on the activation state of the ER, MCF-
7/2a cells expressing the estrogen responsive luciferase gene reporter were used as a 
tool to monitor ER mediated transcriptional activity (cf. section C). By radioligand 
binding, the Y1R protein expression by the MCF-7/2a subline was confirmed (data not 
shown). To investigate the putative signaling cross-talk between the Y1R and the ER, 
MCF-7/2a cells were treated with pNPY at concentrations of 10 and 100 nM for 48 h. As 
shown in Figure D13 (B) NPY neither affected basal lucifease activity nor the activity of 
the 17β-estradiol stimulated cells.  
The data obtained from the present experiment do not support the existence of a link 
between the Y1R-mediated signaling and the transcriptional activity of the ER. In 
agreement with this result, NPY did not influence the ER-dependent proliferation of 
MCF-7 cells. 
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Figure D13: A: Growth kinetics of MCF-7 (b) cells in presence or absence of pNPY; 1 nM 
estradiol was present to maximize the Y1 R expression and proliferation rate; a 
similar result was obtained in absence of estradiol;  
B: Luciferase activity in estradiol-stimulated and unstimulated MCF-7/2a cells in 
presence or absence of pNPY; 100 nM pNPY revealed no activating or inhibiting 
effect on the estrogen receptor; a similar result was obtained for 10 nM pNPY. 
 
 
 
3 Conclusion and Outlook 
 
The novel radiolabeling and functional characterization of the Y1R revealed a high 
functional expression of the G protein coupled receptor in MCF-7 breast cancer cells. 
Y1R incidence was exclusively observed in ER positive breast cancer cells, whereas in 
different subclones of MCF-7 cells the Y1R expression correlated inversely with ER 
content and antiestrogen sensitivity. The study provides the first evidence of an 
estrogen induced up-regulation of the Y1R protein in intact MCF-7 cells. The Y1R protein 
expression showed a maximum after pretreatment with 17β-estradiol at physiologically 
relevant concentrations and was down-regulated by the full ER antagonist fulvestrant 
(ICI182.780) to a sub-basal level. Y1R induction was shown to be exclusively mediated 
by ERα: a potent ERα−selective agonist induced Y1R expression to 100 % of 17β-
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estradiol with a sub-nanomolar EC50 value and ERα−selective full antagonists, 
synthesized within the scope of this thesis, inhibited Y1R expression to the same extent 
than fulvestrant. The Y1R turned out to be an endogenous gene reporter for estrogen 
receptor activity in MCF-7 breast cancer cells. EC50 and IC50 values for the induction or 
inhibition of the Y1R expression by selected (anti)estrogens were reproducible and in 
agreement with data obtained by established gene reporter assays. This was the basis 
to suggest the Y1R radioligand binding assay as a fast and robust method for the 
functional screening of (anti)estrogens. The Y1R was shown to be functionally coupled 
to mobilization of intracellular calcium and inhibition of AC activity, whereas cross-talk 
involving NPY was neither observed on cell proliferation nor on the activation state of 
the ER in MCF-7 cells.  
Implications of the Y1R in cellular functions, such as phosphorylation of Erk1/2, 
transactivation of tyrosine kinases or effects on downstream transcription factors other 
than the ER have not been described for MCF-7 breast cancer cells. The investigation 
of such effects in future studies might shed light on the role of the G protein coupled 
receptor in breast cancer cell biology.  
Due to the high Y1R receptor density, MCF-7 tumors are favorable as a model for in 
vivo imaging using recently developed Y1R selective PET ligands (to be reported). 
Comparing the Y1R densities in MCF-7 tumors from mice with and without estradiol 
substitution or after antiestrogen administration might substantiate estrogen-induced 
Y1R up-regulation in vivo. 
The NPY Y1R was recently reported to be expressed by commonly used prostate 
cancer (PCa) cell lines (Ruscica et al., 2006). In future studies, Y1R expression by the 
PCa lines LNCaP, PC3 and DU145, established in our laboratory, can be exactly 
quantified at the level of functional protein by radioligand binding using [3H]-UR-MK114 
and compared to values for SK-N-MC and MCF-7 cells determined within the present 
study. By analogy with its estrogen responsiveness in ER positive breast cancer cells, a 
putative androgen-induced regulation of the Y1R expression in androgen receptor 
positive LNCaP cells is an interesting subject for coming investigations. 
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4 Experimental 
4.1 General  
 
Drugs and pharmacological tools: 
The Y1 receptor radioligand [3H]-UR-MK114 and the Y1R antagonist BIBP3226 were 
synthesized by Dr. M. Keller. pNPY was synthesized by Dr. C. Cabrele. PPT was 
purchased form Tocris (Ellisville, MO, USA); Genistein was from Roth (Karlsruhe); 17β-
estradiol and 4-hydroxytamoxifen were purchased from Sigma. Fulvestrant (ICI 
182.780) was a gift of Dr. M. R. Schneider (Schering AG, Berlin). 
 
Cell culture: 
T-47-D cells (ATCC) were grown in RPMI medium supplemented with 10 % FCS and 
insulin (0.01 mg/L). MCF-7 and MDA-MB-231 cells were cultivated as described in 
section C.  
 
Preparation of dextran charcoal treated (ct) FCS: 
A suspension of 5.0 g of charcoal (Norit A) in 100 mL of 10 mM Tris buffer (pH 7.4) was 
stirred at 0 °C for 4 h and allowed to stand over night at 4 °C. Particles on the surface 
were removed by suction. 50 mg of dextran 60 were added and this suspension was 
stirred for 15 min. The suspension was split into two aliquots and centrifuged at 5000 
rpm for 15 min. The supernatant was discarded. One pellet was re-suspended in 250 
mL of FCS, stirred at 0 °C for 3 h and finally centrifuged at 9500 rpm for 15 min. The 
supernatant was decanted onto the second charcoal pellet and incubated with stirring 
for 1 h at 56 °C to reach complete inactivation of the serum. After centrifugation (9500 
rpm; 15 min) the supernatant FCS was filtered through a 0.2 µm membrane filter for 
sterilization.  
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4.2 Radiometric Analysis of the Estrogen Receptor Expression 
4.2.1 Cytosol Preparation 
 
The MCF-7- (3 different subclones) and MDA-MB-321 cells were grown in 175-cm2 
culture flasks. When cells were confluent, the medium was removed and cells were 
harvested after trypsination from 8-10 flasks. The pooled cell suspensions were 
centrifuged at 1200 rpm for 7 min. The pellet was washed twice with PBS and 
suspended in 4-5 mL of TED-Mo-buffer (10 mM Tris-HCl pH 7.4, 10 mM Na2MoO4 
(Sigma), 1 mM EDTA, 1 tablet of EDTA-free protease inhibitor cocktail (Roche, Basel, 
Switzerland) per 100 mL). Cells were lysed using an ultrasonic cell disrupter B15 
(Branson, Danbury, CT, USA; 3 × 10 cycles, 10-20 s.) under ice cooling. The 
suspension was centrifuged for 20 min at 5000 rpm. The supernatant cell extract was 
decanted carefully and stored at -70 °C. It was used for protein determination, 
radiometric binding and Western blot analysis.  
The protein content of the cytosols was determined in appropriate dilutions by 
Bradford’s protein assay (Bradford dye reagent, Bio Rad Laboratories) following the 
manufacturer’s protocol. The UV-absorbance was measured at 595 nm in a UV 
spectrophotometer Uvikon 930 (Kontron, Düsseldorf, Germany). Protein contents were 
assigned to the absorption values by a calibration curve using HSA (human serum 
albumin; Behringwerke, Marburg, Germany) standards in a range of 1-12 µg of protein. 
 
4.2.2 Performance of the [3H]-17β-Estradiol Binding Assay 
 
The [3H]-17β-estradiol binding assay was performed in 1.5 mL reaction vessels 
(Eppendorf, Hamburg, Germany) under ice cooling. The radioligand was incubated with 
100 µL- samples of the respective cytosol diluted to a final volume of 500 µL in Tris-
buffer (10 mM Tris-HCl, pH 7.5). [3H]-17β-estradiol was added as 5-fold concentrate in 
Tris-buffer to obtain a final concentration range of 0.1-5 nM. For the determination of the 
non-specific binding, the radioligand was displaced from the specific binding sites by an 
excess (1 µM) of non-labelled 17β-estradiol. For each concentration, total and 
nonspecific binding were determined in triplicate, respectively. The samples were 
incubated for 16-20 h at 4°C under shaking. 
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Unbound radioactivity was removed by the dextran coated charcoal (DCC) method. For 
this purpose 0.5 mL of a suspension containing 0.8 % charcoal (Norit A; Serva) and 
0.008 % dextran 60 (Serva) were added to each sample followed by incubation for 
30 min at 4 °C with shaking. After centrifugation (10 min at 4000 rpm) 200 µL of the 
supernatant were pipetted into a minivial containing 3 mL of liquid scintillator 
(RothiszintTM eco plus; Roth, Karlsruhe, Germany). The bound radioactivity was 
counted in a LS6500 liquid scintillation beta counter (Beckmann Instruments, München, 
Germany). 
The specifically bound radioactivity (total binding minus unspecific binding) was plotted 
as a function of the concentration. The data points were fitted to one site saturation 
binding using the PC-software Sigma Plot version 9. The estrogen receptor status 
(fmol/mgprotein) was derived from the Bmax of the radioligand binding (fmol) that was 
divided by the protein content (mg) from Bradford’s protein assay. 
 
4.3 Analysis of ERα and ERβ Expression 
4.3.1 Western Blot  
Immunoblotting protocol 
40 µL aliquots of the cytosols (preparation see above) were supplemented with10 µL of 
5-fold sample buffer (0.2 M Tris-HCl, pH 6.8, 2 0% Glycerol, 10 % SDS; 10 mM DTT, 
0.05 % bromphenol blue) and heated to 100 °C for 3 min. Total protein was resolved by 
12 % SDS page (5-10 µL per lane, 1.5 h, 150-200 V) and electrophoretically transferred 
onto nitrocellulose (system from Peqlab, Erlangen, Germany; conditions: 1,5 h, 1 
mA/cm2) in transfer buffer (20 mM Tris-HCl, pH 8.3, 192 mM glycerol, 20 % methanol). 
A pre-stained protein marker (Fermentas #SM0441, St. Leon-Rot, Germany) was used 
as molecular mass standard. The membranes were treated with PBS containing 5 % 
milk powder (Roth) for 1 h to prevent non specific binding. After washing with PBS 
containing 0.05 % Tween 20 (PBS-T; 3 × 5 min) the membranes were incubated with 
specific antibodies against ERα (NB200-374, Novus Biologicals, Littleton, CO, USA; 
dilution: 1:5000) or ERβ (AB3576, Abcam, Cambridge, UK; dilution: 1:1000), 
respectively at 4 °C over night in PBS-T containing 5 % milk powder. After washing the 
membranes with PBS-T (3 × 5 min) they were incubated with an anti rabbit HRP-
conjugated secondary antibody (A9169, Sigma, dilution: 1:50,000) in PBS-T containing 
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5 % milk powder for 1 h at room temperature followed by washing once more with PBS-
T (3 × 5 min). Chemoluminesce detection was performed using an Amersham ECLTM 
detection kit (GE Healthcare).  
Data Analysis 
The X-ray films were scanned and analyzed with a system from Bio Rad Laboratories 
consisting of a GS 710 scanner and the corresponding software Quantity one. After 
densitometric analysis the optical density of each band was quantified and corrected by 
the corresponding protein content of the cytosol (OD/mgprotein). 
 
4.3.2 RNA Analysis by Reverse Transcription - Polymerase Chain Reaction (RT-
PCR) 
RNA Isolation 
MCF-7 subclones and MDA-MB-231 cells were seeded on 75-cm2 culture flasks in the 
respective medium (see cell culture) and were grown to 70-90 % confluency. All 
materials used for the RNA isolation were RNAse-free or treated with DEPC water (0.1 
% DEPC (Fluka, Steinheim, Germany) in Millipore water). Total mRNA of each cell type 
was isolated using a Qiagen RNeasy mini kit (Qiagen, Hilden, Germany) following the 
manufacturer’s protocol. The concentration of the mRNA was determined 
photometrically at 260 nm according to the following relation: A260 = 40 µg/mL. 
Reverse Transcription 
cDNA was prepared by reverse transcription according to the following protocol: 
1 µg of RNA and 1 µL of oligo (dT12) primer solution (100 µM; MWG, Ebersberg, 
Germany) were added in 10 µL of autoclaved DEPC water. The solution was heated for 
5 min to 70 °C in a thermocycler (Mastercycler Gradient, Eppendorf, Hamburg, 
Germany). Then, with cooling on ice, 1 µL of MLV-reverse transcriptase (200 U/µL; 
Invitrogen;), 2 µL of dNTP mix (2 mM; MBI Fermentas), 4 µL of 5 × first strand buffer 
(Invitrogen), 2 µL of DTT (Roche), and 1 µL of autoclaved DEPC water were added. 
The samples were incubated for 1 h at 37 °C in the thermocycler, followed by an 
inactivation step for 2 min at 95 °C. The cDNA samples were stored at -20 °C.  
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Polymerase Chain Reaction (PCR) 
For the amplification of specific DNA fragments, 2 µL of each cDNA solution were 
supplemented with the respective primers (1 pmol/µL solution in milipore water; for β-
actin primer pair: 1 µL; others 2 µL) and 8 µL of PCR-Master Mix (Eppendorf) and finally 
filled up with Millipore water to a total volume of 20 µL. cycling parameters were: 1) 
initial denaturation: 95 °C, 2 min; 2) denaturation: 95 °C, 30 s; 3) annealing: 55 °C, 30 s; 
4) extension: 72 °C, 90 s; 5) final extension: 72 °C, 2 min; 6) hold: 4°C; steps 2 – 4 were 
repeated 34 times. Primers were synthesized by MWG. The sequences are shown in 
table D4. 
 
Table D4: Sequences of the used primers for PCR 
gene sense primer antisense primer 
amplified 
product length 
β-actin 5’-CGG GAT CCC 
CAA CTG GGA C-3’ 
5’-GGA ATT CTG 
GCG TGA GGG A-3’ 
304 bp 
ERαa  5’-AGC ACC CAG TGA 
AGC TAC T-3’ 
5’-TGA GGC ACA CAA 
ACT CCT-3’ 
155 bp 
ERβb  5’-GGC CGA CAA GGA 
GTT GGT A-3’ 
5’-AAA CCT TGA AGT 
AGT TGC CAG GAG C-3’ 
257 bp 
 
a(de Cremoux et al., 2002); b(Speirs et al., 1999) 
 
Agarose gel electrophoresis 
2 % agarose (pegGold Universal-Agarose; peqlab) gels were prepared in TAE buffer 
(44.5 mM Tris-base, 44.5 mM acetic acid, 1 mM EDTA). To visualize DNA 0.4 µg/mL 
ethidiumbromide (Janssen Chimica, Beerse, Belgium) was added. 
4 µL of 6 × gel loading dye buffer were added to each PCR reaction mixture and 12 µL 
of each sample were pipetted per pocket. As reference the peqGold DNA ladder 
(Peqlab) mix was prepared according to the manufacturer’s instructions. 
Electrophoresis was performed at 90 V for 45 min or until the tracking dye moved at 
least 2/3 of the gel length. DNA bands were visualized by illumination with UV light at 
254 nm (Gel Doc 2000; Bio Rad Laboratories). Quantity one software was used for data 
analysis. 
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4.4 Analysis of NPY Y1 Receptor Protein Expression 
4.4.1 General Protocol for the Whole Cell Y1R Radioligand Binding Assay 
 
All NPY Y1receptor binding assays using [3H]-UR-MK114 were performed in 24-well 
plates (Becton Dickinson) or 48-well plates (Nunc) on whole cells. 
The cells were seeded into multiwell plates as a homogenous suspension in 500 µL (24 
well) or 300 µL (48 well) of the respective culture medium. Cells were cultivated for 3-5 
days or until they reached confluency. The medium was removed by suction and the 
cells were washed with ice-cold 10 mM HEPES buffer (pH 7.4) supplemented with 150 
mM NaCl, 5 mM KCl, 2.5 mM CaCl·2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4·7H2O and 
25 mM NaHCO3. This HEPES buffer additionally supplemented with 1 % BSA served as 
binding buffer. The cells were incubated with the radioligand (added as appropriate 
concentrate, 25 µL/well) in a total volume of 250 µL (24 well plates) or 150 µL (48 well 
plates) of binding buffer respectively. The unspecific binding was determined by 
incubation of the radioligand in the presence of a 300 fold excess of pNPY. Total and 
unspecific binding were determined at least in triplicate for each concentration. After an 
incubation period of 20 min with gentle shaking the binding buffer was removed by 
suction and the non bound radioactivity was washed away twice with the HEPES wash 
buffer (BSA free). Cells were lysed in 300µL of a solution consisting of 8M urea, 3 M 
acetic acid and 1 % TritonTM X-100. After an incubation period of 30 min, the lysates 
were transferred completely into a minivial containing 3 mL of scintillation fluid and the 
tritium activity was counted in a Beckmann LS 6500 beta counter. 
 
4.4.2 Determination of the NPY Y1 Receptor Status 
 
For the determination of the NPY Y1 receptor status of the investigated cell lines, the 
radioligand was added in various concentrations. KD and Bmax values were determined 
by one site saturation binding fit (Sigma Plot Software).  
The number of binding sites (Bmax) was related to the cell number, which was 
determined from six identically treated control wells by counting with a Neubauer 
improved hemocytometer.  
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4.4.3 Effect of (Anti)estrogens on Y1R Expression  
 
Assay protocol 
Cells were seeded into 48 well plates and grown in ct-FCS containing medium (see 
general methods) until they had reached 70-80 % confluency. 45-50 h before the Y1R 
binding assay was performed, the medium was removed by suction and replaced by 
fresh (ct-FCS containing) culture medium (0.3 mL/well) containing the (anti)estrogens in 
the respective concentrations (by dilution of a 1000 fold concentrate in ethanol). 
Antiestrogens were added in multiple concentrations in the presence of 1nM 17β-
estradiol as stimulating agent. At least six wells per set were processed for each 
(anti)estrogen concentration. All plates were prepared in duplicate as two identical sets. 
One set of multiwell plates was used for the Y1R radioligand binding assay to quantify 
Y1R expression. If not otherwise noted, [3H]-UR-MK114 was added in a concentration of 
12 nM. For each group of identical wells (n= 6-8), one half was used for the 
determination of the total binding (radioligand alone), the other half for the determination 
of the unspecific binding (radioligand plus 300-fold excess of pNPY).  
The second set of plates was used as control to normalize the specifically bound 
radioactivity by the protein content. For this purpose the cells of the control wells were 
lysed by a lysis buffer (50-100 µL, volume depends on the protein concentration) 
consisting of 25 mM tricine (pH 7.8), 10 % glycerol, 1 % TritonTM X-100 and 1 mM DTT 
for 30 min with shaking. 5 µL of each lysate were submitted to Bradford’s Protein assay 
at appropriate dilution.  
Data Analysis 
The specifically bound radioactivity from the Y1R binding assay was related to the 
protein content from Bradford’s protein assay (dpm/mgprotein). The error in the term 
dpm/mgprotein was calculated by error propargation from the corresponding SEMs. For 
calculation of the relative Y1R expression, the normalized bound radioactivity (dpm/mg) 
at a given (anti)estrogen concentration was related to the normalized bound 
radioactivity (dpm/mg) of the 1nM estradiol-stimulated control (per definition 100 %). 
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4.4.4 Autoradiography 
 
Autoradiography was performed according to a protocol recently reported by Keller et 
al. (Keller et al., 2008): 
Subcutaneous MCF-7 tumors were established in female NMRI (nu/nu) mice bearing an 
estrogen depot (Bernhardt et al., 1992) by subcutaneous injection of a cell suspension 
in culture medium without FCS (4 Mio cells/50 µL, 171st in vitro passage). The tumor 
was taken from the animal 48 h prior to experiment, immediately frozen in Tissue-Tek 
with the help of dry ice, and stored at -78 °C. Cryosections (12 µm) were obtained at -16 
°C with a 2800 Frigocut E freezing microtome (Reichert-Jung/Leica, Germany). Two 
adjacent sections were mounted on a microscopic slide (Superfrost Plus, 75 × 25 × 1 
mm), put 1 min into a chamber of 100% humidity and then carefully covered with 
binding buffer or fixed for 20 s in an alcoholic formaldehyde fixative (40 mL of 37 % 
formaldehyde, 360 mL of 95 % ethanol and 0.2 g calcium acetate). The binding buffer 
was removed (after a period of less than 60 min under cooling) by putting the slides 
uprightly on a paper towel (≈ 1 min). For total binding the sections were covered with 
binding buffer (about 800 to 1000 µL for one slide) containing [3H]-UR-MK114 (3 nM) 
and for non-specific binding with binding buffer containing  [3H]-UR-MK114 (3 nM), and 
pNPY (300 nM). The sections were incubated at room temperature (22 - 25 °C) for a 
period of 8 min. After incubation the binding buffer was removed, the slides were 
immerged three times into buffer split to 3 vessels (4 °C, 10 s) and finally rinsed with 
distilled water (4 °C, 3 s). The slides were put uprightly on a paper towel for 1 min and 
then dried in horizontal position in a desiccator over P4O10. The slides were set in close 
contact with a tritium sensitive screen (PerkinElmer, 192 × 125 mm) using an X-ray film 
cassette and stored in a dark room for 10 d. The autoradiographic image was generated 
from the tritium screen using a phosphorimager (Cyclone Storage Phosphor System, 
Packard). 
 
4.5 Functional assays 
4.5.1 Spectrofluorimetrric Calcium Assay 
 
The spectrofluorimetric Ca2+ assay with the fluorescent Ca2+ indicator fura-2 was 
performed by analogy with a protocol established for HEL cells in our laboratory (Müller 
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et al., 1997; Gessele, 1998). MCF-7 cells were incubated with 1 nM 17β-estradiol, 17β-
estradiol plus 100 nM fulvestrant (ICI 182.780) or the respective vehicle 45 h prior to the 
assay. Cells were grown to 70-80 % confluency, trypsinized and resuspended in FCS 
containing medium for trypsine inactivation. Cells were counted, centrifuged at 300 g for 
5 min and resuspended at 1.3 million cells /mL in loading buffer containing 120 mM 
NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 25 mM HEPES and 10 mM glucose. 0.75 
mL of this cell suspension were added to 0.25 mL of loading suspension consisting of 
20 mg/mL BSA, 0.025% pluronicTM F-127 (Invitrogen-Molecular Probes, Paisley, UK; 20 
% stock solution in DMSO) and 1 µM fura-2/AM (Invitrogen-Molecular Probes; 1mM in 
anhydrous DMSO) in loading buffer to obtain a cell density of 1 million cells/mL. The 
cells were incubated for 30 min in the dark, centrifuged and re-suspended in the same 
volume of loading buffer. To achieve complete intracellular cleavage of the AM ester, 
cells were incubated for additional 30 min in the dark, washed twice with loading buffer 
and re-suspended at a density of 1 million cells/mL. 
For the measurement, 1 mL of the cell suspension was transferred into a cuvette 
containing 1 mL of loading buffer under stirring. The baseline was recorded for 20 
seconds before 10 nM pNPY was added to trigger the calcium signal. For inhibition of 
the calcium release, the antagonist BIBP 3226 was added in a concentration of 100 nM 
one minute before the addition of pNPY. Instrument settings were λex = 340 and 380 nm 
(alterating) with slit = 10 nm and λem = 510 nM with slit = 10 nm. Stirring was low and 
temperature was 25°C. 
The ratio R of fluorescence intensity at 510 nm after excitation at 340 and 380 nm was 
used for the calculation of the calcium concentration according to the Grynkiewicz 
equation (Grynkiewicz et al., 1985): 
 
[Ca2+] = KD · (R - Rmin) / (Rmax - R) · SFB 
 
KD:  dissociation constant of the fura-2-Ca2+ complex 
Rmax:  fluorescence ratio in presence of saturating Ca2+ concentration (determined after 
the addition of 10 µL of digitonin solution (2% in water; Sigma), which caused 
lysis of the cells) 
Rmin:  ratio in absence of free Ca2+, caused by addition of 50 µL of EGTA solution 
(600 mM in 1M tris buffer, pH 8.7) to lysed cells 
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SFB:  correction factor; ratio of the fluorescence intensity (λex = 380 nM, λem = 510 nM) 
of the Ca2+ free and Ca2+ saturated dye. 
 
4.5.2 Enzymatic Determination of Intracellular 3’,5’-cyclic AMP (cAMP)  
 
The 3’,5’-cAMP concentration in MCF-7 cells was determined in a multi step enzymatic 
reaction sequence as described by Dr. C. Gessele (Gessele, 1998) for SK-N-MC cells. 
In the enzymatic reaction sequence cAMP was first transformed into ATP in two steps. 
ATP quantitatively phosphoryalated fructose to fructose 6-phosphat, which was 
enzymaticly isomerized to glucose-6-phosphat. Glucose 6-phospat was oxidized by 
NADP+ and the amount of equimolar formed NADPH was flurimetricly measured. 
MCF-7 cells were seeded on 6-well plates and treated as described by Gessele. 
Intracellular cAMP was triggered by co-incubation with IBMX (50µM) and forskolin 
(0.01-1 µM). NPY was added in the given concentrations in order to obtain a 
concentration response curve for the inhibition of the forskolin / IBMX induced cAMP 
accumulation. All steps were performed according to this established protocol using 
enzymes and reagents from commercial suppliers given in the protocol. After the last 
reaction step, the mixtures were centrifuged and 200 µL of the supernatants were 
pipetted into a 96 well plate and flurescence was measured in a GENios ProTM plate 
reader (Tecan, Salzburg, Austria; parameters: bottom 4 × 4, number of reads: 10, λex = 
340 nm; λem = 485 nm). Assays were run in triplicate throughout. From a standard curve 
generated with known NADPH concentrations the fluorescence intensities were 
assigned to the corresponding NADPH amounts and finally the cAMP amount (pmol) 
was derived from the stoichiometry of the reaction sequence (for details see protocol 
(Gessele, 1998)). 
 
4.5.3 Effect of NPY on Cell Proliferation and ER Mediated Transcriptional Activity 
 
Antiestrogen sensitivity and effects of NPY on MCF-7 cell proliferation were studied in 
the kinetic chemosensivity assay following the protocol descriped in Section C. The 
effect of NPY on ER mediated transcriptional activity was studied by the luciferase 
assay with MCF-7/2a cells using the luciferase assay kit (see Section C). 
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E Summary 
 
The estrogen receptor (ER), a member of the nuclear receptor family, is an established 
prediction factor in breast cancer with respect to successful hormonal therapy. The 
class of membrane bound receptors recently gained increasing interest in breast cancer 
diagnostics and treatment. Especially neuropeptide Y (NPY) receptors, members of the 
family of G-protein coupled receptors, have become a topic in breast cancer research in 
recent years, as the Y1 receptor (Y1R) subtype was found to be expressed by the 
majority (85 %) of human mammary carcinomas. This thesis aimed at the investigation 
of the functional expression and cross-talk between ERs and Y1Rs in human breast 
cancer cells. 
 
Selective “pure antagonists” of the ERα and β subtypes are useful pharmacological 
tools for the characterization of ER subtype specific cellular and physiological effects, 
such as cross-talk between ERα or β and the Y1R, which is the subject of this thesis. 2-
Phenylbenzofurans are known as ERβ-selective agonists from recent publications and 
previous work of our group, whereas substituents in position 7 of the benzofuran core 
were reported to be favorable with respect to selectivity. Aiming at ERβ−selective “pure 
antagonists”, functionalized aliphatic side chains were introduced into position C7 of the 
benzofuran core. A 7-formylbenzofuran building block was synthesized for this purpose 
by a Sonogashira coupling reaction, starting from appropriate arylhalide and acetylene 
precursors. Simple alkyl and long “monofunctional” or “bifunctional” side chains were 
linked to the 7-formyl group by a reaction sequence involving a Grignard or a Wittig 
reaction, respectively. 
Benzofuran 24, bearing a small 1-propenyl substituent in C7 position, revealed high 
affinity to ERβ (RBA = 34) and >30-fold selectivity over ERα. 24 was shown to be an ER 
agonist in the luciferase gene reporter assay. Compounds, substituted with aliphatic 
side chains, comprising a thioether or sulfone group or a combination of a thioether and 
an amine function, revealed strongly decreased receptor affinities and selectivities. In 
the luciferase assay, these compounds were either weak antagonists or inactive. 
To obtain ERα−selective antagonists, a library of 2-aryl-tetrahydroisoquinolin-6-ols 
(THIQs), substituted with different functionalized aliphatic side chains in position C1, 
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was synthesized. The THIQs were built up from appropriate phenylethylamine pre-
cursors, that were attached to the corresponding carboxylic acid chlorides of the side 
chains. The resulting amides were transformed into THIQs by a Bischler Napiralski ring 
closure reaction. 
ER affinities of synthesized THIQs strongly depended on the nature of the side chain in 
position C1, whereas a 3’-hydroxy function at the N-phenyl ring was favorable for ERα− 
subtype selectivity. THIQs, containing side chains bearing a tertiary amine group at a 
distance of 6 atoms from the heterocyclic core, revealed binding affinities to ERα in the 
same order of magnitude (RBA ≈ 10) as determined for the potent ER antagonists 
fulvestrant (ICI 182.780) and 4-hydroxytamoxifen. After resolution of selected racemic 
THIQs into the respective enantiomers by chiral HPLC, the eutomers showed 3- to 6-
fold higher ER binding affinity compared to the corresponding distomers. 
ERα−selectivities of 13- and 17-fold over ERβ were observed for compounds 93 and 94 
with an amine and thioether containing “bifunctional” chain or a side chain bearing a 
sulfoxy function in combination with a 3’-hydroxy group, respectively. Both compounds 
exerted full antagonism in the luciferase assay with IC50 values in the sub-micromolar 
range, being appropriate pharmacological tools for blocking ERα−subtype specific 
cellular effects. Furthermore, THIQ 94, containing a sulfoxide side chain, was a potent 
inhibitor of the proliferation of estrogen responsive MCF-7 breast cancer cells, 
suggesting further investigation of its value in the hormonal therapy of breast cancer.  
 
ER and Y1R protein expression by different subclones of MCF-7 breast cancer cells 
showing differential sensitivities against antiestrogen treatment were quantified by 
radioligand binding assays. For this purpose, Y1Rs were labeled by the selective, high- 
affinity radioligand [3H]-UR-MK114, recently developed in our workgroup. Basal 
expression of Y1Rs by MCF-7 cells varied (40,000 to 100,000 binding sites per cell) and 
was inversely correlated with ER expression in vitro. In agreement with published 
results at the mRNA level, the Y1R protein was up-regulated by 100 % after treatment of 
the cells with 17β-estradiol at physiological concentration (EC50 = 20 pM). An estrogen-
induced Y1R expression was also found in T-47-D breast cancer cells, but on a 20-fold 
lower level compared to MCF-7 cells. The incidence of Y1Rs was exclusively observed 
in ER-positive breast cancer cells: Three ER-negative lines (MDA-MB-231, HCC1806 
and HCC1937) revealed no Y1R-specific binding. 
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The potent, highly ERα-selective agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-
pyrazole (“propylpyrazole triol”, PPT), up-regulated the Y1R by 100 % with an EC50 
value of 0.25 nM, indicating a predominant role of ERα in Y1R induction. The “pure ER 
antagonist” fulvestrant abrogated the 17β-estradiol-induced Y1R expression in a 
concentration-dependent manner (IC50 = 5 nM) to 25 % of the basal level. The THIQ-
based moderately ERα-selective antagonists 93 and 94, synthesized within the scope 
of this thesis, down-regulated the Y1R expression to the same extent as fulvestrant. 
Estrogen-induced Y1R protein expression proved to be a useful endogenous reporter for 
the quantification of (anti)estrogenic activity of estrogen receptor ligands. 
Functional coupling of the Y1R to both, mobilization of intracellular calcium and inhibition 
of adenylyl cyclase activity, was demonstrated in MCF-7 cells by triggering intracellular 
calcium transients and suppression of forskolin-stimulated cAMP synthesis with NPY. 
However, there was neither an effect of NPY treatment on the proliferation of MCF-7 
cells nor on ER-mediated transcriptional activity.  
According to the results of this thesis, the Y1R-mediated signaling cascade is not 
involved in downstream processes involved in tumor growth, that might be addressed in 
the therapy of breast cancer. Nonetheless, the Y1R is a useful endogenous gene 
reporter for the quantification of ERα−specific (anti)estrogenic effects in whole-cell 
radioligand binding assays and a potential target for diagnostic imaging of breast cancer 
metastases. 
 
 F Appendix  
 
1  Expression and Function of Histamine Receptors in MCF-7 and 
MDA-MB-231 Breast Cancer Cells  
 
Histamine exerts its various functions through four histamine receptor (HR) subtypes 
H1-H4. The role of histamine in the biology and growth of malignant tumors has been 
discussed for a long time. For example in the mid 1990s, histamine was suggested as 
an autocrine growth factor, regulating breast cancer cell proliferation via H1 and H2 
receptors (Cricco et al., 1994; Davio et al., 1995), and a potential use of H2R 
antagonists in the treatment breast cancer was proposed (Davio et al., 1996). Very 
recently, the H4R was reported to mediate growth inhibition of MDA-MB-231 breast 
cancer cells, whereas after stimulation of the H3R an increased cell proliferation was 
observed (Medina et al., 2008).  
In the present study the incidence of the histamine receptor subtypes H2, H3 and H4 in 
MCF-7 and MDA MB-231 breast cancer cells was explored by radiochemical biding 
assays using appropriate radioligands, distinctly addressing the respective receptor 
subtypes. Data on the expression of functional histamine receptors by human breast 
cancer cells from binding assays have not been available up to date. This study aimed 
on the exploration of the role of the different histamine receptor subtypes in the biology 
of breast cancer. 
 
1.1 Investigation of Histamine H2, H3, and H4 Receptor Expression by 
Radioligand Binding in MCF-7 and MDA-MB-231 Cells  
 
To detect H2R expression, the commercially available radioligand [3H]-tiotidine (KD ≈ 30 
nM) was used. The unspecific binding was determined by displacement of the tritiated 
ligand from specific binding sites located in the plasma membranes by the H2R selective 
antagonist ranitidine. A statistically significant difference between total and unspecific 
binding of [3H]-tiotidine was observed in MDA-MB-231 cells, but not in MCF-7 cells. 
H2R-specific binding increased with higher concentrations of the radioligand (cf. Figure 
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Ap1). The experiment was devised for the qualitative determination of the H2R protein. 
As specific binding was only a samll fraction of nonspecific binding, the number of H2R 
specific binding sites appears to be rather low.  
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Figure F1:  Binding of the H2R selective radioligand [3H]-tiotidine to whole MCF-7 and MDA-
MB-231 cells. Unspecific binding was determined by displacement of the radio-
ligand by the H2R selective antagonist ranitidine.  
 Values represent means of triplicates ± SEM; p values were determined by Student’s t-test; 
p<0.05 was considered as statistically significant. 
 
The tritiated high affinity H3 and H4R ligand [3H]-UR-PI-294 was recently developed by 
Dr. Igel in our research group (Igel et al., 2008). To discriminate between H3 and H4R 
specific binding the radioligand was successively displaced from the receptors by the 
H3R selective agonist UR-PI-97 (Igel, 2008) or the H4R selective antagonist 
JNJ7777120, respectively.  
The H3/H4 R radioligand [3H]-UR-PI-294 at a concentration of 10 nM showed no specific 
binding to MCF-7 cells. In the case of MDA-MB-231 cells total binding was significantly 
decreased after replacement of the radioligand by histamine and the H3R selective 
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compound UR-PI-97. There was neither a statistically significant difference between the 
bound radioactivity in the presence of the radioligand alone nor in combination with the 
H4R antagonist JNJ7777120 (cf. Figure Ap2). The pharmacological profile of [3H]-UR-
PI-294 at the H3R and the H4R (Igel et al., 2008) suggests an occupation of nearly all 
existing binding sites at the applied concentration of 10 nM. Thus, the result of the 
binding experiments suggests a poor expression of the H3R by MDA-MB-231 cells, 
whereas in contrast to literature (Medina et al., 2008), H4Rs were not detected on MDA-
MB-231 cells. 
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Figure F2:  Binding of the H3/H4 R selective radioligand [3H]-UR-PI-294 to MCF-7 and MDA-
MB-231 breast cancer cells.  
 Values represent means of triplicates ± SEM; His: histamine; NS: not significant; p values 
were determined by Student’s t-test; p<0.05 was accepted as statistically significant; a 
similar result was obtained in an additional independently performed experiment. 
 
H4R mRNA expression in MCF-7 and MDA-MB-231 cells was investigated by D. Schnell 
at the department of Pharmacology and Toxicology using a routine RT-PCR method. A 
strong band at the expected product size of 650 was detected in MDA-MB-231 cells but 
not in MCF-7 cells. The high mRNA expression found by RT-PCR-analysis agrees with 
a recently published report (Medina et al., 2006), but does not correlate with the result 
of the binding experiments, where no significant H4R specific binding was detected. This 
might be due to either absent translation of the H4R mRNA or misfolding or impaired 
trafficking of the receptor protein. 
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Figure F3:  
mRNA expression by MCF-7 and MDA-
MB-231 breast cancer cells. RT-PCR was 
conducted using a specific primer pair to 
give a 650 bp fragment of the H4R cDNA.  
Positive control: cDNA generated from SF-
9 insect cells, stably expressing the 
recombinant hH4R. 
 
 
1.2 Studies on the Role of Histamine in Breast Cancer Cell Proliferation 
 
Histamine and H4R agonists have recently been reported to induce a decreased 
proliferation of MDA-MB-231 cells (Medina et al., 2008). According to the binding 
experiments described above, H2, H3 or H4R mediated effects in MDA-MB-231 are 
unlikely, as binding sites were very only present in the case of H2 and H3R in minute 
amounts or lacking as in case of H4Rs. The impact of histamine receptors on the growth 
of MDA-MB-231 and MCF-7 breast cancer cells was extensively investigated in our 
research group in the mid 1990s (Bernhardt, unpublished results).  
None of the growth kinetics experiments revealed any significant effect of a variety of 
histamine receptor ligands (agonists and antagonists) on the proliferation of the 
investigated cell lines. Figure Ap4 shows representative curves for the growth kinetics of 
MDA-MB-231 cells in the presence of histamine or the H2R selective antagonist 
ranitidine.  
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Figure F4:  Growth kinetics of MDA-MB-231 cells in the presence of histamine or the H2R 
antagonist ranititine compared to vehicle control; Crystal violet chemosensivity 
assay Conditions: Mc Coy’s 5A medium + 3% ct FCS  
 
Taken together, MCF-7 cells proved to be negative for all investigated H2-H4 receptor 
subtypes, as specific radioligand binding was not observed. 
MDA-MB-231 cells revealed poor expression of H2 and H3 receptors, while in the case 
of the H4R, there was no statistically significant difference between total and non-
specific binding. H4R mRNA expression was found in the case of MDA-MB-231 cells, 
but the gene appears not to be translated into a functional receptor protein. Regarding 
the low expression of histamine H2 and H3 receptors by MDA-MB-231 cells, the 
relevance of these receptors in cell biology, in particular in cell proliferation appears to 
be unlikely. In accordance with the result of the present binding studies, neither 
histamine nor any other agonist and antagonist influenced cell proliferation of MDA-MB-
231 and MCF-7 breast cancer cells. 
 
1.3 Experimental 
 
Materials: 
[3H]-tiotidine was purchased from PerkinElmer (Waltham, MA, USA); histamine 
dihydrochloride was purchased from Alfa Aesar (Karlsruhe, Germany); ranitidine was 
purchased from Sigma; [3H] UR-PI-294 (Igel et al., 2008) and UR-PI-97 (Igel, 2008) 
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were synthesized in house by Dr. Igel. JNJ7777120 was a gift from Dr. R. Thurmond 
(Department of Immunology, Johnson & Johnson Pharmaceutical R&D, San Diego, CA, 
USA).  
 
Biding experiments:  
All binding experiments were performed in whole cell assays in 24-well plates using the 
respective radioligands in appropriate dilutions. The protocol was adopted from the Y1R 
radioligand binding assay as described in section D. The incubation period was 60 min 
in all experiments guaranteeing full receptor occupation. The concentration of [3H]-UR-
PI 294 was 10 nM. [3H]-Tiotidine was applied at concentrations of 10 and 30 nM. For 
the determination of the unspecific binding [3H]-tiotidine was displaced from receptor 
binding by a 1000-fold excess of the H2R selective antagonist ranitidine. In the case of 
[3H]-UR-PI-294 the radioligand was successively displaced by histamine (100 µM), UR-
PI-97 (10 µM) and JNJ7777120 (10 µM), respectively.  
 
RT-PCR analysis: 
RNA analysis was performed by D. Schnell at the department of Pharmacology and 
Toxicology at the University of Regensburg following a routine protocol (Preuß, 2007). 
Total RNA was extracted from MDA-MB-231 and MCF-7 cells using an RNeasy Kit 
(Qiagen) following the manufacturer’s protocol. Corresponding cDNA was generated by 
MMLV reverse transcriptase (Invitrogen). In a subsequent PCR a specific DNA fragment 
was generated by using the following primers: sense: 5’-GCC ATC ACA TCA TTC TTG 
GAA TTC GTG ATC CCA GTC-3’; antisense: 5’-GAT CCT CTA GAT TAG TGA TGG 
TGA TGA TGG TGA GAA GAT ACT GAC CG-3’; amplified product: 650 bp. 
 
Proliferation assay: 
The growth kinetics of MDA-MB-231 cells in presence of histamine and ranitidine was 
determined in the crystal violet assay as described in section C. 
 
 
 
 
Histamine Receptors in Breast Cancer Cells 207
1.4 References 
 
Cricco, G. P.; Davio, C. A.; Martin, G.; Engel, N.; Fitzsimons, C. P.; Bergoc, R. M. and 
Rivera, E. S., Histamine as an autocrine growth factor in experimental mammary 
carcinomas. Agents Actions 1994, 43, (1-2), 17-20. 
Davio, C.; Mladovan, A.; Shayo, C.; Lemos, B.; Baldi, A. and Rivera, E., Histamine 
receptors in neoplastic transformation: studies in human cell lines. Inflamm Res 
1996, 45 Suppl 1, S62-63. 
Davio, C. A.; Cricco, G. P.; Bergoc, R. M. and Rivera, E. S., H1 and H2 histamine 
receptors in N-nitroso-N-methylurea (NMU)-induced carcinomas with atypical 
coupling to signal transducers. Biochem Pharmacol 1995, 50, (1), 91-96. 
Igel, P., Synthesis and structure-activity relationships of NG-acylated 
arylalkylguanidines and related compounds as histamine receptor ligands: 
searching for selective H4R agonists. Doctoral thesis, Universität Regensburg, 
Regensburg, 2008 
Igel, P.; Schnell, D.; Bernhardt, G.; Seifert, R. and Buschauer, A., Tritium-Labeled N(1)-
[3-(1H-imidazol-4-yl)propyl]-N(2)-propionylguanidine ([(3)H]UR-PI294), a High-
Affinity Histamine H(3) and H(4) Receptor Radioligand. ChemMedChem 2008. 
Medina, V.; Cricco, G.; Nunez, M.; Martin, G.; Mohamad, N.; Correa-Fiz, F.; Sanchez-
Jimenez, F.; Bergoc, R. and Rivera, E. S., Histamine-mediated signaling 
processes in human malignant mammary cells. Cancer Biol Ther 2006, 5, (11), 
1462-1471. 
Medina, V.; Croci, M.; Crescenti, E.; Mohamad, N.; Sanchez-Jimenez, F.; Massari, N.; 
Nunez, M.; Cricco, G.; Martin, G.; Bergoc, R. and Rivera, E., The role of 
histamine in human mammary carcinogenesis: H3 and H4 receptors as potential 
therapeutic targets for breast cancer treatment. Cancer Biol Ther 2008, 7, (1), 
28-35. 
Preuss, H., Species-selective Interactions of Histamine H2 Receptors with Guanidine-
type Agonists: Molecular Modelling, Site-directed Mutagenesis and 
Pharmacological Analysis. Doctoral thesis, Universität Regensburg, Regensburg, 
2007 
 
 
 
 
 
 
 
 
 
 
208 Appendix  
2 Chemosensitivity of Triple Negative Human Breast Cancer Cells  
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Figure F5:  Growth kinetics of triple negative HCC1806 and HCC 1937 breast cancer cells in 
the presence of various cytostatics and the antiestrogen fulvestrant (ICI 182.780); 
Crystal violet chemosensivity assay; conditions: RPMI+10% FCS; 
 vin: vinblastin; “triple negative” refers to expression of ER, PR and HER2 
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